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ABSTRACT 
Infected wounds are one of the most prominent health problems today, and many 
different methods of treatment exist. However, these treatments have their limitations and are 
often costly. By combining organic essential oils with a pre-existing silver antimicrobial, we 
can provide a more effective, less expensive wound dressing for treatment of infected 
wounds. After a series in vitro and in vivo tests for antimicrobial efficacy, these experiments 
validate the combination of actives which inhibit and kill specific wound pathogens in a 
hydrocolloid wound dressing. We used these results to design a three-layered, two-component 
dressing, to diffuse antimicrobials and to inhibit growth of bacteria as well as to remain 
mechanically stable in a wound environment.  
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1. Introduction 
 
Each year, treatment of wounds becomes a more pressing medical issue as the need for 
wound care affects a large number of the population worldwide. Wounds cost the United 
States health system $20 million per year (Jackson 2006). These wounds include incisional, 
acute, and chronic all of which commonly may become infected to cause further 
complications. Chronic wounds can be very painful and can lead to secondary infections and 
complications, which can result in death. Recently, a study conducted at the University of 
Texas stated that approximately 5 million Americans suffer from chronic wounds each year. 
Chronic wounds, which usually result from progressive tissue degradation are termed “non-
healing” wounds and easily result in an infection if not treated properly. Infections therefore 
result in increased cost for all parties involved (Dowsett, 2004).  Incisional wounds along with 
deep lacerations are also problematic and play a large role in the annual cost spent on wound 
healing products. Although incisional wounds rarely take as long to heal as chronic wounds, 
they still pose trouble with proper closure and scar tissue buildup, which can in turn affect 
one’s quality of life. Incisional wounds also run the risk of becoming infected, again causing 
the need for further treatment. 
The need for proper wound care has been a concern throughout time in United States 
healthcare organization, but often the proper treatment is too costly for many disadvantaged 
patients. Treatments for wound care cost $4 billion per year in the United States alone 
(Jackson, 2006). Antiseptics, antibiotics and silver dressings have been providing wound care, 
however each of these treatments is resistant to various microbes commonly found in wounds 
so they do not provide an effective result. Newer technologies and treatment methods using 
silver as the antimicrobial component, such as in the Acticoat™ dressing (Smith & Nephew) 
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and Actisorb Silver 220™ dressing (Johnson & Johnson), have recently been developed and 
each have shown promising results in more immediate wound healing as well as inhibiting 
and killing a broader range of microbes compared to dressings without the silver constituent 
(Thomas, 2002; Smith & Nephew, 2005). 
Each silver dressing on the market has its advantages and disadvantages. Although 
most of the current models kill and inhibit the growth of a variety of wound pathogens, there 
are still many limitations that can be addressed and improved upon. In one study, it was 
concluded that many of the dressings use more than five times the concentration of silver 
necessary to eradicate most microbes (Demling, 2002). The overabundance of silver is costly 
in both dollars and in materials. Also, although silver is effective against many wound 
pathogens, it is limited in microbial resistance. Additionally, many wounds, especially those 
that are infected, have a potent aroma, which can be embarrassing to the patient and make it 
hard for the medical attendant to treat the area. Silver dressings do not provide relief to this 
problem. The lack of pain reduction is also a severe limitation to the current models. Often 
chronic wounds are exceedingly painful and can take months or even years to completely 
heal. Similarly, incisional wounds can stretch the surrounding skin and result in painful scar 
tissue. Constantly applying and removing the dressing can damage the newly forming tissue 
as well as allow for more contaminants to enter the wound environment. 
Due to the previously described limitations of the current silver models, there is a 
strong need for a next generation wound dressing. Essential oils, also known as terpenes, have 
been researched for several years due to their high levels of antimicrobial activity. These 
essential oils are organic compounds that originate from plants so there are many different 
varieties currently being studied. Plants release these oils as a defense mechanism from any 
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intruding organisms such as bacteria or fungi (Llusia, 2000). Extensive work has been 
completed using thirty-two formulations of these compounds by Gary Ostroff, Ph.D (Ostroff, 
2005). Ostroff and colleagues were able to determine the strong antimicrobial properties of 
the various terpenes by testing them against ten wound pathogens. Many of the terpenes were 
broadly active against the bacterium including Staphylococcus aureus, Streptococcus 
pyogenes and Candida albicans. On the other hand, terpenes were not as effective against 
wound pathogens such as Pseudomonas aeruginosa. However, research has shown that silver 
is quite effective against these bacteria (Ostroff, 2005). Therefore, the possibility of 
incorporating both silver and terpenes into a dressing to inhibit a broader distribution of 
wound pathogens could be an exciting solution to creating the next generation of wound care 
dressings (Wright, 2002).  
Terpenes not only possess antimicrobial properties but due to their organic nature, 
they are also less costly than silver and many of these compounds provide a pleasant smell 
that could provide relief to foul odors of infected wounds. These terpenes are also beneficial 
to a wound dressing as some have an added capability of reducing pain as in the case of 
Eugenol, which is used on the gums of teething infants (Jorkjend, 1990; Ostroff, 2005).  
The goal of this project is design a novel wound dressing based on the current models 
in the field. We hope to address and overcome the limitations of these antimicrobial dressings 
resulting in a more optimal dressing. Once our dressing has been constructed, we will 
determine whether or not the dressing effectively decreases the amount of bacteria in the 
wound and if aids in the wound healing process. A team approach will be used in combination 
with a thorough engineering design process to accomplish the aforementioned goals. The 
dressing will include the innovative feature of terpenes, which should provide a broader 
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microbial inhibition and reduction in cost. In order to verify and validate the claim that the 
dressing facilitates enhanced wound healing, a full-thickness wound healing model will be 
analyzed to determine the optimal concentration of terpene in an in vivo environment. 
Bioluminescence technology as well as visual assessment and photographs will be taken to 
evaluate the length, width, area, and color of the wound throughout the testing period. 
While conducting preliminary animal testing to determine proper concentrations as 
well as assess wound healing capabilities, the wound healing dressing will simultaneously be 
constructed. By including silver and terpenes, this system will significantly increase the range 
of bacterial inhibition compared to the current technologies. We will use diffusion disc, zone 
of inhibition, and biocompatibility assays to determine important parameters of our dressing. 
These experiments will allow us to create a superior dressing to the current models by 
comparing our dressing to the present data. 
This dressing will be especially beneficial to patients who suffer from infected wounds 
by providing relief not only in the realm of pain management and of olfaction but also in 
improvements in cost and in overall treatment time.  
   17
2. Background and Literature Review 
 
In order to develop an antimicrobial wound dressing which is superior to current 
wound dressing products, it is vital to understand the anatomy of the skin, the healing process 
of chronic and acute wounds, the available antimicrobials used in wound care, and the most 
often used preclinical wound healing models.   
2.1 The Skin 
 
The skin is part of the integumentary system along with sweat and oil glands, hairs, 
and nails. Skin is often called the integument, which means “covering”. It covers the entire 
human body and makes up about 7% of the total body weight in the average adult (Marieb: 
Chapter 5, 2001). Skin is viscoelastic and therefore is pliable but it also has the ability to 
remain mechanically strong when confronting external agents and movements.  
Skin is made up of two major layers; the epidermis and dermis and is supported by the 
hypodermis (see Figure 1). The outermost layer is called the epidermis and is composed of 
epithelial cells. The epidermal layer acts to protect the middle layer called the dermis. The 
thicker, vascularized dermis layer of the skin provides nutrients for the outer layer. The 
dermis layer is tough, leathery, and is comprised of fibrous connective tissue which contains 
fibroblasts, macrophages, mast cells, white blood cells, collagen, elastin, and reticular fibers 
(Marieb: Chapter 5, 2001). The hypodermis is the innermost layer and is made up of fats, 
loose connective tissue, and elastin and provides insulation and padding for the skin (Wake 
Forest, 2005).  
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Figure 1: Layers of the Skin (Geneve Cosmeceuticals, 2005) 
 
The skin is the primary barrier between the body and the environment, which 
functions to maintain water content within the body and acts as the body’s first line of defense 
against foreign invaders. As long as the epidermis remains intact, the keratinized epithelial 
cells provide a mechanical barrier to keep microorganisms out. However, when body tissues 
are injured this mechanical barrier is broken, permitting microbial invasion into the 
underlying tissues. A second line of defense is the immune system, whose role is to keep 
infectious organisms out of the body. Yet, when pathogens do invade the body, this system 
provides antibodies using bone marrow (“B”) and thymus (“T”) cells.  The immune system 
prevents the spread of foreign invaders to neighboring tissues and it also eliminates pathogens 
and cellular debris (Marieb: Chapter 20, 2001).  
The inflammatory response initiates the necessary steps for tissue repair and 
regeneration. It is the immune system that aides in beginning the wound healing process 
(Marieb: Chapter 20, 2001; Harding, 2002). Those who are immunosuppressed rely on 
another agent to aid in starting and progressing with the wound healing process since the body 
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is unable to start this process alone. Oftentimes a wound is so severe that even healthy 
patients are unable fight infection and the patient requires additional treatment (Ratner, 2004). 
It is important that any implant or wound dressing attract the proper type of cells or 
receptors to the surface of the skin. These cells and receptors are important because they are 
the ones that will trigger certain effects such as blood clotting, and will promote certain 
responses such as initiation of macrophages. Without the proper cellular components and 
receptors, the dressing will not allow for healing and tissue regeneration (Ratner, 2004). For 
example, seeding a synthetic collagen matrix with keratinocytes for a skin graft allows for the 
graft to be more readily accepted by the body because keratinocytes are a natural component 
of the body and will promote advantageous biological functions for the collagen (Harrison et 
al., 2006). Without the kerotinocyte cells on the surface, the graft may be rejected by the body 
and it will take longer to heal and regenerate new tissue. 
2.2 Acute and Chronic Wounds 
 
 Acute wounds are wounds that heal within the expected timeframe of ten to fourteen 
days, without complications (Cardiff University, 2005). Acute wounds include incisions or 
lacerations, which heal best when the ruptured skin is in contact with itself during the healing 
process. On the other hand, chronic wounds can take months or even years to heal. A main 
cause of this delay in wound healing is the existence of micro-organisms in the wound, which 
can prolong the inflammation phase (Dowsett, 2004). With this type of wound, the skin heals 
from the edges of the wound bed inward to fill the large gap.  
The cause of chronic wounds can vary. Some chronic wounds originate from acute 
injuries that develop infections or do not receive the proper treatment in the early stages of 
wound healing. The majority of chronic wounds are the result of progressive tissue 
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degeneration over long periods of time due to various vascular, venous, arterial, or metabolic 
diseases. Tumors, radiation damage, and pressure ulcers can also result in chronic wounds 
(Ellermann, 2005). Chronic wounds are demanding on the patient as well as the physician. 
They are often termed “nonhealing” wounds and require intensive wound care treatments. 
Wounds of this nature hinder the quality of life for millions in the United States alone 
(Harding, 2002). 
 As soon as a wound arises, the dynamic wound healing process is put in motion. This 
process is complex and multiple metabolic pathways and cellular activities overlap one 
another. Therefore, it is often hard to determine where one stage of the wound healing process 
stops and another one begins. However, the process is commonly divided into three phases: 
inflammation, proliferation, and maturation (Figure 2) (Clark, 1996).   
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Three Phases of Wound Closure  
A) early and late inflammation, B) proliferation (formation of granulation tissue and reepithelialization), 
and C) maturation (Clark, 1996). 
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In the inflammatory phase, which begins immediately after a wound has occurred, the 
patient may experience redness, heat, swelling, pain, and loss of function of the area. At the 
same time, the coagulation cascade, as well as growth factors, begins to take effect to reduce 
the loss of fluid from the wound via a fibrin clot formation in order to achieve homeostasis 
(Marieb: Chapter 20, 2001).   Platelets are blood cells that continuously slip and slide in the 
blood and do not adhere to any other bodies or cells as long as prostacyclin is coating the 
vessel walls.  However, when collagen is exposed outside of the damaged vessel, the platelets 
bind to the damaged area and degranulate. This results in the release of the mediators 
serotonin, adenosindiphosphate (ADP), and thromboxane A2, which cause more adhesion of 
the platelets, resulting in a platelet plug, vasoconstriction, and activation of plasma proteins 
called clotting factors. This is the intrinsic activation process (Marieb: Chapter 20, 2001). 
A second clotting pathway, called the extrinsic pathway is also activated when a 
wound is introduced to the skin. The damaged tissue releases thromboplastin, which in turn 
activates plasma proteins Factor VII followed by Factor X to begin coagulation. At this point, 
the extrinsic and intrinsic cascades merge into one unified process. These activation pathways 
rely heavily on calcium ions. Without these ions, blood cannot clot and the wound will 
continue to bleed, hindering the wound healing process. When calcium ions are present, 
Factor X can create a complex that clips part of the prothrombin molecule at protein sites 
Arg273 - Thr274 and then at Arg322 - Ile323 which produces active thrombin, an important clot 
promoter. Thrombin then cleaves soluble fibrinogen into insoluble fibrin, which polymerizes 
with the aid of plasma protein Factor XIII to create a meshwork clot (Rosing, 1985.) 
Once the clot has formed, capillary diameter increases to create space for cellular 
infiltration.   Many other cells are also involved in the wound healing process such as 
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platelets, which are the first cells employed at the wound site after the coagulation processes 
occurs.  They are a source of growth factors, such as transforming growth factor-beta (TGF- 
β) and platelet-derived growth factor (PDGF) in the wound, which start the activation of 
fibroblasts and other mesenchymal cells (Ratner, 2004).  Growth factors are peptides, which 
act on endothelial cells, fibroblasts, and inflammatory cells to stimulate the processes of 
wound healing. Prostaglandins then release cytokines, which cause fever production as well 
as pain (Marieb: Chapter 20, 2001; Martin 2005)   
Within hours after the initial wound, a large angiogenic response is activated.   During 
this response the epidermal layer starts to repair the damaged tissue by the migration of 
keratinocytes from the edges of the wound toward the center of the wound.  Sheets of 
keratinocytes move forward at the border between the wound dermis and the fibrin clot.  The 
connective tissue that is located deeper in the wound is replaced by activated fibroblasts at the 
edge of the wound that proliferate and move to the wound bed to form a granulation bed. 
(Martin, 2005)  
Another class of cells, called macrophages, produces the cytokine interleukin-1 (IL-1) 
and they promote proliferation and angiogenesis, as well as protect the wound from microbial 
invasion.  After about 24-36 hours, circulating monocytes that have entered the wound reach 
their maximum number and mature into macrophages. The macrophages exude substances 
such as basic fibroblast growth factors (bFGF), which stimulates growth for endothelial cells 
and fibroblasts as well as IL-1. A lack in the number of macrophages would cause an 
increased risk of infection resulting in a severe alteration in the wound healing process with 
poor debridement and insufficient fibroblast production and angiogenesis. At the end of the 
inflammatory phase, the wound becomes more mononuclear with less macrophages, which 
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defines the next phase called the proliferative phase (Harding, 2002). Additionally, helper T 
cells, which are a class of mononuclear leukocytes that produce and secrete the cytokine 
interleukin-2, stimulate more T cells to aid in the immunogenic response (Marieb: Chapter 20, 
2001). 
 Approximately two to three days after the injury, the proliferation stage begins with 
the arrival of fibroblasts into the wound site, which then produce various growth factors to 
enhance wound healing such as: bFGF, transforming growth factors (TGF- β), platelet derived 
growth factors (PDGF), endothelial, and keratinocyte growth factors. The proliferation of the 
previous growth factors then allows glycosaminoglycans (GAGs) and proteoglycans to be 
synthesized. These are the foundation for new extracellular matrix of granulation tissue as 
well as collagen (Marieb: Chapter 20, 2001). Collagen is a large component of acute wound 
connective tissue. After the emission of collagen molecules, the fibroblasts assemble the 
molecules into fibers, which are then cross-linked and organized into collagen bundles. 
Production of collagen continues for six weeks and accounts for increasing tensile strength of 
the wound site (Madden, 1971).  
 Once the new extracellular matrix, collagen, and capillaries have formed, the fibrin 
clots begin to degrade. The granulation tissue continues to be produced until the entire wound 
is covered, at which time fibroblast migration and proliferation is discontinued. The 
glycosaminoglycans then act to inhibit fibroblast activity and begin the maturation stage in the 
wound healing process (Clark, 1996). 
  During the maturation phase, the collagen is remodeled into a more organized 
structure to increase the wound’s tensile strength. As scar tissue forms, type III collagen is 
replaced by type I collagen until the ratio between the two is 4:1 for healthy skin, the higher 
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amount being type III collagen (Marieb: Chapter 20, 2001). Type I collagen is made up of 
broad fibrils of low hydroxylysine protein which are distributed throughout the skin and 
account for 90% of body collagen,  whereas Type III collagen is also distributed throughout 
the skin but is made up of high amounts of hydroxyproline protein (Saltzman, 2004). 
Eventually, the wound is closed by the movement of epithelial cells from the wound edge to 
holes in the defect. Finally, the wound fibroblasts differentiate into myofibroblasts, which 
contain actin muscle fibrils that bind together to draw the wound edges closer resulting in a 
healed wound (Grinnell, 1994).   
 This wound healing process is similar in both acute and chronic wounds. However, 
often times an acute model does not represent that of chronic wounds (Dowsett, 2004). An 
acute wound goes through the previously mentioned sequential and timely wound healing 
process and results in restored function and anatomy; however, with chronic wounds, the 
chronological process is disrupted causing a lengthier and often incomplete healing process. 
Chronic wounds lack restoration in anatomical and functional integrity (Harding, 2002). They 
can often get caught in the first two phases of wound healing and this can cause them to take 
months or years to heal as a result of prolonged inflammation and proliferation which may 
lead to elevated extracellular matrix molecules, indicating an unregulated wound and cellular 
dysfunction (Dowsett, 2004). 
 Many factors can contribute to a decrease wound healing. These factors include 
wound infection, repeated trauma, tissue hypoxia, debris, and necrotic tissue. Other factors are 
labeled systemic causes such as malnutrition, the use of certain medicines, immunodeficiency, 
and diabetes mellitus (Harding, 2002; Dowsett, 2004). The most common reason for poor 
wound healing is infection, which can affect all three stages of the wound healing process. 
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Once a wound has become infected, wound healing is delayed. In turn, necrosis can occur, 
which increases the chances of the wound growing in size and severity (Kingsley, 2001).  
 There are numerous microbes that replicate in a wound and cause infection. In both 
acute and chronic wounds, Staphylococcus aureus and Pseudomonas aeruginosa are two 
aerobic pathogens that are often associated with postponed wound healing as well as 
infection. Research has shown that S. aureus is one of the most problematic pathogens in 
when dealing with wound infections. In one study of acute wounds, 14 out of 61 wounds 
showed that they were infected and identified that the most prevalent wound pathogen was S. 
aureus (Bowler, 1999). Enterococcus fecalis is another pathogen that is often common in 
wounds and can lead to infection as well as other sicknesses especially to the intestines, which 
can compound the insult of the wound by further suppressing the immune system (Lu, 2002). 
It is both costly for patients as well as healthcare providers to afford consistent wound 
care. Patients suffer in a reduced quality of everyday life and insurance companies experience 
a financial burden (Dowsett, 2004). Each type of wound varies in treatment, and each 
treatment also varies in cost. Therefore, there is a demand for a more cost effective, long-
lasting antimicrobial wound dressing to satisfy the needs of both patients and healthcare 
providers. 
2.3. Silver 
 
Various forms of silver are currently be used in wound dressings. Although costly, 
silver has proven to be quite effective as an antimicrobial agent. Silver is classified as a nearly 
inert metal and therefore ideally, this material does not react with the human body in its non-
ionized form. However, in its ionized form, silver becomes bioactive. The transformation 
from non-ionized to ionized silver, results from the presence of moisture such as that found in 
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wound exudate. As silver ionizes, silver ions are released along with other ions that are 
biologically active. These ions then bind with proteins, which can be found on the surfaces of 
various cells as well as in bacteria and fungi (Dowsett, 2004).  
There are four main reasons why scientists believe that silver is a successful 
antimicrobial agent. The first reason is that silver interferes with bacterial ion release and 
disrupts electron transport. Second, silver has a tendency to bind to bacterial DNA, which is 
beneficial since the interaction can hinder cellular replication of the bacteria. Third, the 
presence of silver causes damage to the receptor function and structural integrity as it interacts 
with bacterial cell membranes. Finally, silver allows for insoluble and ineffective compounds 
to form, which can in turn hinder microbial activity (Ruszczak, 2004; Brett, 2006).  
Additionally, many limitations of the current silver dressings stem from confusing and 
conflicting ideas about silver as an antimicrobial in general. In a 2006 article entitled, “A 
discussion of silver as an antimicrobial agent: alleviating the confusion”, the author states that 
the makers of the current dressings often supply information about the dressings that conflict 
with data found in literature therefore, clinicians are unsure about what to believe (Brett, 
2006). It is currently used in many different applications for its antimicrobial properties, so 
these various trials cannot all be taken for truth. 
 Some of the negative aspects of silver as an antimicrobial were very crucial to creating 
a successful wound dressing, therefore the team wanted to make sure that all of the limitations 
of the current models were addressed. Some of the limitations were that silver may not be 
affective against all microbes or all strains within a specific pathogen and the test medium 
used plays a role in the silver dissociation properties (Brett, 2006). Additionally, rapid silver 
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delivery is necessary at high doses to be truly effective. However, research has shown that 
silver is not cytotoxic so high concentrations should not be harmful to the user (Brett, 2006).  
2.3.1 Silver Sulfadiazine 
For the past few decades, silver sulfadiazine has been the standard treatment for burns 
and other chronic wounds. In 1968, Fox first synthesized the compound from silver nitrate 
and sodium sulfadiazine for an increased effectiveness as well as minimal pain upon 
application. Since its discovery, silver sulfadiazine has been praised for its antibacterial 
properties. However, recent studies show that the compound may actually hinder and delay 
the wound-healing process. This new finding can possibly be reversed using growth factor 
treatments, but it is now important to look at other forms of silver to find the next generation 
of wound healing agents (Lee, 2005).  
2.3.2 Pure Silver 
Pure silver has also been studied for use in wound healing. In a study conducted by 
Robert H. Demling, M.D. and Leslie DeSanti at Brigham & Women’s Hospital, the objective 
was to determine if exposure to pure silver would increase healing and re-epithelialization 
along partial-thickness wounds. The team compared a silver delivery system with that of 
xeroform, an eight ply gauze dressing with an antibiotic solution. Each patient was treated 
with an antibiotic solution on one graft area and the pure silver delivery system on another 
area. By day seven, in all of the silver areas re-epithelialization was complete and the rate of 
healing was increased by 40%. Therefore this study concluded that silver used in a moist 
wound environment increases the healing rate and re-epithelialization rate compared to typical 
antibiotics (Demling, 2002). 
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2.3.3 Nanocrystalline Silver 
Nanocrystalline silver has been used as a form of silver for wound care management. 
In one study, the aim was to determine if nanocrystalline silver had the physical properties to 
act as a barrier against methicillin-resistant Staphylococcus aureus (MRSA), which is a 
common bacteria found in many wound sites. In initial experiments using MRSA suspension 
and colony culture, it was shown that the silver acts as an effective and efficient antimicrobial 
agent against the spreading of MRSA. A similar test, which “delineated the MRSA load on 
the upper side of the dressing and wound bed” every time the dressing was changed, resulted 
in the silver preventing nearly 95% of the MRSA from spreading. Therefore, nanocrystalline 
silver dressings are being looked at even more closely as antimicrobial wound healing agent. 
Not only does it provide safe and effective containment of the bacteria and increased healing, 
but it also provides cost benefits to the healthcare system and even more importantly, to the 
patients. The results of this study may greatly benefit patients in which systemic antibiotics 
often fail to reach secondary infections such as those with diabetes or those with peripheral 
arterial occlusion. Therefore such a dressing may increase the effectiveness of antibiotic 
treatments and reduce therapeutic treatments (Strohal, 2005). 
It is important to note that in all of the studies conducted, MRSA, S. aureus and P. 
aeruginosa strains were not resistant to silver and silver not only has antimicrobial properties 
but also has shown signs of having anti-inflammatory characteristics (Dowsett, 2004).  
2.4 Silver Products 
 
Recently, it has been estimated that the total market for silver dressings is about $40 
million annually. This number is nowhere near as high as the numbers for devices such as 
cardiac stents. However, some of the largest companies in the medical device industry are the 
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ones showing the greatest interest in the wound healing market and therefore the desire for 
silver dressings is on the rise (Kerber, 2005). A study was conducted evaluating the slow 
release silver dressings and the cost involved with daily to weekly dressing changes. This 
study determined that after rats were treated with various dressings, each of the three different 
products of dressings were all equally effective over time. Therefore, each company that 
claims to have the most effective dressing has been proven wrong, that silver itself acts as an 
effective antimicrobial. Consequently, the race to produce the least expensive yet most 
effective dressing is currently in progress (Heggers, 2005). 
2.4.1 Arglaes™ Antimicrobial Silver Barrier 
One of the current wound healing dressings on the market is the Arglaes Antimicrobial 
Silver Barrier. This product uses controlled release of antimicrobial silver to effectively kill a 
wide variety of bacteria and fungi that are commonly found in wounds, as well as to help stop 
the migration of bacteria that already exists. One of the advantages of this design is that it can 
be worn for up to seven days, which reduces the number of dressing changes, minimizing pain 
for the patient upon removal as well as the time necessary for patient care (Medline 
Industries, Inc., 2005).  
The Medline product comes in a film form, which is ideal for managing post-operative 
incisions and donor sites. They have also commercialized a product called the Arglaes™ 
Island, which is beneficial for managing fluid and bioburden. The Island features a calcium 
alginate pad, used for fluid management, along with the controlled release silver. Finally, this 
product comes in a powder form, which can be easily combined with other dressing systems 
for fluid management and bioburden reduction. This is beneficial for wounds that are of any 
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shape or size, especially those that are difficult to bandage as well as grafted wounds 
(Medline Industries, Inc., 2005).  
 
Figure 3: Arglaes Antimicrobial Barrier (Medline Industries, 2005) 
 
The Arglaes Antimicrobial Silver Barrier can be used for pressure, leg, or diabetic foot 
ulcers, partial- and full-thickness wounds, central lines, donor sites, surgical wounds, 
lacerations as well as first and second degree burns. On the other hand, it should not be used 
on third degree burns, as an implant, or on dry wounds as well as those that are covered with 
necrotic, black tissue. The device should also not be used by those that have a known allergy 
to silver or combined with topical antibiotics (Medline Industries, Inc., 2005). 
2.4.2 Silverlon™ 
Another silver wound dressing currently on the market is the Silverlon™ dressing created 
by Argentum. This dressing consists of silver nitrate deposited onto nylon fibers and attached 
to another fiber layer. This dressing is effective in killing wound pathogens, but unfortunately 
the use of silver nitrate causes the patients skin to turn black, which is not aesthetically 
pleasing. Another limitation is that it is hard to control the amount of silver applied as well as 
released from the dressing so it does not deliver a constant level of effective killing (Canada, 
2005). 
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2.4.3. Actisorb Silver 220™ 
 
 Johnson & Johnson’s silver wound dressing is the Actisorb Silver 220™ and it 
contains activated carbon, which is impregnated with metallic silver. This is a highly porous 
bandage constructed from silver-impregnated charcoal cloth sandwiched between two non-
woven nylon layers. This charcoal is beneficial as it absorbs odor in the wound, but it also 
poses a drawback in that it causes the patient’s skin to turn black and over time often leaves 
debris in the wound bed (Thomas, 2002).  
When Actisorb Silver 220™ is placed onto the wound; the dressing adsorbs toxins, 
amines, and fatty acids, which are primarily responsible for the generation of wound odor. 
This dressing attracts bacteria to the surface of the wound, and the silver kills the pathogenic 
organisms. This product is best designed for chronic wounds including fungated lesions, 
faecal fistulae, infected pressure sores, and heavily exuding leg ulcers. Actisorb™ can be very 
beneficial if it is used properly. However, it should not be used on those who have known 
allergies to nylon and should not be used with excess ointment as it can greatly reduce the 
effectiveness of the dressing. Actisorb Silver 220™ can be applied directly to the wound if it 
is appropriate. It can then be covered with a secondary dressing or held in place with a 
bandage or cloth. This Johnson & Johnson product can be worn for up to seven days and the 
outer absorbent layer can be changed as often as needed. For infected or heavy exuding 
wounds, dressing changes may initially need to be more frequent (Thomas, 2002).  
In order to ensure sterility upon use, this product is presented in a peel pouch, which is 
sterilized by gamma irradiation. The combination is produced under carefully controlled 
conditions using heat and a treated fine viscous fabric. Actisorb™ is enclosed in a sleeve, 
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which is composed of non-woven nylon. It is then sealed along each edge to ease handling 
and decrease fiber and particle loss. Therefore, this product should be used in its 
manufactured state and should not cut down to various shapes and sizes (Thomas, 2002).  
Many clinical trials have been conducted to test the efficacy of this product. Test 
results have shown that this dressing is able to kill and inhibit common wound pathogens.  
However, less killing was observed compared to Smith & Nephew’s Acticoat 7™ (Dowsett, 
2004). 
2.4.4 Acticoat 7™ 
 
Acticoat 7™, marketed by Smith & Nephew, is considered by some as the “gold 
standard” of sliver wound dressings (Supp, 2005). The product has been shown in vitro to be 
effective against nearly 150 micro-organisms as well as demonstrated resistance to prevalent 
wound pathogens such as Methicillin Resistant Staphoylococcus aureus (MRSA), 
Pseudomonas aeruginosa, and Enterococcus fecalis to name a few (Smith & Nephew, 2005). 
 
Figure 4: Acticoat 7™ (London Health Sciences Centre, 2001) 
 
This dressing is made up of five layers that are ultrasonically welded together, which 
increases the strength and integrity of the product. The product is marketed in a laminated 
peel pouch, sealed with a cover, and sterilized with gamma irradiation. Two of the layers are 
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fine silver-coated mesh of high-density polyethylene, which surrounds the core layers, which 
are non-woven rayon and polyester. Finally, the innermost portion is another layer of silver-
coated polyethylene mesh. A vapor disposition process is used to apply the silver onto the 
polyethylene mesh, which in turn results in nanocrystalline silver. It is in this form 
(nanocystalline) that silver exhibits its greatest antimicrobial activity against gram-positive 
and gram-negative bacteria as well as yeasts and fungi (Thomas, 2004). 
This product is marketed for partial- and full-thickness wounds such as leg ulcers, 
pressure sores, and various other chronic wounds (Thomas, 2004). The preparation for this 
product is fairly simple – Acticoat 7™ should be moistened with sterile water for 2 minutes to 
activate the dressing. Saline should not be used because it contains chloride ions, which when 
added to silver cause silver chloride to form as well as a white precipitate that can greatly 
affect the efficacy of the sustained silver release of the dressing. By moistening the dressing 
with sterile water, this will allow for a moist wound-healing environment which increases the 
silver’s efficacy. This dressing can be cut to the right shape and size depending on the wound 
(Smith & Nephew, 2005), which is not permitted by Johnson & Johnson’s dressing. However, 
like Actisorb Silver 220™, Acticoat 7™ also needs to be covered with a secondary dressing 
that is appropriate for the wound type. The product can be worn for up to seven days 
depending on how heavily it exudes fluid. Topical antimicrobials and oil-based products 
should not be used with Acticoat 7™, as drying out may occur and then hinder the healing 
process (Thomas, 2004). One of the major benefits of the dressing is that it provides quick 
and immediate effects, which are often within thirty minutes of application (Smith & Nephew, 
2005).  
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One thing that is important to note is that Acticoat™ cannot be used with magnetic 
resonance imaging (MRI) due to silver’s metallic properties. Also, it may promote some 
staining or discoloration of the wound as the silver oxidizes and turns black. This causes no 
harm as even healthy skin may turn brown, yellow, or black where the dressing has 
overlapped. Some patients also experience a stinging sensation upon application (Smith & 
Nephew, 2005). This can be minimized by draining the excess water before placing the 
dressing on the wound site. However, if the patient continues to feel pain, it could be a silver 
allergy or the patient could be experiencing argyria and the use of the product should be 
discontinued.  
This product has been used in a variety of clinical test settings. In a matched-pair 
randomized analysis the ease-of-use, comfort, and antimicrobial efficacy were determined for 
burn patients. The results of the tests demonstrated that the use of Acticoat 7™ resulted in less 
pain as well as easy application. This product kills more rapidly compared to other silver 
wound dressings on the market including Actisorb Silver 220™.  Smith and Nephew’s device 
demonstrated the lowest minimum inhibitory and bactericidal concentrations (Dowsett, 2004). 
It was also determined in clinical tests that this product had the fastest antimicrobial effect in 
an in vivo setting. This is due in part to the sustained release profile used to manufacture the 
dressing as well as the use of a high concentration of silver (Dowsett, 2004).  
2.4.5 Additional Silver Models 
 
 There are quite a few other silver wound healing dressings on the market today. 
However, they are not as widely recognized either due to the size and name of the company 
that created the dressing or the lack of current clinical data.  
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 Aquacel® Ag is composed of Hydrofiber®, which is impregnated with silver. This 
product contains a gel and non-woven pad for fluid management. It can be used for up to one 
week and is beneficial for chronic wounds (Dowsett, 2004). Contreet® is another silver 
dressing that uses ionic silver and polyurethane foam to deliver a controlled release of the 
antimicrobial agent. Like many of the other current models, this dressing can also last for up 
to seven days (Dowsett, 2004).  
2.4.6 Current Model Summary 
 
 Table 1 demonstrates the advantages and disadvantages of the major current silver 
dressings on the market. It is evident that each of the models contains an antimicrobial 
component, which is silver. The other constituents of the dressing include a breathable layer 
for oxygen permeability, a transport layer that holds the antimicrobial, and a final layer for 
fluid management in order to maintain optimal moisture for wound healing.  
 
 
Table 1: Evaluation of Current Silver Wound Dressings 
 Advantages Disadvantages 
Arglaes™ Antimicrobial 
Silver Barrier 
• Controlled release 
• Can be worn for 7 days 
• Good for donor sites, 1st 
and 2nd  degree burns, 
chronic wounds 
• Not applicable for 3rd degree burns 
• Not good for dry wounds or those 
with necrotic tissue 
Silverlon™ • Effective in killing a 
variety of wound 
pathogens 
• Silver nitrate turns skin 
brown/black 
• Cannot control amount of silver 
released. Therefore not a constant 
level of effective killing 
Actisorb Silver 220™ • Highly porous 
• Odor reducer 
• Good for chronic wounds 
• Can be worn for 7 days 
• Turns skin black 
• Nylon can cause allergic reaction 
• Cannot be cut to size or shape 
Acticoat 7™ • Effective against 150+ 
micro-organisms 
• Cannot be used with saline 
• Cannot be use with MRI 
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• Good for partial and full-
thickness wounds 
• Easy to prepare  
• Can be cut into proper 
shape and size 
• Can be worn for 7 days 
• Quick effects within 30 
minutes 
• Turns skin black 
• Can cause stinging sensation 
 
 
Although many of the current silver dressings on the market are thriving, there is still 
some concern from the individuals using and prescribing these products (See Appendix A). 
Therefore, there is a strong need to identify these drawbacks and further improve upon the 
current technology (Dunn, 2005). 
2.5 Essential Oils 
 
Over the past several years, essential oils have become popular in various applications. 
Essential oils are extracted from different varieties of plants and are known for their broad 
antimicrobial properties (Burt, 2004; Ostroff, 2005). They have been extracted from familiar 
plants such as oregano, lemongrass and thyme, to name a few. These oils, containing terpenes, 
are non-toxic because of their organic nature (Ostroff, 2005) and are present in the plants 
natural environment as a defense mechanism against bacteria and fungi (Llusia, 2000). 
Essential oils are affected by their environment as decreased temperature, pH and oxygen 
levels allow for improved antimicrobial response (Burt, 2004). 
Overall, over ninety-seven plant oils have been reported and many more are still being 
discovered. The effectiveness of the compounds is tested through a series of in vitro assays 
which yield a number known as the minimum inhibitory concentration (MIC). This is the 
lowest concentration where the active (i.e. terpene) is able to achieve growth inhibition of the 
pathogen it is being testing against such as Staphylococcus aureus (Mann, 1997). This 
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primary assay is often followed by another series of antimicrobial assays to measure the 
actual percent of pathogenic kill in the MIC concentration. In a study conducted in Australia 
with 52 essential oils, only three formulations were proven to be effective against inhibiting 
P. aeruginosa while 40 terpenes inhibited the growth of Candida albicans and 
Staphylococcus aureus. The latter pathogens were proven to be the most vulnerable to these 
antimicrobial oils in the primary assays (Hammer et al., 1999).  
Another study was completed analyzing the antimicrobial properties of essential oils 
against Listeria monocytogenes, Salmonella typhimurium, Escherichia coli 0157:H7, Shigella 
dysenteria, Bacillus cereus, and Staphylococcus aureus. Here it was shown that the gram-
negative organisms are less susceptible to antimicrobial killing by essential oils than gram-
positive bacteria. In these assays, the effective minimum inhibitory concentrations (MIC) 
varied between 0.05-5 microliters in vitro. In food applications, the effective concentration is 
higher, at 0.5-20 microliters. Essential oils target the bacterial cell and their hydrophobic 
nature attacks the cell contents and makes cell membranes and mitochondria permeable (Burt, 
2004). Since these oils are hydrophobic they can be encapsulated to make them easier to 
handle, as well as to allow them to solubilize in solution and provide a sustained release 
(Bishop, 1998). For example, Eden Research plc, has developed a technology of 
encapsulating the oils into the membrane of a yeast particle which does not effect the 
antimicrobial activity of the oils as they are still effective in inhibiting pathogenic growth 
(Ostroff, 2005).  
One essential oil that has been used in many burn wound healing applications is 
Thymus oil from a thyme plant. Often burn wounds emit concentrations of nitric oxide which 
not only leads to thrombosis but also to other physiological effects. A study was done 
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submitting 5 different groups of rats to a burn and treating them with silver sulfadiazine, 
thymus oil, olive oil, and silverdine. Rats treated with thymus oil and silver sulfadizine were 
most promising as thymus oil protected the tissues from reaching harmful nitric oxide levels 
(Dursan et al., 2003). 
Essential oils are also effective in flavorings and odor emissions. For example, thymol 
is also effective in reducing unpleasant odor, along with carvacrol as shown through livestock 
wastes in agricultural applications. Fermentation of waste excreted from cattle was observed 
in a flask and 1 g of both carvacrol and thymol were added to determine the control of odor 
emissions. This combination of terpene was extremely effective in reducing odor from 
livestock waste (Varel, 2001). This consideration of is also important to wound healing, as 
many wounds and burns exude odors due to bacterial infection or burnt skin, respectively.  
The uses and applications of essential oils are endless as their major applications are in 
agriculture, food borne pathogens, and oral health, amongst others. Terpene antimicrobial 
activity is promising in effectiveness and in its low cost for treatments in the wound healing 
market. 
2.6 Animal Models 
 
A number of wound healing animal models have been used to test the effect of 
antimicrobial wound dressings. These in vivo studies often follow in vitro experiments and 
test the validity and effectiveness of the dressings. 
 Various companies such as Jackson Laboratories and Charles River Laboratory are 
popular suppliers of animals used in animal models. They can be custom ordered to suit the 
experiment. Animal models can be ordered with medical devices or procedures being 
performed, such as castration, removal of the thyroid gland etc., depending on the necessary 
   39
protocol. Other models available are those ordered already infected with certain strains of 
bacteria such as S. aureus (Charles River, 2005).  
Another consideration is nude mice which have a knocked out immune system, absent 
of antibodies. Oftentimes a common type of mouse is the F1 generation hybrid mouse. These 
mice are advantageous in that they are identical in genetics and phenotype; they also have a 
higher longevity and higher survival under stress as well as are known for their larger litters. 
This model is often extremely beneficial in serving as a host for tissue transplants for their 
parent strains. The F2 generation has more genetic mutations and targeted knockout genes and 
most of them are only similar in genetics, but not identical. Therefore, this constant genetic 
makeup serves as another control in the experiment (Jackson Laboratories, 2005). 
 Currently a project is underway at Tufts studying the cellulitis model of S. aureus in 
hairless mice. The cellulitis form is first cultured as normal, washed/spun with phosphate 
buffered saline (PBS) and then beads are added to this culture. This is then injected between 
the skin and the muscle in the mouse and creates a localized wound once infused into the 
tissue. 
 Another study was completed to observe cultured skin substitutes using athymic mice 
and infected wounds inoculated with P. aeruginosa at 1*105 cfu/wound. This wound was then 
tested in collaboration with Acticoat™ to validate its effectiveness (Supp, 2005).  
Accurate wound healing models have been hard to come by as there are many 
regulations and ethical reasons behind the concept. The most accurate wound model to date is 
in swine as their morphology and functions of their skin are most comparable to that of 
human skin (Singer et al, 2000). Swine have been widely used as wound healing models also 
due to their ability to allow for various studies on multiple sites of their skin rather than only 
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one model having one wound site. The porcine model also reduces variation as it is one 
animal receiving different treatments, rather than a series of models receiving different 
treatments which leads to variation between animals as each are genetically different (Olson, 
2000). Usually smaller animals such as rat and mice are used as the initial experiment, and 
then once the proof of concept is shown in small in vivo models, then a larger model can be 
implemented, and if all goes well, then humans are the next step. 
 A key factor in wound healing models is the type of wound that is formed on the 
animal. In severe wounds such as burns, the graft site to culture new skin is often an area 
which potentially experiences delays in wound healing, and can even be deadly for the patient 
(Olson, 2000). Graft sites were made on the abdomen and thorax of six pathogen-free pigs 
and 72 same size wounds were created using an etched grid. This experiment allowed for 
three different treatment groups on each pig and all pigs were clinically monitored for 
evidence of infection and dressing moistness. Therefore, this extensive study was conducted 
over a period of 10 days and only six pigs needed to be evaluated. If a smaller animal model 
had been chosen, it would have required more attention per mouse and the amount of wounds 
would have had to be dramatically decreased to a smaller number of mice as each mouse can 
only contain one wound. From this porcine study, scientists were able to correlate that the 
healing time in the animal model will be similar to that of human models. The dressings tested 
in this study have reduced concerns of the physicians as they have provided an ideal healing 
environment for donor sites (Olson, 2000). 
 Another of many porcine studies used a 2.5 cm by 2.5 cm burn site for the wound 
application to pigs to analyze the wound healing with a various occlusive dressings. Again, a 
small number of animals were needed, as this study only used 2 and the scientists were able to 
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create four identical sets of 20 burns on each pig. Again, the scientists were able to run the 
experiment against various treatments yet keeping the animal constant to reduce variation. 
Interestingly, the choice of a porcine model in the use of studying burn wounds is limited to 
the actual wound response as pigs do not form blisters. Therefore, with this data, it is hard to 
correlate the burn site with that of humans, as in most cases severe burns do form a blister as a 
wound response (Singer et al, 2000).  
 Again, wound healing models vary not only in animal, but also in metrics used to 
assess the animal, the wound site, and the effect of the treatment. In smaller individual rodent 
models, it is easier to assess different parameters of the wound. For example, in a rat model, 
different cross-linking agents in a hydrogel dressing were measured using parameters such as 
mechanical properties, water-vapor-transmission, swelling, degradation against 
enzymatic/cellular agents, and inflammatory reactions (Chang, 2003). The latter parameters 
would be more difficult to measure in larger animals as there would be many parameters that 
are different per wound that cannot be measured if they are all on one animal. 
 On average it takes between 3 months and one year to get a protocol submitted and 
approved for testing. Therefore, we looked into various protocols that had already been 
approved in hopes to work off of theirs after brief modifications. We were able to discover 
many wound experts and ones who had published animal data from the 2000 to present and 
were within the United States (see Appendix FF). One of the most prominent names is Dr. 
Michael Hamblin of Mass General Hospital. Upon contact, he agreed to collaborate with us in 
using his protocol and his laboratory to perform an in vivo wound healing experiment. Dr. 
Hamblin’s research is focused on the new field of Photodynamic Therapy (PDT). PDT is 
where a dye is combined with light in an oxygenated environment to kill harmful human cells 
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and pathogens. This light treatment targets lysosomes, mitochondria and the plasma 
membrane in mammalian cells as a site for photodynamic inactivation in cells such as 
cancerous growths (PDI). Gram positive bacteria have been proven to be more affected by the 
treatment in comparison to Gram negative bacteria. There is no proven explanation for this 
reaction, however it is proposed that the differences include membrane permeability barriers, 
enzyme and cell size (Hamblin, 2004).  
In Hamblin’s model, bacteria used in PDT are also genetically altered with a lux 
flouresecent gene plasmid to allow for the cells to be viewed by a biolouminescent charge-
coupled device camera (CCD) (Hamblin et al, 2003). The lux gene is found naturally in many 
aquatic mammals and consists of luciferase. Bacterial luciferase uses oxygen and long-chain 
fatty proteins to produce blue-green light (max emission at 490nm) (Eckstein et al, 1990). The 
lux operon used in these experiments originates from P.luminescens in the prescence of 
mamammalian animal models and is usually present in the form lux CDABE (Demidova, 
2005). However, in studying a Gram-positive strain of S. aureus, the lux gene order is altered 
for stability to lux ABCDE. The infected animal is then imaged in the CCD camera, which 
consists of a light-tight chamber where the animal remains stationary on a stand and the CCD 
camera detects the light emitted from the mouse and a computer connection obtains the image 
and analyzes the data. A grayscale image is obtained after a few seconds, and after a two 
minute reading, the bioluminescent signal is read from the wound. This color image is 
superimposed onto the grayscale image and then the magnitude of the regions intensity is read 
using an area function (Demidova, 2005).  
The use of PDT is only used for localized infections due to its targeted light delivery; 
however, burns, infected wounds and tissue infections were studied in BALB/c mice to prove 
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the positive effect of this treatment (Hamblin, 2004). In Dr. Hamblin’s initial PDT application 
he proved that S. aureus is dramatically decreased with this treatment. Dr. Hamblin and his 
research team also completed a study to treat P. aeruginosa infeceted wounds as it was 
topically applied to the wound and followed by illumination. Here treatment was extremely 
successful as all of the control mice died after 5 days, and 90% of the PDT-treatment mice 
survived. Therefore, the PDT-treatment surpassed the control silver nitrate treatment in 
enhancing wound healing. 
2.7 Material Requirements 
There are many aspects that need to be carefully considered when trying to create an ideal 
wound dressing. Some of these features have been tested at Instron ® Corporation (Appendix 
R and S) to provide us a better understanding of the current products on the market. The 
dressing must provide bacterial and mechanical protection as well as maintain the proper 
moisture at the interface between the wound and the dressing (Hom, 1999). Therefore the 
device must promote fluid and gaseous exchange. A wound with excessive amount of fluid 
can hinder the wound healing process by providing an environment that is too moist and also 
ideal for bacterial replication. On the other hand, a dry wound can result in painful cracking 
and bleeding in the wound bed (Harding, 2002).  
Management of an exuding wound is a key in the design of a proper dressing. For 
example, if necrotic tissue reaches a mushy, liquid-like state, the wound exudate level will 
increase. Therefore, it is important that the dressing have good fluid retention and absorptive 
properties while remaining non-adherent to the wound in a normal environment as well as 
under pressure. If the dressing is suited for and can withstand many everyday situations, cost 
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can be improved because wear time will increase due to better protection of the wound (Hom, 
1999; Harding, 2002). 
Other keys to creating a wound dressing include safety and patient acceptability. The 
device must be sterile, non-allergic, non-toxic, and non-sensitizing to the patient as well as the 
medical attendant. To satisfy the needs of the patient, the device should provide pain relief 
and absorb wound odor. Many patients have stated that the healing process can be decreased 
if the wound smells foul due to bacterial growth or if the dressing causes skin staining             
(Holloway, 2002). Finally, the dressing should be easy to use so that it can be quickly applied 
by medical personnel, should not require frequent removal, it should be available in a variety 
of shapes and sizes to cover a broad range of wounds and areas of the body, and it should be 
covered under health insurance, and therefore must be cost effective (Hom, 1999). 
2.7.1 Lyophilization 
 In order to improve the mechanical properties of the certain materials, they are often 
lyophilized or freeze dried, a method is currently used to fabricate collagen scaffolds 
(O’Brien, 2004). Freeze-drying was approved by the FDA in 1996 as a means of creating 
dermal substitutes for burn patients (O’Brien, 2004). The technique results in a highly porous 
hydrocolloid sponge and is beneficial as it allows for a more homogeneous scaffold, gel, or 
hydrocolloid to be fabricated while generating less deviation in pore size throughout the 
structure.  The pore size is determined by the rate at which the network is cooled and can 
therefore be customized according to what material properties one desires (O’Brien, 2002).  
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2.8 Wound Dressing Categories  
 In the United States alone, there are nearly twenty different types of material 
categories for wound dressings (Ruszczak, 2004). Table 2, shown below demonstrates the 
some of the number and variety of dressing categories currently in the United States. 
Table 2: Current Material Categories for Wound Dressings in the US    
(Ruszczak, 2004). 
 Wound 
Dressings 
(Material Categories) 
No. 
Products 
Gauzes (woven and 
nonwoven) 33 
Gauzes (impregnated) 25 
Gauzes (nonadherent) 13 
Gauzes 
(packing/debriding) 17 
Compression bandages 
and system 24 
Specialty absorptives 17 
Composites 20 
Wound fillers 10 
Wound cleansers 28 
Synthetic foams 26 
Contact layers 7 
Hydrocolloids 41 
Hydrogels (amorphous) 30 
Hydrogels (wafers) 19 
Hydrogels (impregnated 
gauze) 14 
Alginates 26 
Collagen 9 
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2.8.1 Tissue Adhesives (Incisional) 
 Tissue adhesives are a painless way of closing incisional wounds for up to seven days, 
which might otherwise require stitches or staples. Products of this nature are usually liquid 
bandages that contain cyanoacrylate derivatives such as enbucrilate, bucrylate, and mecrylate. 
When in contact with a fluid, the materials react exothermically to polymerize. The 
polymerization results in a flexible, sturdy, water resistant adhesive. However, the special 
care is necessary to ensure that none of the adhesive diffuses past the wound borders. Also, 
tissue adhesives are only good for minor lacerations and cannot be used for chronic wounds or 
those that exude fluids (Reece, 2001). Therefore, the use of tissue adhesives would not allow 
us to enhance the current silver wound dressing market.  
 
2.8.2 Silicones 
 
 Silicones are one type of dressing which is biologically and chemically inert so that an 
immune response is not induced.  They are primarily composed of cross-linked polymers that 
are then reinforced with a mesh or fabric (Kestrel Health Information., 2005). This material 
can be porous or non-permeable and is manufactured as sheets or gels that work as non-
adhesives. Silicones can reduce scar tissue as well as scar discoloration by flattening the tissue 
and increasing its elastic properties. This material is beneficial for incisional wounds and can 
be used in conjunction with skin substitutes (Reece, 2001). 
2.8.3 Barrier Films 
Barrier films are versatile in that they can be applied as a fluid and then polymerize 
into a film. These are mostly comprised of polyurethane or polylactate and provide protection 
for the wound from moisture that can cause loosening of the dressing as well as cause new 
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tissue from stripping. Barrier films are considered non-cytotoxic and provide some pain relief 
(Hom, 1999). 
2.8.4 Foams 
 Foams are used in some of the less notable current silver models including Contreet®. 
Polyurethane porous sponges are the key component of this material. The sponges have small 
openings and allow this material to retain fluid. Foams can be easily compliant with other 
materials and are considered the most adaptable dressings out of others on the market. The 
outer layer acts as a barrier to microbes and is beneficial for both partial- and full-thickness 
wounds and is usually waterproof (Worley, 2005). Adhesive borders are an option for this 
material or it can be transparent (Kestrel Health Information., 2005). This material is 
absorbent and can used on many types of wounds. Foams can provide some cushioning, 
which is beneficial for certain areas of the body such as the back and the buttocks. Finally, 
this material is available in nearly every shape and size so it can accommodate many wound 
types (Worley, 2005). 
 However, some foams may require a secondary dressing and cannot be used on dry 
wounds, as the wound healing process may become inhibited and the risk of infection may 
increase. If foams are cut to a desired shape and size, there is an increased chance that the 
material may lose its barrier properties. For proper adhesion, foams require 0.5 inches to 1 
inch overlap onto intact skin. This could potentially be a problem for burn victims who may 
not have viable skin for this product as well as the fact that most foams have strong adhesive 
properties and should not be used on weak or damaged skin (Hom, 1999). 
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2.8.5 Gauze (Impregnated and Non-impregnated) 
  Gauze dressings are the most widely used dressings in wound care due to their 
practical cost and wide variety of shapes and sizes. They manage fluid by capillary action and 
dressings of this nature can be packaged as a roll, strip, ribbon, or pad. These dressings can be 
separated into woven or non-woven categories and their absorbency depends on thickness as 
well as composition (Kestrel Health Information., 2005). Usually this material is composed of 
cotton, rayon, polyester, or cellulose as well as other materials. However, cotton is not used as 
often as some of the other materials due to the increased cost effectiveness of synthetic fibers. 
Gauze ranges in use from cleansing, wiping, absorbing, and protecting new skin formation. 
Gauze has the option of being impregnated with other materials such as saline, hydrogels, and 
antimicrobial agents. There is also a category of “smart” gauze that is non-adherent to the 
wound bed (Worley, 2005). 
 Although gauze is widely used, it does not provide the best wound healing 
environment even if the material is moist. Oftentimes the dressing dries out and even if it is 
remoistened, pain and damage can result when the dressing is removed. Gauze also lacks in 
thermal insulation and requires numerous dressing changes compared to new products on the 
market. Furthermore, there are advantages and disadvantages to using either woven or non-
woven fibers. Woven gauze products are more absorbent than non-woven materials but there 
is more of a chance for the fibers to migrate into the wound. On the other hand, non-woven 
fibers have less of a chance of irritating the wound but unfortunately they retain less wound 
fluid (Worley, 2005). 
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2.8.6 Hydrogels  
 Hydrogels come in many forms including amorphous, impregnated, and sheets 
(Kestrel Health Information., 2005). Amorphous hydrogels lack a concrete shape and are 
made up of polymers and water as well as other additives including collagen, aloe vera, and 
alginates. This type of hydrogel does not contain cross-linked fibers unlike some of the other 
forms (Worley, 2005). The primary role of an amorphous hydrogels is to maintain a moist 
healing environment for the wound and to rehydrate the wound if it were to become dry. In 
this form, the hydrogel is beneficial for both partial- and full-thickness wounds. In addition an 
amorphous hydrogel can be converted into the impregnated form by saturating non-woven 
sponges as well as gauzes with an amorphous hydrogel (Kestrel Health Information., 2005). 
 Hydrogel sheets use cross-linking to create three-dimensional networks. They are 
mostly comprised of water in a bioinert matrix (Worley, 2005) along with hydrophilic 
polymers, which are not soluble in water but rather swell in the presence of aqueous solutions. 
Hydrogel sheets are beneficial to patients who suffer from partial- and full-thickness wounds 
in that the dressing is comfortable, porous, absorptive, and can easily be removed (Kestrel 
Health Information., 2005). 
 In general, hydrogels have natural adhesive properties, which allow them be secured 
with tape alone which makes this type of dressing easy to use by most caregivers. As 
previously mentioned, hydrogels come in a variety of forms depending on the use and 
preference and all forms cool and soothe almost immediately when in contact with the wound 
(Worley, 2005). In a sense, hydrogels can be considered ideal for a wound dressing since they 
can be used throughout all stages of wound healing because they maintain a moist 
environment and reduce pain through cooling the wound site upon application (Hom, 1999).    
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 Hydrogels also have some disadvantages in that they cannot be used on wounds that 
exude heavily or those that are infected as maceration of the skin is a risk especially in the 
healing skin surrounding the wound (Hom 1999; Worley, 2005). When using an amorphous 
hydrogel, it should be noted that the dressing can become decreasingly viscous as the gel 
moves to equilibrium with body temperature (Worley, 2005). 
2.8.7 Hydrocolloids  
 Hydrocolloids first became commercially available in the early 1980s (Worley, 2005) 
and were much more complex compared to hydrogels due to their increased number of 
elements including pectin, gelatin, adhesives, polymers, polyisobutylene, 
carboxymethylcellulose (CMC), and alginate (Hom, 1999; Worley, 2005). They are 
considered “interactive dressings” because they change in physical state as fluids are slowly 
absorbed by particle swelling, which results in a soft gel forming on the wound bed that can 
decrease pain (Hom, 1999; Worley, 2005). It is hypothesized by some experts that the 
resulting gel contains natural growth factors and also allows for bacterial growth inhibition 
(Worley, 2005). 
 There are many advantages to using a hydrocolloid in a wound dressing. 
Hydrocolloids are available in many shapes and sizes as well as gels, fibers, sheets, powders, 
and pastes (Worley, 2005) and are therefore beneficial for wounds that are in a unique shape 
and form (Kestrel Health Information., 2005). Also, they come in a variety of thicknesses 
which is directly related to the fluid management of the material (Kestrel Health Information., 
2005). Some hydrocolloids are manufactured with tapered edges to decrease the chance of 
rolling, while others can be produced with an adhesive outer dressing that can act as a barrier 
against bacterium as well as against fluids from the external environment (Worley, 2005). 
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Hydrocolloids maintain a moist environment, which promotes wound healing and can be used 
on both acute and chronic wounds (Hom, 1999). 
 On the other hand, hydrocolloids are not recommended for use on infected wounds 
and almost always require a secondary dressing (Hom, 1999) even though their adhesives are 
stronger compared to other dressings (Worley, 2005). Additionally, hydrocolloids initially 
need to be changed frequently until the exudate levels are low enough so that the dressing can 
be left on for seven days. Due to the fact that frequent dressing changes are an option, it is 
also possible that the underlying would bed could be damaged more easily due to the stronger 
adhesives and increased dressing changes (Worley, 2005). Finally, a healthy wound can be 
mistaken for an infected wound when using a hydrocolloid since they emit a natural odor, 
which is comparable to an infected wound odor if the dressing comes in contact with certain 
proteins in the wound fluid (Worley, 2005). Therefore, it is important to use other means of 
characterizing a wound as healthy or infected when using a hydrocolloid dressing. 
Hydrocolloids are one of the most widely used types of wound dressings today. They 
have not been known to cause any adverse side effects or allergic reactions and are easy to 
use. Most only require changing every 3-5 days and they do not disturb the wound bed when 
removed (Thomas, 1992). Hydrocolloids are therefore advantageous as they cut down on the 
cost of materials and on nurse care by reduced dressing changes since they successfully heal 
the wound after a few dressing changes (Kim, 1996). Easy removal allows for a less painful 
treatment as well as one for a diverse application of severe wound types and burns. One of 
their early applications that is still used today is to apply a hydrocolloid to a wound bed 
undergoing maggot therapy. Maggots require oxygen, and also need a barrier to keep them in 
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the wound and hydrocolloids have been proven effective in providing a healthy environment 
for both the maggots and the wound (Sherman, 1997).  
 Hydrocolloids are currently in competition with new dressing formulations known as 
“hydropolymer” dressings. These new dressings are favorable in the aspects of reduced 
dressing leakage and reduced odor characteristics as compared with traditional hydrocolloid 
dressings. However, both dressings were tested in diabetic leg ulcer wound and both were 
equally effective in wound healing (Thomas, et al, 1997). 
2.8.8 Carboxymethylcellulose 
A common material used in synthesizing a hydrocolloid is carboxymethylcellulose 
(CMC) which is prevalent in wound dressings and in food applications. CMC is considered to 
be water soluble which means it dissolves in water, so in most applications the CMC requires 
a cross-linking agent to stabilize the gel. A few other additions to CMC have been 
polyacrylamide gels, chitin, chitosan, copolymers and mixtures of these various cross-linkers 
(Queen, et al, 1996). On average these cross-linking agents are added between the ranges of 
0.01% of weight to 20% of weight.  
Sodium Carboxymethylcellulose often requires the addition of a plasticizer to stabilize 
the gel and make it less brittle, therefore propylene glycol and pectin can be used towards this 
application. Glycerol can also be substituted in a volume of 7% of the total weight (Barnes et 
al, 2005). We must keep in mind that the main component of the gel must be water, and it 
should be at least 70% of the formulation. Many of these gels can be sterilized by wet heat in 
tubes before they are poured into their casting trays or onto the wound site. These 
hydrocolloid formulations on average swell 10 grams of liquid per gram of hydrocolloid foam 
(Qin et al, 1999). 
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 Since hydrocolloids have a wide variety of applications, they must not interfere with 
the bodys natural functions. For example, some CMC gels are particularly effective in 
applications to the eye, where this area is usually very sensitive to outside materials (Cini et 
al, 1995). Therefore, it is important our hydrocolloid has a neutral pH and is not acidic as it is 
packed into many wound sites (Qin et al, 1999). Oftentimes, human growth factors may also 
be incorporated into the formulation which allows for more stability in a moist environment, 
more biocompatibility, and also adheres better to contoured wounds (Cini et al, 1995). 
2.8.9 Alginates  
 Natural polysaccharide fibers derived from seaweed are the primary constituent of 
alginate dressings. They also contain the primary structure of guluronic (G) and mannuronic 
(M) acid. G alginates are more secure and therefore rope or ribbon-like. On the other hand, M 
alginates are in a gel form and are soft. In turn, these dressings are produced as non-woven, 
non-adhesive pads or ribbons (Hom, 1999).  
Alginates are characterized by having biodegradable and highly absorbent properties 
(Hom, 1999). By using a process called ion exchange, the dressing forms a moist gel when it 
comes in contact with the wound exudate (Kestrel Health Information., 2005), which 
minimizes the chance of bacterial contamination and wound discharge (Heenan, 1998). 
Therefore, the dressing should be dry prior to its application (FMC Corporation, 2005). By 
chemical ion exchange, alginates not only control the amount of fluid in the wound but there 
has also been evidence to support a bioactive effect by triggering macrophages, which in turn 
increase wound healing (Hom, 1999).  
In the past few years, alginates have become one increasingly popular as wound 
dressings as they are manufactured as sheets and cavity dressings (FMC Corporation, 2005), 
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and they are soft and easy to shape, as well as easily manipulated for non-uniform wounds 
(Kestrel Health Information., 2005). Alginates can be used on wounds with heavy exudate 
(Kestrel Health Information., 2005) as well as surgical wounds and have shown to be less 
likely to encounter a microbial attack compared to other various carbohydrates (FMC 
Corporation, 2005). 
One study set out to compare calcium alginate dressings with conventional gauze 
dressings in a controlled, randomized setting. Thirty-four patients with abscess cavities were 
analyzed and the results were quite promising. Not only were the calcium alginate dressings 
easier to remove than the gauze dressings, but they also decreased the overall pain 
experienced by the patient (National Prescribing Centre, 1999). In a similar study, ninety-two 
patients with pressure ulcers were observed to compare calcium alginate dressings to 
dextranomer paste, which serves as a wound healing paste. The test was conducted over an 
eight week period and the results showed that significantly more patients with the calcium 
alginate experienced a decrease in wound area and increased healing rates compared to the 
paste group (National Prescribing Centre, 1999). 
Like all wound components, alginates have their drawbacks. Most alginates must be 
used in conjunction with a secondary dressing, which can add to the complexity of the overall 
device (Kestrel Health Information., 2005). In addition, alginate dressings should not be used 
on dry or infected wounds (Hom, 1999). Also, there are many forms of alginate and each type 
has its own unique properties making the proper choice of alginate a hard decision to make 
(FMC Corporation, 2005). 
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2.9 Material Description 
The materials that were described in the previous sections have different advantages 
and disadvantages when used in wound healing dressings.  Each material’s evaluation was 
used later in the design process to determine the best material for each layer of the dressing.  
Table 3 below describes the advantages and disadvantages of materials that are currently used 
in various wound healing dressings. 
 
 
Table 3: Advantages/ Disadvantages of Material 
 
Detailed Description of 
Materials 
Advantages Disadvantages 
Hydrogels (Kestrel Health 
Information., 2005; Worley, 
2005) 
 
• SPENCO 2nd skin moist gel 
pad 
• Mueller More Skin 
• 3M Tegaderm Wound filler 
• Water based, can activate 
antimicrobials 
• Can be impregnated 
• Natural adhesive 
• Good for wound hydration 
• Absorption properties 
• Easy to use and apply 
• Cooling and soothing 
properties 
• Sterile  
• Good for partial and full-
thickness wounds 
• Variety of forms 
• Not good for heavily exuding 
wounds 
• If in the amorphous form, 
gels decreases in viscosity at 
body temperature 
Hydrocolloids (Kestrel Health 
Information., 2005; Worley, 
2005) 
 
• DuoDerm CGF 
• 3M Tegasorb Hydrocolloid 
Dressing 
• CMC 
• Drainage control 
• As it absorbs, matrix forms 
soft gel over wound 
• Gel contains natural growth 
factors 
• Can include outer layer for 
bacterial and viral barrier 
• Available in many forms, 
shapes, and sizes 
• Good for moderate amounts 
of exudate 
• Some have tapered edges to 
prevent rolling 
• Good external barrier 
properties 
• Strong adhesive can damage 
skin 
• Natural smell when in 
contact with certain proteins 
can be misleading that an 
infection is present 
• Not to be used on infected 
wounds 
Foams  (Kestrel Health 
Information., 2005; Worley, 
2005) 
 
 
• Porous 
• Drain wound while keeping 
it moist 
• May have adhesive 
component 
• Cannot be used on dry 
wounds 
• Needs 0.5” to 1” of intact 
skin for adhesion 
• Barrier properties can 
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• Polyurethane Foam 
• 3M Foam Dressing 
• Outer layer normally 
waterproof and is a barrier 
against microbes 
• Very adaptable 
• Can provide cushioning 
• Good for a variety of wound 
types 
• Comes in many shapes and 
sizes  
decrease if cut 
• Some may have strong 
adhesives that can damage 
fragile skin or stick to the 
wound bed 
Alginate (Heenan, 1998; Hom, 
1999; National Prescribing 
Centre, 1999; FMC Corporation, 
2005;Kestrel Health Information., 
2005) 
 
 
• Calcium Alginate 
 
 
  
• Controls amount of fluids 
• Triggers macrophages 
• Soft 
• Easy to shape 
• Good for wounds that need 
contouring 
• Good for surgical and 
wounds with heavy exudates 
• Least likely to undergo 
microbial attack compared to 
other carbohydrates 
• Decreases pain 
• Decreases wound healing 
time 
• Needs secondary dressing 
• Not to be used on dry or 
infected wounds 
• Many types with many 
properties: not all suitable for 
wound dressings 
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3. Approach 
 
 Once the background research is completed and evaluated, the design team can 
concentrate on the specifics of the project.  The steps that first must be taken are to define the 
project hypothesis, assumptions and aims.  These definitions identify the project objectives 
and anticipated outcomes of the design.  
3.1 Project Hypothesis 
 
 The objective of this project is to develop an antimicrobial wound dressing that will 
inhibit and kill the growth of wound pathogens using a combination of silver and essential 
oils.  The current wound dressings approved by the Food and Drug Administration (FDA) 
have various forms of silver incorporated in their design.  However, there are no current 
wound dressings that include a combination of silver and essential oils as the active 
antimicrobial agents.  The current silver dressings are expensive and are limited by their 
microbial resistance in that they do not inhibit the growth of all wound pathogens. 
 The hypothesis of the design is that the combination of silver and essential oils will 
increase the efficacy of the antimicrobial property of the dressing while decreasing the overall 
cost.  The combination is hypothesized to be effective against a broader range of wound 
pathogens and overall becoming more effective than the current silver wound dressings.   
3.2 Project Assumptions 
 
The project hypothesis indicates that the design of a silver and essential oils 
combination wound dressing will increase the efficacy of the antimicrobial properties and 
eliminate wound pathogen replication in a shorter time period than the current silver wound 
dressings.  However, some assumptions must first be made: 
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• Dressing will only be tested against three chosen wound pathogens 
• The efficacy of both silver and terpene can be predicted through supporting data 
from in vitro assays 
• Silver chloride is insoluble and may form a white precipitate yet provide 
effective antimicrobial properties 
• Silver will be effective in becoming encapsulated in the terpene combination 
• Eugenol and Thymol (ET) are an effective terpene combination for inhibiting 
growth of a broad range of wound pathogens 
3.3 Project Aims and Specification 
 The goal of this project is to develop the described antimicrobial wound dressing 
which is more effective and less expensive than current available silver wound dressings. The 
specific aims of this project include: 
• To produce a silver and essential oil combination that is effective against a broad 
range of wound pathogens. 
• To increase the wound healing process in infected wounds. 
• To eliminate pain and odor from the wound. 
• To create a wound dressing using materials that have similar mechanical 
properties and flexibility of the skin. 
• To develop an antimicrobial dressing whose cost is equivalent or less than 
current silver wound dressings. 
• To generate and conduct analysis to assess the hypothesis. 
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4.  Design 
 
 Before we began designing the anti-microbial wound dressing, we needed to identify 
the objectives of each stakeholder involved in the project.  The major stakeholders include the 
designers (students), Eden Research plc (Kerry Walker and Gary Ostroff), the user (doctors, 
registered nurses and patients), and also insurance companies.   
 We used a design process to create a revised client statement that would provide a 
solution to the objectives and constraints identified by the stakeholders.  The initial problem 
statement provided to the design team is listed below: 
 
Design and develop an implantable bandage that inhibits microbial infection. 
 
This statement was vague and the objectives needed to be more concise and clearly 
defined.  The design team revised the statement after discussing with each stakeholder their 
desires and constraints of the project in order to develop a clear and focused client statement.   
To gain a broad understanding of the basis of our objectives, we researched current 
wound dressing models and evaluated the functions and limitations of each design (Chapter 
2).  We also gained information from interviews with each of our clients.  For each 
stakeholder, we began by first discussing their desired objectives and functions for the wound 
dressing.  However, we needed to quantify the desires of the stakeholders so we could 
integrate their weighted goals into our Revised Client Statement.   
4.1 Clarification of Design Goals 
 
This section describes the different design techniques we used to develop our Revised 
Client Statement.  This process began with a brainstorming session, which led to the creation 
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of a Pairwise Comparison Chart completed by each stakeholder.  Several steps followed the 
comparison chart which led us to our Revised Statement.  
4.1.1 Brainstorming Functions, Objectives, Constraints 
 
 The first task we had to complete was to clearly and qualitatively determine the 
requirements of the project.  After interviews with the stakeholders and current product 
research, the project team was able to generate the overall project goals.  The functions of the 
device were established along with the objectives, and constraints of the product.  The general 
goals of the project are listed in the table below. 
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Figure 5: Overall List of Project Goals 
  
The project goals were differentiated between objectives, functions, and constraints 
and labeled as such.  An indented objectives, functions, and constraints list was created and is 
illustrated below (Figure 6). 
 
ANTI-MICROBIAL 
o Inhibits growth/ kills wound pathogens 
o Decreases wound healing time 
 
SAFETY OF DEVICE 
o Meets FDA standards 
o Does not hinder healing process 
 
COST OF DEVICE 
o Costs less than current silver wound dressings 
 
EXPANDABLE 
o Can be used with other antibiotics/medicines 
 
ALTERABLE 
o Change size depending on wound dimensions 
 
FLEXIBLE 
o Similar properties to skin 
o Strong in flexure 
 
EASY TO APPLY/REMOVE 
o Sterilized and packaged 
o Removal does not damage healing tissue 
 
RELIABLE 
o Quick response system on contact 
o Minimize dressing changes 
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Figure 6: Indented Objectives, Functions, and Constraints List 
 
 
 
PROJECT OBJECTIVES: 
1. Wound dressing should increase wound healing  
a. Should kill/ inhibit microbial activity 
2. Wound dressing should be safe for patient 
 a. Meets FDA standards 
 b. Reliable 
  i. Does not interfere with healing process 
 c. Durable 
3.  Wound dressing should be easy to use 
 a. Ease of application 
b. Ease of removal 
4. Wound dressing should be practical to make 
 a. Inexpensive- cost less than current silver wound dressings 
 b. Must be able to be sterilized 
 c. Simple design 
 
PROJECT FUNCTIONS: 
1. Reduce odor 
 a. Terpenes  
2. Minimize pain 
 a. Eugenol, a terpene that has been proven to be a natural pain reliever 
3. Long lasting 
 a. Limit number of dressing changes 
  i. Current wound dressing models used for 7 day time periods 
4. Permeability rate 
 a. Oxygen required for healing process 
5. Provide moisture 
 a. Moisture to activate silver delivery 
 
PROJECT CONSTRAINTS: 
1. Cost of production 
2. Timeline of project 
a. Design and prototype must be completed by April 
3. Testing limited to certain wound pathogens 
4. Use of certain forms of silver 
 a. Silver nitrate light sensitive  
 b. Silver nitrate soluble 
 c. Silver chloride insoluble
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The indented objectives, functions, and constraints list allowed us to clearly define our 
goals and categorize them appropriately.  We further broke down the constraints and 
elaborated on their definition and application to our wound dressing as shown below in Figure 
7.  
 
Figure 7: Design Constraints 
 
 The functions of the project, which are defined as what the dressing design must 
accomplish, need to be clearly determined before the design process can begin.   In Figure 8, 
the functions are listed with an explanation.  Only after the constraints and functions are fully 
established can the design process continue.  
CONSTRAINTS 
 
Cost for production  
– Must be feasible to produce and manufacture, can be easily scaled up for larger 
output 
Timeline of project  
–     Project must be completed by April  
Does not hinder wound healing  
– All components are activated and it does not interfere with the natural wound   
      healing process and tissue regeneration 
–    Does not induce a secondary immune response  
Testing against specific pathogens  
–     Its efficacy has been proven in wound pathogens and in wound models 
Timeline for production 
– The dressing must be easy to use and ready for testing of efficacy no later than 
January 
– The dressing should be easy to manufacture 
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Figure 8: Design Functions 
 
4.1.2 Development of Revised Client Statement 
 
The results of the indented objectives, functions, and constraints list gave us a clear 
understanding of the basic goals of the design project.  However, the list did not illustrate 
which objectives were most important to consider in the design process.  Since we have 
design constraints such as time and cost, we used design tools to establish which objectives 
were most important to take into account when developing the wound dressing.  We created 
an objectives tree, which is a hierarchical list that branches from the top-level design goal to 
FUNCTIONS 
To act as an antimicrobial  
- Kill and inhibit common wound pathogens 
- Cut down on infection and length of wound healing process 
To provide oxygen to the wound (breathable) 
- Oxygen required for healing process 
- High moisture-vapor transmission rate (MVTR) (Koch, 2001) 
- Provide enough protection to foster wound healing as well as protect the wound from the 
outside environment  
To provide transport of antimicrobials  
 -     Reservoir for antimicrobials 
 -     Provides moisture to activate and transport antimicrobials 
To manage fluids 
- Provide moisture to the wound to allow for wound healing 
- Enough moisture to activate silver 
- Remove excess moisture which could decrease wound healing and could result in exudate 
buildup 
To reduce odor 
- Mask and decrease the odor of the wound site while acting as an antimicrobial 
- Increase patient comfort and security  
To relieve pain 
- Provide pain relief without prescription medicines which would increase the  
cost and responsibility for the patient 
- Reduce the number of dressing changes 
- Avoid adhesives which may disturb surrounding healthy tissue as well as the wound bed 
making the dressing harder to remove 
To be long lasting  
- Limit the number of dressing changes 
- Structurally sound and components are durable for at least 1 week which is comparable to 
current models 
- Provides sustained release of antimicrobials and active compounds over the duration of 
usage 
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sub-objectives.   The objectives tree is located in Appendix B.  The top-level design goals 
included increase wound healing time, safety, ease of use, and practical to make.  
After the objectives tree had been developed, a Pairwise Comparison Chart was 
developed for each tier of the objectives tree and used to rank the design objectives.  Each 
stakeholder completed Pairwise Comparison Chart, ranking which of the objectives were 
most important according to their needs.  The Pairwise Comparison Chart (Figure 9) works by 
comparing each of the objectives against one another to determine the rank of importance.  
Starting on the left column and working across, rank the one objective versus another 
objective all the way along the row. The ranking system works as follows: 1 = yes, more 
important, 0.5 = equally important, 0 = no, less important. For example: Increased wound 
healing is (more/equal to/less) important than Safety etc. 
The Pairwise Comparison Chart was completed by the MQP design team, Professor 
George Pins, Drs. Kerry Walker and Gary Ostroff from Eden Research plc, and also Lisa 
Szocik, a Medical Esthetician. This process provided us with varied responses because each 
stakeholder has different interests and primary goals the wound dressing must address. We 
also interviewed Dr. Raymond Dunn of UMASS Medical School, Department of Plastic 
Surgery (see Appendix A) and although we did not ask him to fill out a Pairwise Comparison 
Chart, his input as a stakeholder contributed to our revised client statement. 
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PAIRWISE COMPARISON CHART 
1st Tier 
 
 
 
 
2nd Tier 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3rd Tier 
 
Goals Includes terpenes Flexible Simple Design Score 
Includes terpenes X    
Flexible  X   
Simple Design   X  
Figure 9: Pairwise Comparison Chart 
Goals Kills/Inhibits  
Microbes 
Reliable Durable Easy to 
apply 
Easy to  
Remove 
Cost Score
Kills/Inhibits  
Microbes 
X       
Reliable 
 
 X      
Durable 
 
  X     
Easy to apply 
 
   X    
Easy to remove     X   
Cost 
 
     X  
Goals Increase wound  
Healing 
Safety Easy to 
Use 
Practical to
Make 
Score 
Increase wound 
Healing 
X     
Safety 
 
 X    
Easy to Use 
 
  X   
Practical to make 
 
   X  
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The results from the Pairwise Comparison Chart were compiled from each stakeholder 
(Appendix C-H) and were useful tools to determine the different needs and desires of each 
client. The design team took in to consideration that each stakeholder does not carry the same 
magnitude when the weighted objectives were established.  
Each stakeholder has their own goals and constraints. Therefore, it was important for 
our group to determine which stakeholders hold the most weight so that the team could 
concentrate on a more focused project. Through our background research and after careful 
consideration, Dr. Kerry Walker of Eden Research plc was determined to be the most 
important stakeholder and given the most weight (35%). This was due to her vast knowledge 
in wound care as well as the fact that Eden was providing the monetary funding to sponsor 
this project. Dr. Gary Ostroff was given the next highest weight as he is a pioneer of working 
with terpenes as antimicrobials. He is also very knowledgeable in wound healing. The MQP 
team ranked in the middle of the stakeholders as far as weight. The team has had experience 
with both prototype design techniques as well as with wound care. However, the team lacks 
extensive knowledge in wound management.  
Finally, nurse practitioners, medical personnel (Lisa Szocik) and Professor George 
Pins were assigned the least amount of weight, respectively. George Pins acted as an outside 
advisor in this activity and therefore his responses were ranked the lowest. Our dressing is to 
be created so that it is easy to use for not only medical personnel but also everyday caregivers 
that may not possess in depth knowledge of the sensitivity of wound care. Therefore, we did 
not rank stakeholders in this category very high. We did however consult a variety of doctors 
and medical personnel to better understand the limitations of current products (Appendix A). 
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Accordingly, a weighted objectives tree was developed, which was based on the 
responses given in the Pairwise Comparison Charts. The weighted objectives tree is used to 
illustrate the hierarchical layout of the objectives. Appendix I shows each objective with its 
two weighted values.  The left value is the weight compared to the other objectives on that tier 
out of 100, while the second number, more importantly gives the relative weight of the 
objective compared to all of the objectives.   Safety and decrease wound closure time were the 
top objectives based on the second value of the weighted objectives tree.  The objectives are 
ranked based on the critical second value, which is shown in Table 4.   
Table 4: Weighted Objectives 
 
OBJECTIVE WEIGHTED %
Tier 1  
Safety 43.1 
Decrease wound closure 
time 
32.8 
Easy to use 13.8 
Practical to make 10.3 
TOTAL  100 
Tier 2  
Delivers bioactive agent 16.7 
Reliable 15.1 
Mechanical strength 14.6 
Flexible 13.4 
Ease of removal 8.39 
Pain reducer 8.04 
Odor reducer 8.04 
Low cost 6.17 
Ease of application 5.41 
Simple design 4.13 
TOTAL  100 
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Through the design techniques previously explained, we were able to generate a 
revised client statement. The revised client statement states: 
 
Design and develop an anti-microbial wound dressing that will effectively inhibit and kill the 
growth of wound pathogens using a silver based dressing.  Screen the anti-microbial effects 
both in vitro through designing a series of engineering and biochemical assays to evaluate the 
efficacy of these bandages. In vivo studies will be conducted using animal models to assess 
the rate of healing in incisional wounds. The dressing should decrease the surface area of the 
wound indicating healing.  The dressing must minimize pain, decrease odor, last at least 7 
days to reduce the number of dressing changes as compared to current models. This dressing 
must not interfere with healing process and the removal of the dressing should not harm 
surrounding healthy tissue.  The dressing must be easy to apply by medical staff and once 
applied be flexible and durable in that it can withstand and support the normal mechanical 
strength of the skin. The dressing should have tensile stress and strain values similar to 3.61 
MPa and 4.9%, respectively. Finally, this dressing must be produced at a cost less than 
current silver wound dressings. 
 
4.1.3 Brainstorming of Layers  
 After the revised client statement was developed, brainstorming of the dressing layers 
could begin.  Literature research provided an understanding of the layers that were required 
for a wound healing dressing.  Based on our knowledge of the current wound dressings and 
our revised client statement, the layers required were proposed (see Figure 10).  
 It was determined that the dressing must have a layer closest to the wound that would 
be biocompatible and absorb the excess exudate from the wound.  A transport layer would be 
used to hold the antimicrobial agents, which also act as pain and odor reducers, and allow for 
them to actively diffuse into the wound.  The second fluid layer would be used to activate the 
silver components and facilitate the diffusion of agents from the transport layers.  Lastly, the 
dressing would need to have an outer layer to protect the wound from contamination while 
also allowing the delivery of oxygen to the wound.  
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Figure 10: Brainstorm of Dressing Layers 
 
 
 A 3-D image of the basic dressing layers was created using Computer Aided Design 
(CAD) to give a more detailed look at the structure of the design (see Figure 11).   
 
 
Figure 11: 3-D Drawing of Dressing Layers 
 
 
4.1.4 Morphological Chart 
 
 The morphological chart is an organized chart often used to illustrate various possible 
methods to accomplish each necessary function (Dym, 2004). During our brainstorming 
session for possible variations of effective wound healing dressings, we came up with means 
to accomplish each function as seen below in Table 5. 
 
 
 
   71
Table 5: Morphological Chart 
 
FUNCTION POSSIBLE MEANS 
To act as an 
antimicrobial 
Silver Terpene Triple 
antibiotic 
ointment 
Combination 
of Silver and 
Terpene 
     
To provide 
oxygen to the 
wound 
(breathable) 
Gauze 
Outer 
Layer 
Bioclusive 
 
Silk Medical 
Tape 
 
Omnifix Andovers 
Powerflex 
Ace  
Bandage 
Coverlet 
O.R. 
 
To provide 
transport of 
antimicrobials 
Moore 
Medical 
Corp. 
PU foam Mesh 
HDPE 
Spenco 2nd 
skin moist 
gel pad 
Duoderm 
CGF 
Hydrofiber Mueller 
More 
Skin 
3M Tegasorb 
Hydrocolloid 
Dressing 
3M 
Tegaderm 
Wound  
filler 
To manage 
fluids  
3M 
Foam 
Dressing 
Non-
woven 
Nylon 
Non-
woven 
Rayon/ 
polyester 
Calcium 
Alginate 
Agar     
To reduce 
odor  
Charcoal Terpenes        
To relieve 
pain 
Eugenol Prescribed 
pain 
relievers 
       
 
We then took each of the possible means and created a detailed list of each of their 
advantages and disadvantages, which will later help us in determining the best possible means 
to accomplish our functions (Tables 6 – 11). 
 
Table 6: Evaluation of Antimicrobial Agents 
 
To act as an antimicrobial Advantages Disadvantages 
Silver (Demling, 2002; Dowsett, 
2004; Strohal, 2005) 
 
• Effective against many 
microbes found in wounds 
• Activated in moist 
environment (i.e. wound 
site)  
• Microbial resistance  
• Light sensitive 
• Can turn skin colors 
• May form a precipitate 
Terpene (Ostroff, 2005) • Antimicrobial properties 
• Effective against different 
microbes than silver 
• Many combinations 
• Some smell pleasant 
• Some have pain relief 
capabilities 
• Not effective against all 
microbes found in wounds 
• Can be toxic in high 
concentrations 
• Hydrophobic if not 
encapsulated 
Triple Antibiotic Ointment (Mayo 
Clinic, 2005) 
• Used often with acute 
wounds 
• Effective against surface 
pathogens 
• Cannot be used internally 
• Makes wound oily 
• Can hinder wound healing 
• Effective for surface wounds 
• Microbial resistance 
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Combination of Silver and 
Terpene  (Demling, 2002; 
Dowsett, 2004; Ostroff, 2005; 
Strohal, 2005) 
 
• Most broad range of 
antimicrobial activity 
• May reduce odor 
• Many provide pain relief 
• Activated by natural 
moisture in wound site 
• Can potentially be harmful in 
high concentrations  
• Silver can turn skin 
brown/black 
• Silver is often light sensitive 
• May form a precipitate 
• More difficult loading 
technique 
 
Table 7: Evaluation of Means to Provide Oxygen Transport (breathable) 
 
To provide oxygen to 
the wound (breathable) 
Advantages Disadvantages 
Gauze outer layer (Kestrel 
Health Information., 2005; 
Worley, 2005) 
• Most widely used dressing 
in wound care 
• Good for absorption and 
protection 
• Can be impregnated with 
antimicrobial dressings or 
hydrogels 
• Variety of shapes and 
sizes 
• “Smart” gauze won’t 
adhere 
• Least expensive dressing 
• Commercially available 
• Some are cotton based and are 
not as cost effective and 
synthetic fibers are better 
• Does not create best healing 
environment  
• Painful to take off if dries out, 
even if  remoistened 
• Poor thermal insulator 
• If woven, fibers in wound 
• If non-woven, less absorbent 
Bioclusive (Thomas et al, 
1988) 
• Transparent  
• Moisture vapor permeable 
• Hypoallergenic 
• Viral barrier 
• Semi-strong adhesive 
• Causes fluid build up 
• Low breathable properties 
Silk (Jin, 2002) • Good in tension and 
compression 
• Beneficial in wound 
closure 
• Used for tissue scaffolds 
• Non-degradable in the 
short term 
• Expensive 
• In order to achieve beneficial 
properties must be refined to 
remove sericin 
Medical tape (Karwoski, 2003; 
Carver, 2005) 
• Good for security 
purposes 
• Minimal breathable capabilities 
• Strong adhesives can disturb 
wound bed and healthy skin 
upon removal 
Omnifix (MEDCO School  
First Aid, 2006) 
• Breathable 
• Porous 
• Not too strong of an 
adhesive 
• Cost effective ($12/box) 
• Absorptive 
• White – aesthetically 
pleasing 
• Only stretches in one direction 
• Cotton based (not as durable as 
compared to other dressings) 
Andover’s Power Flex  
(Carver, 2005; Andover 
Coated Products, 2006) 
• Waterproof 
• Sticks to itself 
• Lacks in breathable capabilities 
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Ace Bandage (O'Meara, 2002; 
Carver, 2005; Antibody, Inc., 
2006) 
• Can easily secure dressing 
to certain body parts 
(extremities) 
• Can have rubber 
component so no metal 
clips are necessary 
• Minimal breathable capabilities 
• Weak in fluid transport as it 
hinders fluids from entering 
and exiting 
Coverlet O.R. (Carver, 2005; 
Worley, 2005) 
• Gauze adhesive • Adhesive may be too strong for 
fragile skin 
Polyurethane Foam (Dowsett, 
2004) 
• Can be loaded with silver 
• Allows for silver to be 
dispersed homogeneously 
• Foam acts as a  protection 
for the wound bed from 
harmful contact  
• Too porous and may allow for 
bacterial ingrowth 
 
 
Table 8: Evaluation of Means of Transporting Antimicrobial Agent 
 
 
To provide transport of 
antimicrobials 
Advantages Disadvantages 
Moore Medical Corporation 
(Hom, 1999;  Carver, 2005) 
• Non-adherent pad • Not very durable or long 
lasting 
Polyurethane Foam (Dowsett, 
2004) 
• Can be loaded with silver 
• Allows for silver to be 
dispersed homogeneously 
• Foam acts as a  protection 
for the wound bed from 
harmful contact  
• Too porous and may allow 
for bacterial ingrowth 
Mesh HDPE (Thomas, 2004; 
Smith & Nephew, 2005) 
 
• Used in Acticoat™  
• Durable 
• Allows for some absorption 
• Can be easily loaded with 
antimicrobials 
• More difficult to 
manufacture  
• Larger degradation rate 
SPENCO 2nd skin moist gel pad 
(Surgical Materials Testing Lab, 
2002). 
• 80% water, 4% PEO 
• Won’t stick to skin 
• Just add water to re-hydrate  
• Cool – must be stored in a 
cool place 
• Soothing 
• Becomes part of skin 
• Only breathable in one 
direction 
DuoDerm CGF (Chakravarthy, 
2004) 
• Flexible 
• Hydrocolloid composition 
• comfortable 
• Adhesive skin contact layer 
Hydrofiber®  (Dowsett, 2004) • Can be impregnated with 
silver 
• Provides moisture to 
activate silver 
• Used in current silver 
dressings that are not as 
widely recognized (i.e. 
Aquacel® Ag) 
Mueller More Skin (Carver, 
2005; Mueller Sports Medicine, 
Inc., 2006 ) 
• Hydrogel 
• Can load particles in pores 
of gel 
• May be difficult to 
incorporate other layers 
3M Tegasorb Hydrocolloid • Sterile wound dressing • Hydrocolloid adhesive 
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Dressing 
(3M United States, 2005) 
• Hypoallergenic 
• Hydrocolloid adhesive 
• Clear adhesive film covers 
and keeps liquids, bacteria, 
and viruses out 
• Outer film is breathable 
• High moisture transmission 
rate 
• Can wear from up to 7 days 
could damage healthy tissue 
upon removal 
3M Tegaderm Wound filler 
(3M United States, 2005) 
• Amorphous hydrogel 
• Provides moisture 
• Sterile 
• Easy to apply 
• Good for ulcers and surgical 
wounds 
• Filler needs to be placed in 
other material 
• More complex for 
production 
 
 
Table 9: Evaluation of Means to Manage Fluid 
 
To manage fluids Advantages Disadvantages 
3M Foam Dressing  
(3M United States, 2005) 
• Fast wicking 
• Does not swell 
• Polyurethane foam 
• Highly breathable 
• Barrier to outside pathogens 
• Dressing can stay in contact 
and prevents leakage 
• Must be used with 3M 
Tegaderm Transparent 
Dressing 
Non-woven nylon  
(Thomas, 2002) 
• Found in Actisorb Silver 
220™ 
• Absorbs excess fluid 
• Can cause an allergic 
response 
Non-woven rayon/polyester  
(Thomas, 2004; Smith & 
Nephew, 2005) 
 
• Can catch excess silver 
flakes 
• Absorbs excess fluid 
• Used in Acticoat™ 
• Non-woven so no fibers in 
wound site 
• Less absorption compared 
to woven counterpart 
Calcium Alginate (Hom, 1999) • Very absorbable 
• Biodegradable 
• Contains seaweed 
(suggestion of Lisa) 
• Activates macrophages 
• Contains constituents of 
mannuronic acid and 
guluronic acid 
• Secondary dressing 
necessary 
• Cannot be used on dried out 
wounds 
• Poor choice for infected 
wounds 
Agar • Porous 
• Much data if used in 
agarose form 
• Insufficient data 
• Possibly unsafe 
• Can induce an immune 
response 
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Table 10: Evaluation of Means to Reduce Odor 
 
To reduce odor Advantages Disadvantages 
Charcoal  (Thomas, 2002) • Decreases odor by adsorbing 
toxins, amines, and fatty 
acids 
• Turns skin black 
• Somewhat complex and 
difficult to work with 
Terpenes (Ostroff, 2005) • Variety of smells 
• Also have antimicrobial 
properties 
• Some smells may have 
adverse effect 
 
 
 
Table 11: Evaluation of Means to Relieve Pain 
 
To relieve pain Advantages Disadvantages 
Eugenol (Ostroff, 2005) • Terpene 
• Has antimicrobial properties 
• Toxic in high doses 
Prescribed pain relievers • Known to decrease pain 
when used alone 
• Could interfere with wound 
healing 
 
4.2 Preliminary Design 
  
 Once we have defined means to accomplish each function, these must then be ranked 
according to their ability to meet the objectives and constraints. These design alternatives are 
then ranked according to defined metrics. These metrics were based on quantitative and 
qualitative measurements of the objectives for the wound dressing. The metrics were used to 
give each of the possible means a score for which design option was the best at accomplishing 
most of the objectives. This allows us to see which idea is most favorable, or even narrow 
down the options to the top three to give us a better area of focus in creating our model 
prototype design. These metrics allowed us to analyze the overall weighted scores according 
to the objectives raking from the objectives tree to decide which method is most favorable and 
in turn create conceptual designs as shown in Figure 12 – 16. 
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Figure 12: Conceptual Design #1 
 
 
 
Figure 13: Conceptual Design #2 
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Figure 14: Conceptual design #3 
 
 
 
Figure 15: Conceptual Design #4 
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Figure 16: Conceptual Design #5 
 
4.2.1 Metrics 
 In creating the metrics, we further analyzed and defined the objectives we had 
identified from the design statement (Appendix J). Metrics were scored on a scale of 1 to 3, 1 
being the worst, and 3 being the most favorable. These rankings allow us to determine the 
most favorable design options by being able to compare each option with their ability to 
achieve the certain function. Therefore, the best design has the top overall score as it ranks the 
highest in all areas. For example, if the antimicrobial components of silver and terpene each 
have a history of providing successful antimicrobial action, then the combination of silver and 
terpene should provide a more cost efficient bandage than current models using just silver. 
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Therefore, the combination of actives may be our most favorable option, leading us to further 
research and consider into our design. 
 Metrics were defined and justified to decide on a constant method of scoring for each 
design possibility (Appendix K). For example, a justification for flexible is that the dressing 
would be ranked according to the fact that it should not constrict any normal motions or 
movements of the skin. This dressing should exemplify the normal longitudinal stresses, 
transverse stresses and flexure properties of the skin and if achieved, it will receive a high 
score of a 3. If these values are unfavorable and below that of the skin, then the score received 
will be a 1. 
4.2.2 Selection Matrices 
 A selection matrix, also referred to as a decision matrix, was used to rate each possible 
design alternative against predefined constraints and objectives.  These scores are then added 
to obtain an overall number, the highest overall number being most favorable (Dym, 2004). 
This matrix determines the option that best meets the objectives set out by the stakeholders. 
The first step is to evaluate the means and if they satisfy the constraints. If the constraint is 
met, the box receives a “Y” for “yes” and can then be evaluated further against all of the 
objectives. If the constraint is not met, then the box receives an “N” for “no” and does not 
receive any further evaluation as it is no longer evaluated against any objectives. If the 
method does not apply to the objective to be evaluated against, then the box receives an “X” if 
it is not applicable. For example, in our evaluation, the aspect of the antimicrobial layer 
components such as silver and terpene cannot be evaluated against the objective of flexible as 
their physical properties are not essential to this layer as actives and also would not be able to 
be tested as they are just constituents of the antimicrobial layer. The score received for 
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satisfying each objective is based on the metrics, which is then multiplied by the weight of the 
objectives which has been previously determined by the client and stakeholder evaluation of 
the Pairwise Comparison Charts. This product of the weights and metrics provides an overall 
score of the means being evaluated. The design with the highest number suggests that this 
option is most effective in accomplishing all of the objectives and is a strong candidate for the 
final design.  
 All of the objectives were considered in the selection matrix as even though some did 
not apply to a specific layer, they applied in other layers or other components of the dressing. 
Therefore, since our objectives tree was split into two tiers, each totaling 100%, and the 
highest possible score received is a 3, we took the overall tier total of 200 and multiplied it by 
3 to yield a total maximum score of 600. Therefore, the score closest to 600 is the most 
effective method in deciding components of the dressing.  The tables below demonstrate the 
previously described process as well as show the final overall scores of each of the means. 
 The first layer evaluated is the antimicrobial layer which was scoring each option 
against the objectives as shown in Table 12. In this category, triple antibiotic ointment was 
eliminated because it has not been tested against a wide range of wound pathogens nor has it 
been used in various severe wound healing applications. It is a topical ointment used for small 
cuts and lesions, but not necessarily for chronic wounds or ulcers which are our target wounds 
for the dressing. The ointments oils could be detrimental to wound healing (Thomas, 2004). 
The other three options were then scored, yielding the most favorable result of the 
combination of silver and terpene as they have been proven through in vitro assays that they 
are effective in killing and inhibiting growth of most pathogens (Ostroff, 2005). The terpenes 
kill certain wound pathogens, and the silver also kills certain wound pathogens but is more 
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resistant to wound microbes, both antimicrobials being different in their breadth of 
antimicrobial activity. Therefore, where the terpenes couldn’t kill, the silver compensates, and 
vice versa. In addition, the use of two different antimicrobial agents reduces the risk of 
microbial resistance. Therefore, this option scored the highest and also received the top score 
out of all of the antimicrobial options. This is a favorable choice in that current wound 
dressings use only silver to act as an antimicrobial, not a combination of two different agents.  
 
Table 12: Antimicrobial Design Selection Matrix 
 
Design 
Constraints 
Silver Terpene Triple 
antibiotic 
Ointment 
Combination 
silver 
and terpene 
 
C: Cost for 
Production 
Y Y Y Y  
C: Time Y Y Y Y  
C: Doesn’t 
hinder 
wound 
Healing 
Y Y Y Y  
C: Testing 
against 
Specific 
wound  
Pathogens 
Y Y N Y  
C: Timeline 
for  
Production 
Y Y Y Y  
Design 
Objectives 
(weight %) 
Score Weighted 
Score 
Score Weighted 
Score 
Score Weighted 
Score 
Score Weighted 
Score 
Score Weighted 
Score 
O: 
Decreases 
Wound 
closure time 
(32.8) 
2 75.6 2 75.6   3 98.4   
O: Safety 
(43.1) 
2 86.2 2 86.2   2 86.2   
O: Easy to 
use (13.8) 
X  X    X    
O: Practical 2 20.6 2 20.6   2 20.6   
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to Make 
(10.3) 
O: Delivers 
bioactive 
agent (16.7) 
2 33.4 2 33.4   3 50.1   
O: Reliable 
(15.1) 
2 30.2 2 30.2   2 30.2   
O: Dressing 
mechanical 
strength 
(14.6) 
X  X    X    
O: Easy to 
apply (5.41) 
X  X    X    
O: Easy to 
remove 
(8.39) 
X  X    X    
O: Low 
Cost (6.17) 
1 6.17 3 18.5   2 12.3   
O: Provides 
pain relief 
(8.04) 
1 8.04 3 24.1   2 16.1   
O: Reduces 
odor (8.04) 
1 8.04 3 24.1   2 16.1   
O: Flexible 
(13.4) 
X  X    X    
O: Simple 
Design 
(4.13) 
2 8.26 3 12.4   1 4.1   
Total 
(200*3) 
 276.5  301.0   334.1   
 
 For the fluid management layer selection matrix (Table 13), agar was eliminated as 
there was no strong data to prove it had been used in fluid management applications, only in 
testing the efficacy of antimicrobial agents. This option may not be favorable in that it is 
poured onto plates to solidify bacterial growth medium and does not manage fluids unless it is 
heated to liquid form. Therefore, agar does not have the tendency to absorb or provide fluid to 
the wound environment. Non-woven nylon was also eliminated from the options as it hinders 
wound healing by often causing an inflammatory or allergic response to many patients who 
are prone to nylon allergies (Thomas, 2002). Therefore, the most favorable choice was the 
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calcium alginate although the others were not far behind this option. The calcium alginate was 
safer than the other methods as it is found in seaweed so like terpene, it is an organic, natural 
material (Hom, 1999). Calcium alginate is currently a very popular material used in wound 
dressings because it is very absorptive and can provide some cushioning, which is beneficial 
to patients with wounds on their back and buttocks (Krestel Health Information, 2005). 
 
Table 13: Fluid Management Design Selection Matrix 
 
Design 
Constraints 
3M foam 
dressing (non-
adhesive) 
Non-woven 
rayon/polyester 
Calcium 
Alginate 
Agar Non-woven 
Nylon 
C: Cost for 
Production 
Y Y Y Y Y 
C: Time Y Y Y Y Y 
C: Doesn’t 
hinder 
wound 
Healing 
Y Y Y N N 
C: Testing 
against 
Specific 
wound  
Pathogens 
Y Y Y Y Y 
C: Timeline 
for  
Production 
Y Y Y Y Y 
Design 
Objectives 
(weight %) 
Score Weighted 
Score 
Score Weighted 
Score 
Score Weighted 
Score 
Score Weighted 
Score 
Score Weighted 
Score 
O: 
Decreases 
Wound 
closure time 
(32.8) 
1 32.8 2 75.6 3 98.4     
O: Safety 
(43.1) 
2 86.2 2 86.2 3 129.3     
O: Easy to 
use (13.8) 
3 41.4 2 27.6 1 13.8     
O: Practical 
to Make 
(10.3) 
2 20.6 2 20.6 2 20.6     
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O: Delivers 
bioactive 
agent (16.7) 
X  X  X      
O: Reliable 
(15.1) 
X  X  X      
O: Dressing 
mechanical 
strength 
(14.6) 
2 29.2 2 29.2 2 29.2     
O: Easy to 
apply (5.41) 
X  X  X      
O: Easy to 
remove 
(8.39) 
X  X  X      
O: Low Cost 
(6.17) 
2 12.3 2 12.3 1 6.17     
O: Provides 
pain relief 
(8.04) 
X  X  X      
O: Reduces 
odor (8.04) 
X  X  X      
O: Flexible 
(13.4) 
2 26.8 2 26.8 2 26.8     
O: Simple 
Design 
(4.13) 
X  X  X      
Total 
(200*3) 
 249.3  278.3  324.3     
 
 The next functional layer to be determined was to act as an odor reducer (Table 14). 
Often severely infected wounds release a powerful odor which is often embarrassing for the 
patient and also shows a sign of delayed wound healing (Dowsett, 2004). The charcoal option 
is currently used in Johnson and Johnson’s model, Actisorb™ Silver 220 as an odor reducer, 
but has the drawback of impregnating the wound with charcoal pieces after leaving the 
dressing on for a long period of time (Thomas, 2002). Since terpenes are organic, most of the 
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formulations have pleasant aromas as many of the essential oils are used in aromatherapy 
(Szocik, 2005). Not only do terpenes provide a pleasing scent to overpower the infection, they 
also act as an antimicrobial (Dursan, 2003; Ostroff, 2005), having two properties that are 
favorable in the design of a wound dressing to inhibit microbial infection.  
Table 14: Odor Reducer Design Selection Matrix 
 
Design 
Constraints 
Charcoal Terpenes   
C: Cost for 
Production 
Y Y   
C: Time Y Y   
C: Doesn’t 
hinder 
wound 
Healing 
Y Y   
C: Testing 
against 
Specific 
wound  
Pathogens 
Y Y   
C: Timeline 
for  
Production 
Y Y   
Design 
Objectives 
(weight %) 
Score Weighted 
Score 
Score Weighted 
Score 
Score Weighted 
Score 
Score Weighted 
Score 
O: 
Decreases 
Wound 
closure time 
(32.8) 
1 32.8 3 98.4     
O: Safety 
(43.1) 
2 86.2 2 86.2     
O: Easy to 
use (13.8) 
X  X      
O: Practical 
to Make 
(10.3) 
2 20.6 2 20.6     
O: Delivers 
bioactive 
agent (16.7) 
1 16.7 2 33.4     
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O: Reliable 
(15.1) 
2 30.2 2 30.2     
O: Dressing 
mechanical 
strength 
(14.6) 
X  X      
O: Easy to 
apply (5.41) 
X  X      
O: Easy to 
remove 
(8.39) 
X  X      
O: Low Cost 
(6.17) 
2 12.3 3 18.5     
O: Provides 
pain relief 
(8.04) 
1 8.04 3 24.1     
O: Reduces 
odor (8.04) 
3 24.1 3 24.1     
O: Flexible 
(13.4) 
X  X      
O: Simple 
Design 
(4.13) 
2 8.26 3 12.4     
Total 
(200*3) 
 239.2  347.9     
 
  
In choosing the component with the most desirable pain reducing properties, we 
eliminated the original option of acetaminophen (active ingredient in Tylenol) that we had 
initially considered, as acetaminophen cannot be considered part of the dressing as it is proven 
most effective in oral medicines (Micromedex, 2006). There has been no previous research 
completed using acetaminophen in wound dressings. In this decision matrix (Table 15), 
eugenol, the terpene component of clove oil, was the most favorable result with a score of 
311.9 as it is currently used to relieve pain during the teething stage of infant development 
(Ostroff, 2005). Once again, the eugenol not only provides pain relief to the wound site, but it 
also provides antimicrobial properties as it kills and inhibits microbes and has the pleasant 
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aroma of cloves (Ostroff, 2005). Prescribed pain relievers are often used in combination with 
the wound dressing to help ease pain in the wound. This would cause the dressing to be more 
complicated if it must be used in combination with pain relievers since the dressing itself does 
not ease pain. 
Table 15: Pain Reducer Design Selection Matrix 
 
Design 
Constraints 
Prescribed 
Pain 
Relievers 
Eugenol    
C: Cost for 
Production 
Y Y    
C: Time Y Y    
C: Doesn’t 
hinder 
wound 
Healing 
Y Y    
C: Testing 
against 
Specific 
wound  
Pathogens 
Y Y    
C: Timeline 
for  
Production 
Y Y    
Design 
Objectives 
(weight %) 
Score Weighted 
Score 
Score Weighted 
Score 
Score Weighted 
Score 
Score Weighted 
Score 
Score Weighted 
Score 
O: 
Decreases 
Wound 
closure time 
(32.8) 
1 32.8 3 98.4       
O: Safety 
(43.1) 
3 129.3 2 86.2       
O: Easy to 
use (13.8) 
X  X        
O: Practical 
to Make 
(10.3) 
X  X        
O: Delivers 
bioactive 
agent (16.7) 
1 16.7 3 50.1       
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O: Reliable 
(15.1) 
3 45.3 2 30.2       
O: Dressing 
mechanical 
strength 
(14.6) 
X  X        
O: Easy to 
apply (5.41) 
X  X        
O: Easy to 
remove 
(8.39) 
X  X        
O: Low 
Cost (6.17) 
1 6.2 3 18.5       
O: Provides 
pain relief 
(8.04) 
2 16.1 2 16.1       
O: Reduces 
odor (8.04) 
X  X        
O: Flexible 
(13.4) 
X  X        
O: Simple 
Design 
(4.13) 
2 8.3 3 12.4       
Total 
(200*3) 
 254.7  311.9       
 
 
In considering materials for the breathable oxygen permeable layer, the material must 
allow for oxygen transport in and out of the dressing to allow for proper wound healing (see 
Tables 16 and 17). Medical tape was immediately eliminated from consideration as it hinders 
wound healing by being too adhesive to use on a damaged tissue wound site. When removing 
this tape, healthy or wounded skin could potentially be removed with the tape due to its high 
adhesive properties (Karwoski, 2003). We also eliminated silk from the decisions as it is a 
very expensive material so it would produce a costly dressing. The top choice for this 
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category was Coverlet™ O.R. which is a gauze dressing currently used in hospitals to wrap 
wound sites. This dressing had a weighted score of 397 as it is favorable consideration in 
accomplishing all respective objectives. 
However, after performing mechanical testing at Instron Corporation in Nowood 
(Appendix R), Covelet™ O.R. was ruled out as it has an extremely high adhesive strength 
compared to similar materials. By using the results obtained at Instron, we were able to 
further evaluate these materials as well as other materials we later decided to investigate to 
finally choose polyurethane foam as a strong candidate for this functional layer. 
 
 
 
 
 
Table 16: Breathable Design Selection Matrix 
 
Design 
Constraints 
Gauze outer 
Layer 
Silk Medical Tape Omnifix  
C: Cost for 
Production 
Y N Y Y  
C: Time Y Y Y Y  
C: Doesn’t 
hinder 
wound 
Healing 
Y Y N Y  
C: Testing 
against 
Specific 
wound  
Pathogens 
Y Y Y Y  
C: Timeline 
for  
Production 
Y Y Y Y  
Design 
Objectives 
(weight %) 
Score Weighted 
Score 
Score Weighted 
Score 
Score Weighted 
Score 
Score Weighted 
Score 
Score Weighted 
Score 
O: 
Decreases 
Wound 
closure time 
1 32.8     2 65.6   
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(32.8) 
O: Safety 
(43.1) 
2 86.2     1 43.1   
O: Easy to 
use (13.8) 
3 41.4     2 27.6   
O: Practical 
to Make 
(10.3) 
X      X    
O: Delivers 
bioactive 
agent (16.7) 
X      X    
O: Reliable 
(15.1) 
X      X    
O: Dressing 
mechanical 
strength 
(14.6) 
2 29.2     1 14.6   
O: Easy to 
apply (5.41) 
2 10.8     3 16.2   
O: Easy to 
remove 
(8.39) 
3 25.1     2 16.8   
O: Low 
Cost (6.17) 
3 18.5     2 12.3   
O: Provides 
pain relief 
(8.04) 
X      X    
O: Reduces 
odor (8.04) 
X      X    
O: Flexible 
(13.4) 
3 26.8     2 13.4   
O: Simple 
Design 
(4.13) 
3 12.4     2 8.3   
Total 
(200*3) 
 283.2      217.9   
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Table 17: Breathable Design Selection Matrix Continued 
 
Design 
Constraints 
Andover’s 
Powerflex 
Ace Bandage Coverlet O.R. Bioclusive    
C: Cost for 
Production 
Y Y Y Y  
C: Time Y Y Y Y  
C: Doesn’t 
hinder 
wound 
Healing 
Y N Y Y  
C: Testing 
against 
Specific 
wound  
Pathogens 
Y Y Y Y  
C: Timeline 
for  
Production 
Y Y Y Y  
Design 
Objectives 
(weight %) 
Score Weighted 
Score 
Score Weighted 
Score 
Score Weighted 
Score 
Score Weighted 
Score 
Score Weighted 
Score 
O: Decreases 
Wound 
closure time 
(32.8) 
2 65.6   3 98.4 2 65.6   
O: Safety 
(43.1) 
2 86.2   2 86.2 2 86.2   
O: Easy to 
use (13.8) 
2 27.6   2 27.6 2 27.6   
O: Practical 
to Make 
(10.3) 
X    X  X    
O: Delivers 
bioactive 
agent (16.7) 
X    X  X    
O: Reliable 
(15.1) 
X    X  X    
O: Dressing 
mechanical 
strength 
(14.6) 
3 43.8   2 29.2 2 29.2   
O: Easy to 
apply (5.41) 
2 10.8   2 10.8 3 16.2   
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O: Easy to 
remove 
(8.39) 
1 8.4   2 16.8 2 16.8   
O: Low Cost 
(6.17) 
2 12.3   2 12.3 2 12.3   
O: Provides 
pain relief 
(8.04) 
X    X  X    
O: Reduces 
odor (8.04) 
X    X  X    
O: Flexible 
(13.4) 
2 13.4   2 13.4 2 13.4   
O: Simple 
Design 
(4.13) 
2 8.3   2 8.3 2 8.3   
Total 
(200*3) 
 276.4    303.0  189.4   
 
 
The final layer and one of the most important layers is the transport layer (see Tables 
18 and 19). This layer is responsible for holding the antimicrobial materials and active 
compounds. We were able to rule out the 3M Tegaderm™ wound filler as it can actually 
extend the amount of time it takes for the wound to heal, compared to actual dressings and is 
also harder to manufacture. It acts as a topical ointment to place into a wound bed and was not 
used in incisional or severe wounds so it was eliminated from our matrix (3M United States, 
2005). The 3M Tegasorb™ Hydrocolloid dressing prevailed in the transport category with a 
score of 379.1 which was followed by the Spenco™ Second Skin hydrogel. Both of these 
products are currently used in wound healing models, proving their safety and efficacy in 
allowing normal wound healing (Surgical Materials Testing Lab, 2002). 
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Table 18: Transport Layer Design Selection Matrix 
 
Design 
Constraints 
Moore 
Medical 
Corp. 
Mesh HDPE Spenco 2nd 
Skin 
Duoderm CGF PU foam 
C: Cost for 
Production 
Y Y Y Y Y 
C: Time Y Y Y Y Y 
C: Doesn’t 
hinder 
wound 
Healing 
Y Y Y Y Y 
C: Testing 
against 
Specific 
wound  
Pathogens 
Y Y Y Y Y 
C: Timeline 
for  
Production 
Y Y Y Y Y 
Design 
Objectives 
(weight %) 
Score Weighted 
Score 
Score Weighted 
Score 
Score Weighted 
Score 
Score Weighted 
Score 
Score Weighted 
Score 
O: Decreases 
Wound 
closure time 
(32.8) 
1 32.8 1 32.8 3 98.4 1 32.8 1 32.8 
O: Safety 
(43.1) 
2 86.2 2 86.2 2 86.2 2 86.2 2 86.2 
O: Easy to 
use (13.8) 
2 27.6 1 13.8 3 41.4 2 27.6 2 27.6 
O: Practical 
to Make 
(10.3) 
X  X  X  X  X  
O: Delivers 
bioactive 
agent (16.7) 
X  X  X  X  X  
O: Reliable 
(15.1) 
X  X  X  X  X  
O: Dressing 
mechanical 
strength 
(14.6) 
2 29.2 3 43.8 1 14.6 3 43.8 3 43.8 
O: Easy to 
apply (5.41) 
1 5.4 2 10.8 3 16.2 2 10.8 1 5.4 
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O: Easy to 
remove 
(8.39) 
3 25.2 2 16.8 3 25.2 2 16.8 2 16.8 
O: Low Cost 
(6.17) 
2 12.3 2 12.3 3 18.5 3 18.5 2 12.3 
O: Provides 
pain relief 
(8.04) 
X  X  X  X  X  
O: Reduces 
odor (8.04) 
X  X  X  X  X  
O: Flexible 
(13.4) 
2 26.8 2 26.8 3 40.2 3 40.2 2 26.8 
O: Simple 
Design 
(4.13) 
2 8.3 2 8.3 1 4.1 1 4.1 2 8.3 
Total 
(200*3) 
 253.8  251.6  344.8  280.8  260.0 
 
 
Table 19: Transport Layer Continued 
 
Design 
Constraints 
Hydrofiber Mueller More 
Skin 
3M Tegasorb 
Hydrocolloid 
Dressing 
3M Tegaderm 
Wound Filler 
 
C: Cost for 
Production 
Y Y Y Y  
C: Time Y Y Y Y  
C: Doesn’t 
hinder 
wound 
Healing 
Y Y Y Y  
C: Testing 
against 
Specific 
wound  
Pathogens 
Y Y Y Y  
C: Timeline 
for  
Production 
Y Y Y N  
Design 
Objectives 
(weight %) 
Score Weighted 
Score 
Score Weighted 
Score 
Score Weighted 
Score 
Score Weighted 
Score 
  
O: 
Decreases 
Wound 
closure time 
2 65.6 1 32.8 3 98.4     
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(32.8) 
O: Safety 
(43.1) 
2 86.2 2 86.2 3 129.3     
O: Easy to 
use (13.8) 
2 27.6 2 27.6 2 27.6     
O: Practical 
to Make 
(10.3) 
X  X  X      
O: Delivers 
bioactive 
agent (16.7) 
X  X  X      
O: Reliable 
(15.1) 
X  X  X      
O: Dressing 
mechanical 
strength 
(14.6) 
2 29.2 2 29.2 3 43.8     
O: Easy to 
apply (5.41) 
2 10.8 2 10.8 2 10.8     
O: Easy to 
remove 
(8.39) 
2 16.8 2 16.8 1 8.4     
O: Low 
Cost (6.17) 
2 12.3 2 12.3 2 12.3     
O: Provides 
pain relief 
(8.04) 
X  X  X      
O: Reduces 
odor (8.04) 
X  X  X      
O: Flexible 
(13.4) 
2 26.8 3 40.2 3 40.2     
O: Simple 
Design 
(4.13) 
2 8.3 2 8.3 2 8.3     
Total 
(200*3) 
 283.6  264.2  379.1     
X = does not apply 
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4.3 Proposed Final Design   
 With these selection matrices, we are able to choose a final design to consider for each 
layer. Also, these matrices allow us to choose the second best option if we come across 
limitations of the top scoring material, or if it ends up being out of the scope of the project 
cost-wise or production-wise. From the selection matrix, it is suggested that we make a 
dressing from a combination of silver plus terpene, use a hydrocolloid for transport, and use 
Coverlet™ O.R. for a breathable gauze layer as shown in Figure 17. However, Instron® 
mechanical testing allowed the group to rule out Coverlet™ O.R. and as a second choice we 
considered polyurethane foam as it has a very desirable adhesive strength (Appendix R). The 
usage of these terpenes also provides an odor reducing option as well as a pain reliever and an 
antimicrobial. Therefore, the incorporation of these terpenes with silver should set our 
dressing above the others, accomplishing our design goals. 
 
 
Figure 17: Conceptual Design with Materials 
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4.4 Modifications 
 Upon further review, professional input, and quantitative analysis we were able to 
modify our proposed final design into a dressing that can be easily manufactured. We realized 
that our proposed design had many layers and was quite complex compared to other current 
silver wound dressings. Therefore, we were able to reduce the number of functional layers to 
three instead of our original five, while still complying with our quantitative functions and 
constraints.  
4.4.1 Transport Layer Modifications 
We began our studies by choosing carboxymethylcellulose (CMC) and alginate as the 
main materials in making a hydrocolloid based on the hydrocolloids on the market. With both 
materials, we produced 0.5%, 1%, 2%, 3% w/w gel formulations by dissolving each material 
in 45 mL of sterile water (see Appendices U and T, respectively). In this experiment we also 
added sodium azide to the formulation to act as an antimicrobial in the gel. To one group of 
both CMC and Alginate gels, we added 7% w/w glycerol, to a second group of both gels we 
added 6.6 mg/ml amount of terpene to supply antimicrobial properties, and a third group of 
gels lacking any additives acted as the negative control. For the alginate gels, 10 ml of 1% 
sodium nitrate was added to allow for cross-linking. These gels were then air dried under a 
sterile hood to form a film. 
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Figure 18: Dry Alginate and CMC hydrocolloids, 
(top row –alginate control, middle row – alginate + terpene, bottom row – CMC control, left to right are 
3%, 2%, 1%, 0.5% formulations by row) 
 
 
 
Figure 19: Dry 3% Alginate + Calcium Nitrate –    
brittle and curled gel, non-homogeneous 
 
 After the hydrocolloid films were made, we ran a water absorption test to measure the 
amount of swelling and fluid absorption per sample (see Appendix V). This experiment was 
run in duplicate so two small samples of hydrocolloid were cut from the large gel and placed 
in a tube with 1 mL water and weighed at different time points. Again, the 0.5% CMC was 
undesirable as it couldn’t be removed from the tray because it was still wet in areas that had 
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not dried. The remaining CMC samples (1%, 2%, and 3%) were rubbery and stretchy and 
remained mechanically stable before being put into the water. All of the alginate samples 
were brittle and the groups without terpene dissolved when submerged in the water. The CMC 
hydrocolloids showed high yields of water absorption, however, the negative controls 
dissolved on contact. From this experiment we concluded that the 1%, 2% and 3% CMC 
formulations were most favorable in the creation of a wound dressing as they absorbed the 
most fluid and did not dissolve as easily as alginate. 
 From the water absorption test previously described, we were able to rule out alginate 
as a component for our antimicrobial layer, and we proceeded with CMC. Since 1% CMC 
was the lowest concentration that was mechanically stable, we tested 3 different 
concentrations, 1%, 1.5% and 2%.  In order to overcome the brittle properties of the CMC 
formulations, a plasticizer was added to each formulation.  This experiment served to test the 
efficacy of glycerol plus terpene in CMC.  We kept the terpene concentration and the glycerol 
concentration constant, but this time we cast larger gels in 4 inch by 6 inch plastic containers. 
We had four different groups per CMC concentration, a CMC + glycerol only group, a CMC 
+ terpene only group, a CMC + glycerol + terpene group, and a CMC only negative control. 
(see Appendix X).  
 Once these hydrocolloids were dry, we ran the water absorption test, which 
demonstrated that CMC began to dissolve in water over time. Overall the 1% CMC + glycerol 
+ terpene had the most consistent results, however, was not much more favorable than the 
other CMC groups (see Appendix Y).   The addition of glycerol proved to overcome the 
brittle nature of the CMC formulations, but unfortunately the CMC’s stability in water did not 
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improve.  From this test we were able to determine we must alter a step in the manufacturing 
process to create a more stable hydrocolloid in water. 
Lyophilization is another method for drying the CMC hydrogel, which can allow for 
more a homogeneous hydrocolloid and can possibly improve the stability of the formulation. 
We cast 6 gels into plastic containers and after approximately 1 hour of freezing at -80°C, the 
frozen gels were placed in a lyophilizer overnight to be freeze-dried (see Appendix BB). For 
this experiment we used the same concentrations as described above when we air dried them. 
After freeze-drying, the hydrocolloids became more foamy and firm, much more desirable 
physical and mechanical properties than those seen by air drying.   
 After the water absorption of the lyophilized CMC hydrocolloids, we concluded that 
the CMC alone absorbed the most water by almost 2 fold, as compared with the glycerol and 
terpene formulation. We concluded that the glycerol amount may be too high as it produced 
sticky gels and also did not play an effect on the absorption of the formulations (see Appendix 
Y). 
Although the physical properties of the lyophilized CMC hydrocolloids were 
desirable, the CMC was still not stable in water as observed through running the water 
absorption test.  We hypothesized that the addition of a cross-linking agent would produce a 
stable CMC formulation.  Based on literature, chitosan was first selected to act as a cross-
linker stabilizing the matrix, and two gels were cast incorporating chitosan into the formula 
(Queen, et al, 1996). To one tray 1% w/w chitosan was added to 1% CMC, and to another 
tray, 0.5% chitosan was added to 2% CMC. The chitosan cross-linked the CMC on impact 
and therefore made it hard to mix. Also, throughout the gel there were strings of fibers that 
formed from the reaction between the chitosan and CMC, again causing a non-homogeneous 
   101
gel. However, when water absorption was performed, the chitosan containing CMC gels did 
not dissolve and was more promising than the previous CMC only control gels tested.  
 Although the chitosan created a more stable CMC hydrocolloid, the cross-linking 
occurred on impact and the non-homogeneous formulation was undesirable to work with.  We 
next evaluated another thermal gelling hydrocolloid, agarose with CMC formulation to 
provide act as a stabilizer to reduce CMC dissolving during water contact (Queen, et al. 
1996). We added molten agarose in 5 different concentrations (0%, 0.1%, 0.2%, 0.3%, 0.4%, 
0.5% w/w) to the CMC + glycerol + terpene formulation in a 50ºC water bath to avoid gelling 
with agarose. Upon gelling and freezing these gels were then lyophilized to again test their 
stability (Appendix PP).  
 After the water absorption test, we concluded that 1.5% CMC plus 0.2% or 0.3% w/w 
agarose were stable and absorbed the most water (Appendix QQ). From this experiment we 
chose 0.3% w/v agarose as a stabilizer for the CMC formulations.  
The initial glycerol concentration as a plasticizer had been chosen from the literature 
and an optimal concentration in the CMC formulation had not been identified. When the 
glycerol concentration was 7% w/w, the CMC formulations did not have suitable 
characteristics because of its sticky nature. Therefore, we tested 4 different glycerol amounts 
with the previously determined CMC plus agarose formulations, keeping all parameters 
constant except the glycerol level (Appendix RR). The purpose of this experiment was to 
identify the glycerol concentration that created a CMC formulation with the most desirable 
physical properties.  CMC plus agarose formulations were prepared with 1.75%, 3.5%, 
5.25%, and 7% w/w glycerol and again lyophilized to produce dry hydrocolloid materials.  
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 The water absorption test demonstrated that 1.75% w/w glycerol containing CMC 
formulations worked best. By calculating the weight of the sample, and knowing the original 
weight of the gel, we were able to determine the overall percent water absorption. 
Characterization of other wound dressings from the literature indicated that water absorption 
should be between 13g-20g of water/wt absorbed by the hydrocolloid (Queen et al. 1996). 
Water absorption characterization of our dry CMC materials demonstrated that CMC 
containing 1.75% w/w glycerol absorbed water between these ranges and was also the lowest 
amount of glycerol tested. This concentration of glycerol resulted in dry CMC materials that 
were effective in absorbing water and had sufficient flexibility without being sticky 
(Appendix SS).  This experiment allowed us to identify that 1.75% w/w glycerol was the most 
effective glycerol level, and also demonstrated again that 0.3% agarose stabilizes the dried 
CMC gel when wetted.  
 
4.4.2 Fluid Management Contact Layer Modifications 
 We determined the need for a dressing layer between the skin and the CMC active 
layer for two reasons; 1) to provide a biocompatible skin contact layer and 2) to prevent the 
actives from migrating into the wound bed and possibly hindering wound healing.  Based 
upon literature research we chose to prepare a calcium alginate film.  
Our initial work used alginate cross-linked with calcium nitrate.  However, the MSDS 
of Calcium Nitrate indicates that calcium nitrate is a skin irritant. Therefore, since we did not 
have success with the alginate and calcium nitrate, and also because the calcium nitrate would 
have been toxic to the wound, we tried casting the gels again using calcium chloride (see 
Appendix CC). We identified the amount of calcium chloride necessary to crosslink different 
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concentrations of alginate. The 0.5% w/w alginate was too soft, and continued to test the 1%, 
1.5% or 2% w/w alginate in further formulation experiments. The lowest concentration of 
calcium chloride to crosslink the alginate gels was 0.25% w/v. 
 Initially the team set out to discover the best combination of sodium alginate and 
calcium chloride to produce an effective skin contact and active barrier layer (see Appendix 
CC). The calcium chloride is necessary to cross-link the sodium alginate to form insoluble 
calcium alginate.  Dry sodium alginate films of 1.5% and 2.0% were produced and soaked in 
varying amount of calcium chloride for 24 hours to form insoluble calcium alginate gels. 
After cross-linking, the calcium alginate gels were washed at 20 minute intervals for 1 hour to 
remove the excess sodium and unreacted calcium chloride, producing calcium alginate gels. 
These formulation experiments provided the group with very important results: 1.5% alginate 
provided better mechanical properties than 2.0% alginate, and in order to obtain the best 
cross-linking the amount of calcium chloride should be between 13.75g – 27.5g of 0.5% w/w 
calcium chloride per 55g of 1.5% alginate gel.   
To ensure the plasticity of the calcium alginate gel it was hypothesized that this layer 
would benefit from the addition of glycerol.   To test this hypothesis, an additional 
formulation experiment was conducted to finalize the best combination of sodium alginate 
and calcium chloride, as well as determine the importance of glycerol as a constituent of the 
layer, and if so, over what concentration range (Appendix DD).  The experiment described in 
Appendix DD allowed the team to conclude the best overall gels included 1.75% and 3.5% 
glycerol and 0.5% calcium chloride. These results allowed us to determine the final 
formulation of the alginate layer, composed of 1.5% w/w sodium alginate, 1.75% w/w 
   104
glycerol, which coincides with the amount of glycerol in the CMC layer for homogeneity and 
stability purposes, and 0.5% calcium alginate.  
4.4.3 Secondary Dressing Modifications 
We were able to use the results from Instron Corporation (Appendix R) as well as the 
terpene resistance assay described in the Methodology section to choose polyurethane (PU) 
foam as our outermost breathable barrier. PU foam also has fluid absorptive capabilities 
(Worley, 2005) therefore we were able to eliminate one of the calcium alginate layers because 
it’s functionality was fluid management and PU foam can act both as a breathable barrier and  
remove excess exudate when necessary (Worley, 2005).  
4.5 The Final Design 
Medical grade carboxymethylcellulose (CMC) was chosen as the primary constituent 
of the active transport layer. This hydrocolloid promotes a moist environment, which allows 
for better wound healing (Hom, 1999) as well as serving as a matrix to carry and release the 
actives. The CMC layer also swells when placed on the wound, which is beneficial as it 
supplies a significant amount of padding for pain relief. A dressing that provides a form of 
cushioning can be used on nearly any part of the body including the buttocks and back, which 
are hard to dress areas if there is insufficient padding. Through further research and testing as 
shown in Appendices RR and PP, a plasticizer (glycerol) and gelling agent (agarose) 
respectively were also added to this layer to obtain the necessary physical and mechanical 
properties. (See Figure 20) 
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Figure 20: Final Dressing Prototype 
 
The actives contained with in the CMC layer were 6.6 mg/ml YP-ET and 41.8 µg/ml 
YP-silver chloride. These values were determined by research of current silver wound 
dressings as well as in vitro and in vivo antimicrobial experiments. For example, the terpenes 
had been tested in meat which is closer to an in vivo environment, and yielded MIC values of 
6,600 ppm (6.6 mg/ml). This was further tested in an in vivo animal study and validated this 
value (see Section 6.6, page 134). The silver was half of the amount of silver dressings 
currently use on the market (70-100 ppm) so the terpene can compensate for this loss. There 
was still significant activity of silver at 41.8 ppm as shown through the corrected zone of 
inhibition assay (see Section 6.9). Additionally, the concentration of YP-silver chloride was 
chosen based on the team’s previously stated objective, which was to decrease the cost of the 
dressing by reducing the amount of silver. YP-ET also provides pain relief and order 
reduction, which were two other objectives that the team set out to accomplish. 
 The third layer of the team’s dressing is a contact layer of calcium alginate, which is 
multifunctional. This layer absorbs fluid and changes physical states to create a soft gel on the 
wound, which can decrease pain (Hom, 1999; Worley, 2005) as it is easier to remove the 
dressing without disturbing the underlying wound bed. Additionally, this layer maintains the 
actives contained in the CMC layer so that a sustained release profile is achieved and the 
actives do not flood into the wound site. Glycerol was also added to this layer to increase the 
Secondary Dressing: Breathable 
 
 
Actives Reservoir 
 
Active Retention, Interfacial Barrier 
   106
homogeneity and stability of the overall dressing as the CMC layer also required the same 
plasticizer to smooth out the dressing. 
 The secondary dressing that will be used in conjunction with our primary dressing is 
the PU Foam covering, which was previously described.  Figure 21 demonstrates the final 
design prototype, which can now be considered for possible animal studies to determine the 
overall efficacy of the dressing in an in vivo setting. 
 
 
Figure 21: Final Dressing Prototype 
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5. Methodology  
 
 In the methodology section, there will be a detailed discussion of the materials used to 
construct the wound dressing, how each component was constructed, and how the 
functionality of the components as well as the efficacy of the entire dressing was determined. 
Further, we will discuss the animal experimentation including both Phase I and Phase II and 
the various qualitative and quantitative observations necessary to determine the efficacy of 
our dressing design. 
5.1 Antimicrobial Production 
 The antimicrobial agents were produced and encapsulated in yeast cell wall particles 
(YP).  This section explains how the silver and terpenes were encapsulated into YP.  
5.1.1 Eugenol Thymol (ET) 
     The terpene formulation of choice was Eugenol and Thymol (ET), 50% of each. A 
previous study tested 31 combinations of the terpenes: citral, geranial, eugenol, thymol and L-
carvone. (Ostroff, 2005)  ET was one of the 31 YP encapsulated terpene combinations 
screened in an in vitro assay.  Each of the 31 combinations was tested with an initial 
concentration of 4 mg/ml against ten wound pathogens: S. aureus, methicillin resistant 
Staphylococcus aureus (MRSA), Staphylococcus epidermis, methycillin-resistant 
Staphylococcus epidermis (MRSE), E. faecalis, Vancomycin-Resistant Enterococcus (VRE), 
P. aeruginosa, Streptococcus pyogenes, Escherichia coli, and Candida Albicans.    
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5.1.2 YP- Silver Nitrate 
 Silver nitrate was purchased and encapsulated into particles following the protocol 
found in Appendix L.  After completing the protocol, an YP- Silver Nitrate powder was 
formed.   
5.1.3 YP- Silver Chloride 
 YP-Silver chloride was produced following the protocol found in Appendix L.  The 
YP- Silver chloride was also in powder form.   
5.2 Antimicrobial Activity  
Once the YP encapsulation process of ET terpene, silver nitrate, and silver chloride 
was completed, the efficacy against wound pathogens needed to be determined.  To make sure 
the materials had effectively been encapsulated, they were tested against three selected wound 
pathogens; E. faecalis, P. aeruginosa, and S. aureus.  E. faecalis was chosen because silver 
formulations have been shown to be less effective against this species of bacteria.  Terpenes 
are not extremely effective in inhibiting or killing the growth of P. aeruginosa.  However, 
terpenes become effective against these pathogens at higher concentrations, such as 2000ppm 
or higher.  Both terpenes and silver formulations are effective against S. aureus.  Due to time 
constraints, only three strains of wound pathogens could be tested; however, the three chosen 
pathogens provide a range to test for antimicrobial efficacy.  The hypothesis is that the 
combination of YP-silver and YP-terpene will be more effective then YP-silver or YP-terpene 
alone. 
A liquid broth 96 well plate-based antimicrobial screening assay was used to 
determine the Minimal Inhibitory growth Concentration (MIC) activity of YP- Silver nitrate, 
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YP-silver chloride, and YP-ET.   The purpose of this assay was to determine if the silver 
formulations and terpene were active, which would be verified by whether the antimicrobial 
agent inhibited the growth of the three pathogens.  The inhibition of the pathogens was 
determined from optical density readings by comparing the optical density of the plate after 
24 hours of microbial growth to the original reading at the start.  The minimum inhibition 
concentration (MIC) was defined as the lowest concentration of active that inhibited optical 
density greater than or equal to 75 percent of average of the positive, bacteria only, control 
wells.  The inhibition due to the three selected antimicrobials was further observed through 
the use of a metabolic indicator dye, resazarin.  The purple dye changes to pink in the 
presence of metabolic activity, which visually shows the wells with inhibited bacterial growth 
(see Appendix M).   
5.3 Synergy Experiments  
 A synergy assay was run in a 96 well plate to test for synergy between different 
concentrations of YP- silver nitrate and YP-ET and YP-silver chloride and YP-ET against E. 
faecalis, P. aeruginosa, and S. aureus (Appendices N – P). This experiment was run to test 
the hypothesis that the combination of silver and terpene would be more effective than either 
antimicrobial agent alone.  If the silver concentration required to effectively inhibit the growth 
of E. faecalis was lowered by the addition of inexpensive YP-terpenes, it would support the 
goal of reducing the amount of silver required for antimicrobial activity.  This would in turn 
reduce not only the cost of the actives, but also reduce the final cost of the antimicrobial 
dressing. 
To test this hypothesis, silver and terpene were diluted serially in microtiter plates to 
determine a concentration at which both antimicrobials were effectively killing alone and in 
   110
combination.  Although this experiment was repeated for all three wound pathogens, the 
experiment with E. faecalis will be described as a representative example.  The MIC’s for YP-
silver and YP-ET alone from the primary screening MIC assays were used as the basis for the 
MIC synergy assay.  In order to ensure that the actives will be above the MIC, a start 
concentration of higher than the MIC is selected.  The MICs from the primary assay against 
E. faecalis were that YP-ET had an MIC of 500 ppm, YP-Silver Nitrate had an MIC of 250 
ppm, and YP- silver chloride had an MIC of greater than 250 ppm.  In the synergy assay, the 
concentration of the initial solution added to the first well for both YP-silver and YP-terpene 
must be made at a concentration of four times the desired initial concentration because of the 
duplicate serial dilutions performed during the assay and to account for the volume of bacteria 
added to inoculate the microplate.   
For both YP- silver nitrate and YP-silver chloride the first well was designed to 
contain a concentration of 1000ppm, so an initial concentration of 4000 ppm was produced 
and 100 µl was added to the first well of Row A.  For each bacterium, plates 1 and 2 
contained YP-silver nitrate and plates 3 and 4 tested YP-silver chloride.  The silver was 
serially diluted across Row A, but no active was added to the last column.  Next YP-ET was 
added at a start concentration of 4000 ppm to achieve the intended 1000ppm.  The terpene 
was diluted serially down the first column, but no active was added to the last row.  E. 
faecalis was added to every well and the plates were incubated overnight.  This assay was 
repeated for P. aeruginosa, and S. aureus, however, the concentration of silver and terpene 
varied depending on the primary assay results.  Additionally, this synergy assay was repeated 
using a combination of bacteria, E. faecalis and P. aeruginosa mixed together, to test the 
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hypothesis that the combination of antimicrobials is more effective than each active alone 
against a broad range of mixed pathogens. 
 5.4 Terpene Resistance 
 Since terpenes can dissolve some materials, such as polystyrene, the materials that 
were considered for the layers of the dressing had to be tested for their resistance to terpenes.  
A simple protocol using the free and encapsulated terpene ET was developed to test four 
materials; 3M Tegasorb™, Coverlet O.R., calcium alginate and Polyurethane foam.  The 
protocol can be found in Appendix Q.  
5.5 In Vivo Vehicle Formulation 
For the in vivo experiment, the vehicle for the actives was chosen in a simple particle 
settling experiment, which showed that CMC remained homogeneous at 24 hours. Therefore, 
we had to decide on the concentrations of actives to be tested. As previously mentioned, based 
on a meat experiment for food borne pathogen applications, meat was inoculated with bacteria 
and then terpenes were added to the meat and the residual media was serially diluted in a 96-
well plate. This assay yielded an MIC terpene concentration of 6.6 mg/ml, which is 6 times 
the normal MIC. Therefore, we decided this would be our middle value and should chose 
significantly higher and lower values than this benchmark. We increased this concentration by 
almost 4 times to 24 mg/ml to act as our high value. This value is 24 times the normal MIC. 
Then we chose a value that is significantly lower than 6.6 mg/ml so we chose 1.5 mg/ml, 
slightly above the normal MIC. Therefore, these choices made up the medium, high and low 
concentrations of terpene, respectively. This experiment will test which concentration is most 
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effective in an in vivo environment. These formulations were then made up by adding the 
terpene to 0.75% CMC vehicle to act as the animal experiment formulations.  
To test the different vehicles, we referred back to the antimicrobial dressing layer and 
choice of CMC or alginate. Our next step was test the concentration of the both options and 
their settling properties in a particle settling experiment to determine which could be used in 
the in vivo experiment, and also to test the ability to homogenize if left to rest for a 24 hour 
time point (see Appendix W). Different concentration vehicles were made by diluting 1% 
CMC and also diluting 1% alginate into 1%, 0.75%, 0.6%, 0.45%, 0.3%, 0.15%, 0.1%, 0% 
formulations, with a uniform amount of commercial grade terpene (YP-ET) per tube. All 
tubes were vortexed and left on the bench top overnight. 
Since the YP-terpene particles had not settled in formulations containing 0.45% and 
higher CMC in the particle settling experiment, we chose to move forward with CMC as the 
vehicle for the animal experiment. We made up more 0.45%, 0.6%, 0.75% and 1% CMC and 
using a 3 mL syringe, created a ribbon of vehicle onto an orange peel. An orange peel can be 
thought of to have similar properties to that of skin, so we chose to use it as a surface to place 
the ribbon. From this test we determined that the 0.75% CMC was most desirable for our 
animal study as YP-terpene particles did not settle at 36 hours and also stayed put on the skin 
once the ribbon left the syringe. The 1% also stayed put on the skin, however, the terpene was 
not mixed very well in the syringe due to its high viscosity. A drop of the formulations was 
placed on a paper towel and their spreading was measured after 10 minutes. The 1% and 
0.75% CMC had moved the least. (Appendix Z). 
Since we were able to determine that 0.75% CMC remained most homogeneous, it 
was mixed with 3 different concentrations of YP- terpene to be used for the animal 
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experiment (see Appendix EE). Here these formulations contained a high (24 mg/ml), 
medium (6.6 mg/ml) and low dose (1.5 mg/ml) of YP-terpenes to be tested in vitro for activity 
before beginning the animal study. Once they have been proven for antimicrobial activity, we 
can proceed with applying the formulations onto the wound of the animal. 
5.5.1 In Vivo Formulation Antimicrobial Activity  
We had to prove that the actives maintained their antimicrobial effectiveness in the in vivo 
vehicle formulation composed of 0.75% CMC and the three concentrations of YP-ET described 
in section 5.5.  YP-silver chloride was not tested in vivo because the antimicrobial properties of 
silver are known and it is widely used in current silver dressings.  The main concern of our in 
vivo testing was to assess YP-terpenes antimicrobial properties and in an infected wound 
model. 
 The measurement of antimicrobial activity of the YP-ET formulated in the in vivo vehicle 
was carried out using the in vitro MIC assay against S. aureus.  This assay was conducted 
before the animal study to ensure that the terpenes in the vehicle would be active during the in 
vivo study and was also repeated after the study to prove the samples were still active at the end 
of the in vivo study (Appendix TT). 
5.6 In Vivo Testing  
 
Once we had formulated the actives in vehicle to be used in vivo, we then based our 
experiment off of Dr. Hamblins past protocol using P. aeruginosa and other non-published 
experiments (Hamblin et al, 2003). Many of Dr. Hamblin’s studies had been performed in 
vitro first and then proceeded to be tested in vivo. As mentioned, the first phase of the 
experiment is to genetically alter the bacteria (Staphylococcus aureus) with a lux fluorescent 
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gene, culturing it, and plating it in the dark overnight, taking an optical density reading and 
then testing it for bioluminescence (Demidova, 2005). Some of this bacterial stock was set 
aside for the in vivo study.  
The backs of male BALB/c mice were shaved using Nair hair removal and marked 
using colored markers. This mouse species was chosen due to prior research, and due to their 
size and anatomy. Mice were anesthetized by intraperitoneal injection of ketamine-xylazine 
cocktail (90 mg/kg ketamine, 10 mg/kg xylazine) for surgery and also for bioluminescent 
imaging. A full thickness wound was created on the skin by tracing a box onto the mouse’s 
back, and then cutting the first layer of skin using scissors and a forceps. There were no signs 
of bleeding in any of the wounds once they had been created and mice were euthanized when 
their conditions had reached sepsis or extremely visible agitation and infection of the wound 
site (Hamblin et al, 2003). Bioluminescent S. aureus was inoculated into the wound at 5*106 
CFU in 50 µl and then imaged for bioluminescence after 20 minutes. At this time point, active 
antimicrobial was topically applied to the wound at 0.1 ml per wound. This was spread into a 
thin layer by hand. The YP-terpene treatment groups consisted of three previously formulated 
concentrations of YP-terpene, high (24 mg/ml), medium (6.6 mg/ml) and low (1.5 mg/ml) 
groups (n=4). In the control groups (n=2), two mice received a vehicle only treatment, another 
two mice received no treatment, only an infected wound, and lastly, one of the control mice 
received a wound only, no infection (Figure 22). After 20 minutes, the mouse was imaged 
again with the bioluminescent camera and black and white and the color images were 
superimposed to gain an idea of the active effectiveness. The active application or vehicle 
only application was repeated daily in respective groups after bioluminescent images were 
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taken daily.  During this whole experiment, mice were monitored for signs of sepsis or severe 
irritation or aggravated behavior. 
 
Figure 22: Distribution of animals for the in vivo experiment 
 
After Time 0, the protocol was simplified to first take a light image using a still-life 
digital camera. Next the mouse is placed on a stand in the ARGUS camera setup and a black 
and white image is recorded. (Figure 23) 
Mouse Population
 
18 mice 
High Terpene 
 
(24 mg/ml high 
dose) 
 
4 mice 
 
n=4 
Medium Terpene
 
(6.6 mg/ml 
medium dose) 
 
 4 mice 
 
n=4 
Low Terpene 
 
(1.5 mg/ml low 
dose) 
 
4 mice 
 
n=4 
Control 
No treatment, 
CMC vehicle only 
Wound only 
 
(2 no treatment, 
2 vehicle only, 1 
wound only) 
n=5 
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Figure 23: Bioluminescent ARGUS camera setup. Left is the visual screen,  
imager and intensity controls, center is the computer for ARGUS commands, and to the right is the 
camera stand light-tight box. 
 
 
Here the black and white image is read with the ARGUS software with the 
luminescence on, which freezes a black and white image of the mouse on the stand. Next the 
mouse must be imaged for fluorescence. The memory must be switched to memory two, and 
pick the photon counting option under the Imaging drop down menu. A color image of the 
mouse will be taken by counting the amount of bioluminescent photons in each area within 
the range of the camera. This will show up as a rainbow of colors around the wound site. The 
overall analysis is assessed with the superimpose option, which superimposes the color image 
on top of the black and white image. This can then be further assessed by using the area 
analysis option, and drawing a selected area to measure the bioluminescent intensity. This 
value is dependent on the bit size of the image. By multiplying the intensity gained at a 
   117
certain bit range, the numbers are standardized through a series of factors which are 
multiplied by the intensity to yield a series of intensities consistent to each other. 
 
Table 20: Ranges of bit sizes of bioluminescent images  
and their respective multiplicative factor 
 
Bit range 3 4 5 6 7 8 9 10 11 12 13 14 
Multiplicative 
Factor 
1 2 4 8 16 32 64 128 256 512 1024 2048
 
 
After seven days of repetitive treatment and imaging, the treatment was stopped, and 
animals were to be assessed at day ten of the study. After 10 days, the animals were 
euthanized using a ten-fold increase in anesthetic and animals were properly disposed of in a  
-60ºC freezer, as indicated by the Animal Care Facility. 
5.7 Materials of Construction 
 Various materials were considered and were tested in vitro for use in an antimicrobial 
wound dressing. As previous described (Chapter 4) many of the materials that the team first 
looked at had limitations that including cost, manufacturability, and functionality. Therefore, 
after careful consideration through research and in vitro assays the final materials of the 
antimicrobial wound dressing include: 
Secondary Layer 
 
• Polyurethane Adhesive  Foam 
 
Active Layer 
 
• 1.5% Medical Grade Carboxymethylcellulose (CMC) 
• 0.3% Agarose 
• 1.75% Glycerol 
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• 6.6 mg/ml YP-ET 
• 41.8 µg/ml YP-Silver Chloride 
 
 
Contact Layer 
 
• 1.5% Sodium Alginate 
• 1.75% Glycerol 
• 0.5% Calcium Chloride 
 
5.8 Dressing Assembly 
 The assembly of the team’s antimicrobial wound dressing prototype is quite simple. 
The dressing can be manufactured in bulk in nearly any standard chemical or biological 
laboratory using inexpensive, readily available materials. 
 The calcium alginate layer is the first to be constructed by creating a dry sodium 
alginate-glycerol film, which is then soaked in calcium chloride for 24 hours and washed with 
water to remove the excess sodium and unreacted calcium chloride. After washing, the 
calcium alginate film is cut to size and placed in a freezer (See Appendix JJ) to create a stable 
base on which the active layer will be poured on top of. 
 Next, the active layer is constructed (See Appendix KK) using the materials listed in 
Section 5.7. A 50°C water bath is used to warm all of the materials for this layer as agarose 
begins to solidify at temperatures below 40°C. After the materials have reached temperature 
equilibrium in the bath, 1.5% w/w CMC, 1.75% w/w glycerol, 6.6mg/ml YP-ET, and 
41.8µg/ml YP-silver chloride are respectively added to a 100ml glass bottle. After the 
addition of all of the materials, the bottle must mixed to obtain a homogeneous mixture. Then, 
agarose is added to achieve a 0.3% w/w final concentration to the bottle and vortexed to mix 
all of the ingredients once again. The sealed bottle containing the CMC active formulation is 
kept in the heated water bath until use.  
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 To assemble the dressing, the CMC, glycerol, YP-ET, YP-silver chloride, and agarose 
mixture is poured over the frozen alginate film to form the two layer dressing. The tray 
containing the two layer formulation is frozen at -80°C freezer for approximately 1 hour and 
lyophilized (freeze-dry) for at least 24 hours as described in Appendix KK. After 24 hours, 
the dry two layer dressing is removed from the lyophilizer, and the polyurethane foam 
adhesive secondary dressing is firmly attached so that the excess adhesive overlaps the 
dressing evenly. The dressing can applied easily to a wound and remain in place for at least 7 
days. 
5.8.1 Lyophilizing (Freeze-Drying)  
 In order to obtain the material properties that were previously specified, the team 
sought to lyophilize or freeze-dry the mixture for more desirable properties (see Table 21). 
The overall process of freeze-drying takes approximately 24 hours. The desired mixture is 
placed into the lyophilizer at -40 °C. As the amount of water in the mixture decreases due to a 
drop in chamber pressure, a continuous interpenetrating network is formed, which has 
improved thermo-stability meaning the hydrocolloid or gel is less soluble and won’t fall apart 
when in contact with the wound bed (Koken, 2005).  
Table 21: Evaluation of Drying Techniques 
 
 Advantages Disadvantages 
Lyophilizer - more homogeneous 
- takes 24 hrs to cycle 
- produces foamy material 
- can control porosity by choosing different 
temperatures for the pre-freezing process 
 
- Max limit to number of trays 
lyophilizer can hold 
- gel must be frozen before 
entering the lyophilizer 
Conventional Air 
Drying 
 - large amount of gels can be dried at once - takes at least 48 hours to 
completely dry 
- non-homogeneous drying 
- resultant gel is brittle without 
addition of plasticizer 
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5.9 Primary Dressing Characterization 
 Once the primary dressing, consisting of the contact and active layers, was assembled, 
tests were conducted to determine its effectiveness.   The dressing had to be tested to 
determine if it was an effective barrier against contamination and could inhibit the growth of 
wound pathogens. 
5.9.1 Antimicrobial Barrier Assay 
 The antimicrobial barrier assay is used often in research to validate the effectiveness 
of a wound dressing. It has been used by groups such as Holder et al, 2003 to determine if a 
prototype dressing is an effective antimicrobial layer, by inhibiting microbes on the surface of 
the dressing to enter the wound bed and increase the chance of bacterial infection from an 
outside source. A punch biopsy was used to create discs of the prototype dressings as well as 
sterile filter paper (negative control). Five disc specimens from each sample were placed on a 
separate Mueller-Hinton agar plate as shown in Figure 24. A drop of S. aureus, which was 
calibrated using a 0.5 McFarland Standard, was placed on the top of each disc as shown in 
Appendix MM. The plates were placed in an incubator and discs were removed at 1, 2, 4, 8, 
and 24 hours, respectively to look for bacterial growth under the dressing. 
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Figure 24: Antimicrobial Barrier Assay Plate Set-up 
5.9.2 Disc Diffusion Assay 
 In order to determine the optimal concentration of YP-ET for the prototype dressing as 
well as if the active contained within the CMC layer truly does diffuse out of the dressing and 
into the wound bed, a disc diffusion assay was conducted (Holder et al, 2003).  A disc 
diffusion assay was also performed to determine the final concentration of YP-silver chloride 
needed in the dressing in the same manner used to assess the YP-terpene value (Appendix 
LL).  P. aeruginosa and S. aureus were grown on Mueller-Hinton agar plates for 24 hours. 
The plates were then visually sectioned off into four areas and a disc created using a punch 
biopsy of either dressing or sterile filter paper was added to each section as shown in Figure 
25. 
 The plates were then incubated for 24 hours as described by the protocol in Appendix 
LL. Upon removal from the incubator, the radius of clearing was measured for each disc. Any 
clear zones of 1mm or greater indicate that the active released from the dressing and diffused 
onto the plate. Additionally, clear zones would conclude that the concentration of active was 
high enough to kill and inhibit the growth of microbes.  
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Figure 25: Disc Diffusion Assay Agar Plate Set-up 
5.9.3 Corrected Zone of Inhibition 
 This assay will be used to determine the duration of antimicrobial efficacy of the 
dressing.  The dressing will be cut to an appropriate size and placed on a lawn of bacteria, 
such as P. aeruginosa or S. aureus, grown on a Petri dish.  The dishes will be incubated for 24 
hours and the zone of inhibition measured.  The piece of dressing will then be applied to a 
new lawn of the same bacteria, incubated again for 24 hours, and the zone of inhibition 
measure as shown in Appendix NN.  This process will continue for 7 days or until the 
dressing no longer produces an antimicrobial effect. 
5.9.4 Transport Calculations 
In order to determine the transport properties of our prototype we modeled our dressing as 
diffusion through a 2-phase medium (Figure 26). We also had to make a variety of mass 
transfer assumptions including that the reaction: 
• Is in an unsteady-state 
• No accumulation of product occurs 
• No convective force is present 
• The diffusion of water controls the release of the actives (YP-silver chloride and  
      YP-ET) 
• Diffusion in other directions besides the one specified are negligible 
• The diffusion across the first phase (CMC layer) is constant and uniform as it contains 
the actives 
• No bulk flow 
• No chemical reaction 
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Figure 26: Diffusion Calculations 
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5.10 Secondary Dressing Characterization 
 Polyurethane foam was selected for the secondary dressing to be used in combination 
with the primary dressing we constructed.  The material properties of the foam were tested 
and compared to other secondary dressing products.  The test protocols that were used to test 
multiple secondary dressings are described in the following sections. 
5.10.1 Instron® Mechanical Testing- Peel Test Configuration 
An Instron peel test was used to determine the adhesive strength for various secondary 
dressing candidates as shown in Appendix R. When conducting a test of this nature it is 
important to use a configuration that is similar to the environment in which the material will 
later be used. The results of this test will then be used to aid the team in quantitatively 
determining the most viable option for the outer component of the dressing to ensure that the 
adhesive will not disturb the underlying wound bed upon removal or fall off prematurely.  
Using the ASTM standard D3330, a 3345EH electromechanical test frame configured 
with a 50 N load cell and 250 N capacity pneumatic grips at 70 psi with 25 x 25 mm flat 
metallic faces were used for this test. A variable angle peel fixture was set at 135 degrees to 
simulate an individual pulling the specimen off the skin. The complete test configuration is 
shown in Figure 27.  The test methodology called for a test speed of 5 mm/min.  The set up of 
the variable angle sled is shown in Figure 28. A piece of leather was used as the substrate to 
simulate skin as suggested by Instron employees. Figure 29 shows a close up of a test 
specimen during the peel test. The test specimens were all cut into rectangular strips having a 
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length of 100 mm, a width of 25 mm to ensure consistency among each sample group and 
individual specimens. 
The most common method for characterizing adhesives is a basic peel test. Bluehill® 2 
(Instron® software) can easily perform this test method. This test method was used to evaluate 
the adhesive strength of various specimens. 
 
 
Figure 27: Complete test configuration for 135 degree peel test 
 
 
 
 
 
 
 
 
 
 
Figure 28: Close up of sled with leather substrate 
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Figure 29: Close up of adhesive specimen during peel test. 
 
5.10.2 Instron® Mechanical Testing- Tensile Test Configuration 
This testing is necessary to aid the team in reaching its project goal, which is to create 
a dressing that enhances the current silver dressings that are on the market. Therefore, 
Acticoat™ 7 (“Gold Standard”) and SilvaSorb™ were tested in tension to determine their 
mechanical properties (Appendix S). These two products were not tested using the peel 
fixture as they to do have any adhesive properties. 
Using the ASTM standard D882, a 5567 electromechanical test frame configured with 
a 50 N load cell and 250 N capacity pneumatic grips at 70 psi with 25 x 25 mm flat metallic 
faces were used for this test. The complete test configuration is shown in Figure 27.  Using 
the ASTM standard, the test speed was calculated to be 24.5 mm/min using A=BC where A is 
the test speed, B is the initial distance between the grips (50.8mm), and C is the initial strain 
rate (0.5mm/mm*min).   Figure 30 shows a close up of a specimen being pulled to failure and 
Figure 27 shows the specimen after the test. Figure 32 demonstrates a close up of the other 
specimen tested. 
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The samples were prepared as indicated by the manufacturer’s guide: the Acticoat™ 7 
was moistened with sterile water and then drained for two minutes (Smith & Nephew, 2005) 
and SilvaSorb™ was moistened with saline to simulate making contact with the skin as the 
wound is to be washed out with saline prior to use (AcryMed, 2005). Each specimen was cut 
precisely into a rectangular strip, which was 115 mm long and 25 mm wide. 
Bluehill® 2 can easily perform this test method. This test method was used to evaluate 
the maximum extension and load, tensile stress and tensile strain at the maximum load, 
maximum tensile strain, and modulus of the specimens. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 30: Complete test configuration for tensile test. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 31: Specimen being pulled to failure. 
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Figure 32: SilvaSorb™ specimen during tensile test 
 
 
 
 
Figure 33: Acticoat™ 7 specimen after testing. 
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 6. Results 
This section describes the results found following the methods and procedures 
previously explained.  Results for antimicrobial activity test and terpene resistance test are 
described in detail.   
6.1 Antimicrobial Formulations 
 As described in the methods section, three formulations of antimicrobial were 
encapsulated and tested in vitro to determine if each had antimicrobial properties against 
wound pathogens and the concentrations at which each was effective. 
6.1.1 Eugenol Thymol (YP-ET) 
In most strains, YP-ET showed signs of inhibited growth and in most cases the most 
favorable MIC.  YP-ET demonstrated a broad range of growth inhibition against the different 
pathogens and therefore, when it is incorporated in a wound dressing would be effective 
against a variety of wounds infected with different pathogens.  Eugenol has also shown to 
posses odor reducing and pain reducing properties, making it a positive consideration for our 
experiment. Therefore, due to this preliminary data, we predict this terpene formulation to be 
most effective in inhibiting microbial growth in the wound. 
6.2 Antimicrobial Activity 
 After the silver nitrate, silver chloride, and YP-ET terpene had been encapsulated 
following the protocols described in the previous section.  The antimicrobial activity of these 
three agents was determined and the results from the test against E. faecalis, P. aeruginosa, 
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and S. aureus are displayed in Appendix M. All three of the antimicrobial agents showed 
activity against the selected wound pathogens.   
 The data indicated that although all three antimicrobial agents showed activity, there 
were differences in their effectiveness.  As expected, the two silver formulations were not 
extremely effective against E. faecalis; however, the formulations were effective against P. 
aeruginosa, and S. aureus.  Also as anticipated, YP-ET was most effective at inhibiting the 
growth of S. aureus, but also showed inhibiting of E. faecalis and P. aeruginosa.  The silver 
formulations could compensate where the YP-ET had lower inhibition, and the YP-ET could 
compensate where the silver had lower inhibition. The results of the primary assay support the 
hypothesis that the combination of YP- silver nitrate, YP-silver chloride and YP-ET should be 
more efficient than any of the three alone.   
6.3 Synergy Experiments 
The results from the synergy assays showed the antimicrobials inhibited growth 
against E. faecalis, P. aeruginosa, and S. aureus.  The table below lists the MIC for terpene, 
silver nitrate, silver chloride for the four plates for each of the bacteria that were tested.  The 
values in the table demonstrate that each combination of silver and terpene resulted in a lower 
MIC concentration of the active than compared to the actives alone. 
Table 22: Average Synergy MIC Values 
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All three antimicrobial agents demonstrated growth inhibition.  The MICs were close 
to the hypothesized values.  For example, terpenes were previously found to be less effective 
against P. aeruginosa and the MIC values from the synergy experiment were higher when 
compared to the terpene MIC values for E. faecalis, and S. aureus. 
When the MIC values of the combinations of YP-ET and YP- silver are compared the 
MIC values for each active alone, the values of the combination of actives are equivalent or in 
most cases lower. In both the primary and synergy assay the MIC of terpenes against P. 
aeruginosa was 500 ppm because of its resistance to terpenes.  The MIC of YP-silver nitrate 
and YP-silver chloride was equivalent or lower in the synergy assay.   The results support the 
hypothesis that the combination of silver and terpenes will be more effective at inhibiting a 
broader range of bacteria.  The synergy assay proved that the combination of silver and 
terpenes was effective against the three chosen strains of bacteria.  The assay also 
demonstrates that the concentration of silver required to inhibit the growth of bacteria can be 
reduced with the addition of terpenes.   
The synergy assay that was conducted with the combination of bacteria, E. faecalis 
and P. aeruginosa, demonstrated that the encapsulated forms of silver and terpenes inhibited 
the growth of the bacteria.  Due to resistance of bacteria, YP-silver nitrate and YP-silver 
chloride alone would have not been effective against E. faecalis. The combination of YP-ET 
with the encapsulated silver forms provided the same antimicrobial effectiveness than either 
of active alone.  Table 23 shows the MIC values from the synergy experiment against the 
combination bacteria.  When YP-ET was added to silver, the silver MIC value was lowered.  
For the case of YP-silver nitrate, alone the MIC was 62.5ppm, but with the addition of YP-ET 
the MIC values was reduced to a range of 15.63- 31.25ppm as shown in Figure 28.   
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Table 23: Synergy MIC Values for Combination Bacteria 
 
 
 
 
 
 
 
Figure 34:  Antimicrobial Activity of the YP-ET and YP-Silver Chloride 
 
6.4 Terpene Resistance 
 After completing the terpene resistance test, which was explained in Section 5, the 
materials were further evaluated.  Any material that was dissolved by terpenes was eliminated 
and no longer eligible for consideration for the final dressing.  The results from the terpene 
resistance test are shown in Table 24.   
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Table 24: Terpene Resistance Test 
Material Control (water) YP-ET Free ET 
Tegasorb No Change No Change Fell Apart 
Calcium Alginate No Change No Change No Change 
Coverlet™ O.R. Inner No Change No Change No Change 
Coverlet™ O.R. Outer No Change No Change No Change 
Polyurethane Foam No Change No Change Doubled in size 
  
The results from the terpene resistance test eliminated the use of 3M Tegasorb™ in 
the dressing because of its deterioration when in contact with free ET.   However, 3M 
Tegasorb™ did not show changes from YP-ET.  Once the 3M Tegasorb™ samples were 
removed from the tubes, it retained the liquid with little drainage from material.   
 
Figure 35: Terpene Resistance Test- 3M Tegasorb™ 
 
The calcium alginate did not change in the presence of terpene; however, the free 
terpene was absorbed less than the YP-ET and water. The free ET has an oily consistency 
making it more difficult to absorb by the calcium alginate.  After removal from the tube, the 
calcium alginate did not retain as much liquid as did 3M Tegasorb™.  The control sample, 
containing water, appeared to maintain the largest volume of liquid.   
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Figure 36: Terpene Resistance Test- Calcium Alginate 
 
 Both the outer section, which is an adhesive material and the inner section, which is a 
gauze material of Coverlet™ O. R. were tested for their resistance to terpenes.  The adhesive 
outer layer demonstrated no changes in the presence of YP-ET or free ET.  After removal 
from the liquid, the sample of Coverlet™ O. R. that had been soaked in YP-ET exhibited the 
most adhesive ability when compared to the other two samples.  The control sample also 
retained some adhesive properties, while the sample soaked in free ET was least adhesive.   
 
Figure 37: Terpene Resistance Test- Coverlet™ O. R.  Outer Section 
 
 
   136
 The inner section of the Coverlet™ O. R., which has gauze-like properties, was not 
affected by the terpenes.  All three samples absorbed the liquid and displayed no physical 
changes from the YP-ET or from the free ET.   
 
 
Figure 38: Terpene Resistance Test- Coverlet™ O. R. Inner Section 
 
  
The polyurethane foam was highly absorptive in the free-terpene solution, but did not 
appear to absorb any water or any of the YP-ET solution as the surface seems to repel water. 
In the free terpene, the sample doubled in size yet in the others there was no physical change.  
 
 
 
 
 
Figure 39: Terpene Resistance Test – Polyurethane Foam sample 
 
Control    Encap.Terpene    Free Terpene
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The results collected from the terpene test eliminated the use of 3M Tegasorb™ in the 
final design of the dressing.  The results of the other samples provided positive feedback in 
the use of calcium alginate, Coverlet™ O. R., or Polyurethane Foam in the dressing.   
6.5 In Vivo Vehicle Formulation 
Interestingly, in the particle settling experiment, after 24 hours all of the alginate 
concentrations separated into a cloudy layer and a liquid layer, the terpene fully settling to the 
bottom of the tube. The 1% alginate resulted in 23% settling occur, and each respective 
concentration ranged between 14% and 23% settling, not favorable for delivery of 
antimicrobials. On the other hand, the 0.45% CMC and higher were effective in remaining 
homogeneous and showed little to no signs YP-terpene settling. Therefore, we can conclude 
that alginate is not an effective vehicle for the animal experiment, and also it is not an 
effective material for delivery of actives to the wound bed as we can deduce that the 
antimicrobials will settle deep into the wound after 24 hours (see Appendix W). 
 
Figure 40: Evidence of particle settling 
Left: 0.6% CMC + terpene, right: 0.1% CMC + terpene 
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6.5.1 In Vivo Vehicle Assay Results 
 The in vivo vehicle was tested in vitro, as described in the methods section, to 
determine if the antimicrobials were still active after the suspension in CMC.  The results 
from this test prove that the YP-ET suspended in CMC retained its antimicrobial properties 
and was still effective in inhibiting the growth of S. aureus.  Table 25 shows the MIC Values 
for the three concentrations of YP-ET in CMC, CMC alone, and three concentrations of YP-
ET with no vehicle.   
Table 25: In Vivo Vehicle MIC Values 
 
Sample MIC µg/ml 
High YP-ET 24.0 mg/ml in CMC 250 
YP-ET 24.0 mg/ml  250 
Med YP-ET 6.6 mg/ml in CMC 206 
YP-ET 6.6 mg/ml  412.5 
Low YP-ET 1.5 mg/ml in CMC 375 
YP-ET 1.5 mg/ml 375 
CMC only No kill 
YP-ET 4.0 mg/ml 500 
 
  
The table demonstrates that although the MIC values change depending on the 
concentration of YP-ET, all of the formulations show inhibition of bacterial growth.  As 
expected, the CMC alone, which has no antimicrobial benefit, did not inhibit bacterial growth.  
Since the YP-ET suspended in CMC retained its antimicrobial activity in the in vitro assay, 
the formulations will be further tested in an in vivo wound model.    
6.6 In Vivo Testing 
 Overall, all of the terpene groups showed positive wound healing results evidenced by 
a decrease in wound area over time (Figure 35). These terpene groups had the greatest 
reduction in percent change in the wound area as compared with the control group of vehicle 
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only.  Here, the control group was shown to get worse by increasing in wound area, and then 
gradually getting better at a later time point. In the terpene treatment groups, the wounds 
immediately show improvements in wound area and wound closure, as the wounds in all 
groups decrease in area over time (see Appendix GG).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 41: Percent change in wound area over time in animal groups 
 
After ten days, where treatment had been stopped for three days, the wounds showed 
signs of bacterial growth. The mice had suppressed immune systems, so they therefore cannot 
fight of any remaining bacteria on their own. Fortunately, the mice which had received 
terpene treatment had a lower bacterial count and lower bioluminescent intensity of bacteria 
as compared with those who had been treated. 
Interestingly, the mice weights varied fluctuated at three different time points of 
measurement as shown in Appendix HH. At the middle time points, all mice had lost weight, 
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signs of their change in feeding and activity, reflective of the pain or fighting of the bacteria 
in the wound site. Fortunately, by the third time point, many of the mice had gained weight in 
the terpene groups, correlated to wound healing and pathogen inhibition. However, in all of 
the control groups, the mice had lost weight over time, and even at the third time point, there 
was no indication of further weight gain. 
When analyzing the bioluminescent data, again, the terpene groups showed the most 
promising results as the bacterial load was decreased to a few small dots of color if not 
completely eradicated by day 7 (Figure 42; Appendix OO). In the control (vehicle only) 
mouse, the animal did not recover from anesthesia so we submitted the mouse to testing to 
determine what the cause of death was. A swab of the heart was streaked onto a plate and 
after 24 hours of incubation, the whole plate bioluminesced, indicating death due to a 
systemic infection of bioluminescent S. aureus. The lighter the color on the spectrum means 
the higher fluorescence in J/cm2, as indicated by the color bar to the side of the figure (Figure 
42). The best visual inhibition of growth was indicated by the high concentration of terpene, 
whereas the least inhibition was indicated by the no treatment group (Figure 42). 
 
   141
Intensities (J/cm2) 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 42: Bioluminescent images at four time points  
for terpene and control treatment groups 
  
 When further analyzing these images, an area was isolated around the wound side and 
ARGUS software used calculated the bioluminescent intensities as a function of the bit size. 
These numbers allow us to numerically analyze the bacterial inhibition at each daily reading 
(Appendix II). Again, the terpene groups yielded similar results, except the low concentration 
of terpene peaked before decreasing over time. The vehicle only control gradually decreased 
the bioluminescence, indicating slow inhibition of bacteria, however was not as instant as the 
terpene treatment groups and increased toward the end of treatment. The lowest values of 
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intensity were reached by the high and medium terpene treatment groups. The no treatment 
control showed that the infection in the wound increased dramatically over time, indicating 
the mouse was not able to fight the infection on its own. 
 
6.7 Material of Construction 
 The materials selected are listed next to each of the functional layers in the figure 
below.  The primary dressing contains the interfacial barrier and actives layer.  The materials 
selected for the interfacial barrier are calcium alginate and glycerol.  The actives retention 
layer includes CMC, glycerol, and the antimicrobial actives.  The second component of the 
dressing is the outer barrier which is composed of PU foam.  
 
 
Figure 43: Materials Selected for Final Dressing 
 
6.8 Dressing Assembly 
 The steps for the dressing assembling the dressing are described in this section. 
 
 
Step 1:  Cast alginate layer 
  
This step involved the cross- linking of the alginate with CaCl2.  This layer was rinsed 
with water to remove excess sodium and excess calcium chloride to produce the calcium 
alginate formulation.  The calcium chloride was cut to fit the casting tray, shown in Figure 44.  
PU Foam 
 
CMC 
Glycerol 
Antimicrobial actives 
 
Calcium alginate, Glycerol 
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Figure 44: Calcium Alginate Cut to Size 
 
 
Once the calcium alginate was cut, it was placed in the casting container and prepared for the 
actives to be added. Figure 45 shows the calcium alginate layer cast and ready for next layer 
to be produced. 
 
 
 
 
 
 
 
 
 
 
Figure 45: Calcium Alginate Cast 
 
 
Step 2: Create CMC active layer 
 
 The second layer, the actives layer, was prepared by weighing out the components of 
1.5 % CMC, 1.75% glycerol, 0.3% agarose, 6.6 mg/ml YP-ET, and 41.8 µg/ml YP-silver 
chloride.  As previously described, each of these components was kept in a 50°C water bath 
prior to weighing.  Once each component was measured, the entire formulation was 
immediately poured on top of the calcium alginate layer.  Figure 46 shows the addition of the 
actives layer to the calcium alginate layer.   
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Figure 46: Addition of Actives Layer to Calcium Alginate 
 
 
Step 3: Lyophilze dressing layers 
  
 After the CMC actives layer was added to the calcium alginate layer, the dressing was 
frozen at -80°C for one hour.  The freezer shown in Figure 47 was used to freeze our dressing.   
 
 
 
 
 
 
 
 
 
 
 
Figure 47:  -80°C Freezer 
 
 
The frozen dressing was lyophilized for 24 hours using the lyophilizer shown in Figure 48.  
This lyophilizing process created a dressing with more homogeneous characteristics and more 
desirable properties.   
 
 
 
 
 
 
 
 
 
Figure 48: Lyophilizer 
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Step 4: Apply the secondary dressing and place dressing on wound area 
 
 Once the lyophilization process was finished, the primary dressing consisting of the 
contact and actives layer was ready to be used with the secondary dressing.  The final primary 
dressing formulation is shown below.   
 
 
 
 
 
 
 
 
Figure 49: Final Primary Dressing 
 
The primary dressing was adhered to the secondary dressing, PU Foam.  This was the final 
step in producing our antimicrobial dressing, which is shown in Figure 50. 
 
 
 
 
 
 
Figure 50: Final Antimicrobial Dressing 
 
The final dressing, consisting of both the primary and secondary dressing, was complete and 
could be placed on a wound site.  The adhesive properties of PU Foam secured the dressing to 
the wound area.  An example of the dressing applied to a human arm is illustrated below. 
 
 
 
 
Figure 51: Final Dressing 
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6.9 Primary Dressing Characterization 
 The following results demonstrate the outcome of the test conducted on the primary 
dressing using varying concentrations of YP-ET and YP-silver chloride.  The results proved 
that the concentrations of actives we selected for our final design were most effective when 
compared to the primary dressings with varying concentrations. 
 6.9.1 Antimicrobial Barrier Assay - YP-ET  
This assay allowed the team to determine that the prototype dressing does act as an 
antimicrobial barrier to S. aureus. It is important that the dressing act as an antimicrobial 
barrier in order to keep microbes out of the wound site originating from an external 
environment. If external microbes were able to enter the wound, they could possibly hinder 
wound healing as well as increase the chance of infection. Table 26 demonstrates that 
bacterial growth was observed under the sterile filter paper discs (negative control) at 24 
hours. On the other hand, our dressing formulations were effective antimicrobial barriers as 
no growth was seen under these dressings at any of the specified time points. 
 
Table 26: Results of Antimicrobial Barrier Assay 
 
 
 
 
 
  
Bacterial Growth Under 
Dressing at Time Points         
Plate 1 (Sa) 1h 2h 4h 8h 24h 
Filter Paper (5 pieces) None None None None  
Yes – radius 
of disc 
Plate 2 (Sa)      
Control (5 pieces) None None None None None 
Plate 3 (Sa)      
6.6 mg/ml YP-ET (5 pieces) None None None None None 
Plate 4 (Sa)      
24 mg/ml YP-ET (5 pieces) None None None None None 
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6.9.2 Disc Diffusion Assay 
By using the criteria set forth by the disc diffusion assay protocol found in Appendix LL 
(Holder et al, 2003), it was determined that the prototype dressing with YP-ET as the 
antimicrobial did provide antimicrobial actives to the plates of bacteria in concentrations high 
enough to kill pathogenic growth. Table 27 provides the radii of clearance for each pathogen 
and dressing type. 
Table 27: Average Radius of Clearing 
Including Area under Dressing during Disc Diffusion Assay 
 
 
 
 
The results above show that no clearance was observed with either the sterile filter 
paper or the control dressing without YP-ET when using both P. aeruginosa and S. aureus. 
On the other hand, kill occurred when using the dressings with 6.6mg/ml and 24.0 mg/ml. 
increased kill was seen when the higher concentration of terpene was present in the dressing. 
Additionally, the dressings with the active were more effective against S. aureus than P. 
aeruginosa, which supports in vitro data previously conducted.  Finally, by using the results 
from the in vivo animal study along with the results demonstrated here, the team was able to 
select 6.6 mg/ml as the final YP-ET concentration for the prototype dressing. 
  By repeating the disc diffusion assay using the dressing with the combined 
antimicrobial agents, YP-ET and YP-silver chloride, the team was able to determine that not 
only is the combination of YP-ET and YP-silver chloride effective, but they also inhibit more 
pathogens than either of the two constituents alone as shown by an increased zone radius of 
clearing in Table 28.  
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Table 28: Average Radius of Clearing Including Area under Dressing  
during Disc Diffusion Assay Using YP-ET and YP-Silver Chloride 
 
Sa 
Average Radius  of 
Clearing (mm) Pa 
Average Radius  of 
Clearing (mm) 
Filter Paper 0 Filter Paper 0 
Control –  
13.6ppm YP-Silver Chloride  4.01 
Control  -  
13.6ppm YP-Silver Chloride 4.63 
6.6 mg/ml YP-ET,  
13.6 ppm YP-Silver Chloride 5.70 
6.6 mg/ml YP-ET,  
13.6 ppm YP-Silver Chloride 5.99 
6.6 mg/ml YP-ET,  
41.8 ppm YP-Silver Chloride 6.07 
6.6 mg/ml YP-ET,  
41.8 ppm YP-Silver Chloride 9.15 
6.6 mg/ml YP-ET,  
70.0 ppm YP-Silver Chloride 6.15 
6.6 mg/ml YP-ET,  
70.0 ppm YP-Silver Chloride 5.52* 
* Zone had more depth than width. 
 
  
Furthermore, this assay allowed the team to choose the final YP-silver chloride 
concentration for the dressing. The low concentration (13.6 ppm) was quite effective in the 
present assay. However, the team chose 41.8 ppm for the silver active component, which is 
nearly half of the currently used concentration, which ranges from 70-100 ppm (Smith & 
Nephew, 2005). The medium concentration of YP-silver chloride was the best choice for the 
dressing as it was very effective at inhibiting both Sa and Pa when used with 6.6 mg/ml YP-
ET. This prototype dressing provided inhibition both in the radial direction as well as through 
the agar plate. The high concentration “ate” through the agar and therefore, the team 
speculates that this may be harmful to a patient’s skin. Additionally, the low concentration 
was ruled out as it provided slightly less inhibition than the medium dose and as the team 
experienced with YP-ET, it is necessary to use a higher concentration in vivo to acquire the 
desired bacterial inhibition.  
6.9.3 Corrected Zone of Inhibition 
The results of the corrected zone of inhibition assay using the YP-ET prototype were 
inconclusive. However, they did give the team some valuable insight about the capabilities 
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and limitations of the current dressing. The active was released from the dressing and did 
provide killing and inhibition for over 72 hours before the assay was terminated, which proves 
that the dressing is capable of providing a sustained release of the antimicrobial. Additionally, 
the data on day 1 demonstrates that the higher the concentration of terpene equals more 
inhibition, which is what the team had hypothesized. As the days progressed, the data was less 
and less accurate as the dressing was difficult to move and small portions of the dressing were 
lost during the transfer from plate to plate using sterile tweezers.  
The assay was supposed to run for 7 days as that is the lifespan of most silver 
dressings currently on the market, yet the dressing swelled considerably and was very hard to 
transfer from day to day. By day 4, the dressings could no longer be placed on a new plate of 
bacteria. 
 As a result of this assay, we determined that when the punch biopsy was taken and the 
dressing was placed on the Mueller-Hinton agar plate, the CMC layer swelled over the 
alginate layer. Therefore, we came up with the solution of using bottle caps to cast the gels to 
use for the next phase of this assay. This way the alginate layer would keep the CMC layer 
sealed on the sides and reduce swelling caused by the punch biopsy pieces. The swelling that 
was observed using the biopsy pieces is uncharacteristic of the whole dressing as it is 
surrounded by the alginate contact layer on the sides. 
 
Table 29: Results of Corrected Zone of Inhibition Assay 
using YP-ET Prototype Dressing Against Sa 
 
 
Radius of  Inhibition 
(mm)   
Plate 1 (Sa) 1 day 2 days 3 days 
Filter Paper 0 0 0 
Control 0 0 0 
6.6 mg/ml YP-ET 1.06 2.03 2.72 
24 mg/ml YP-ET 1.63 0.14 Not enough dressing left 
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Table 30: Results of Corrected Zone of Inhibition Assay  
using YP-ET Prototype Dressing Against Sa 
 
 
Radius of  Inhibition 
(mm)   
Plate 2 (Sa) 1 day 2 days 3 days 
Filter Paper 0 0 0 
Control 0 0 0 
6.6 mg/ml YP-ET 1.47 0.48 0.52 
24 mg/ml YP-ET 1.57 1.52 0.14 
 
  
 Additionally, the team performed the same assay using the final prototype dressing, 
which contained both YP-ET and YP-silver chloride to determine the longevity of the overall 
dressing. The results demonstrated that the dressings were effective for 7 days and still 
provided considerable inhibition on Day 7 as shown in Table 31. 
 
 
Table 31: Results of Corrected Zone of Inhibition Assay  
using YP-ET and YP-Silver Chloride Prototype Dressing Against Sa 
 
 
 
Radius of  Inhibition 
(mm)   
 
Plate 1 (Sa) 1 day 3 days 5 days 7 days 
Filter Paper 0 0 0 0 
Control -  13.6ppm YP-Silver 
Chloride 4.52 4.06 3.85 
 
3.27 
6.6 mg/ml YP-ET,  
13.6 ppm YP-Silver Chloride 5.73 5.56 4.02 
 
3.98 
6.6 mg/ml YP-ET,  
41.8 ppm YP-Silver Chloride 6.02 5.68 5.43 
 
4.69 
6.6 mg/ml YP-ET,  
70.0 ppm YP-Silver Chloride 6.20 6.01 5.73 
 
4.71 
 
 
 The team was then able to us the disc diffusion results as well at the corrected zone of 
inhibition results to finalize our selection of 41.8 ppm as the concentration of the YP-silver 
chloride active.  
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6.10 Secondary Dressing Characterization  
 The following sections describe the results of the secondary dressing characterization 
tests that were previously explained. 
6.10.1 Instron® Mechanical Testing- Peel Test 
The polyurethane foam and the island foam showed similar results and the 
hydrocolloid demonstrated only a slightly lower adhesive strength. A very low adhesive 
strength could result in the dressing prematurely falling off. On the other hand, Coverlet™ 
O.R. has a considerably higher adhesive strength and should be taken into consideration as 
one of our objectives is easy removal. The high adhesive strength shown by Coverlet™ O.R. 
could be detrimental to the underlying wound bed upon removal.  
6.10.2 Instron® Mechanical Testing- Tensile Test 
Acticoat™ 7 was considerably higher in all categories except tensile strain at 
maximum load and maximum tensile strain when compared to SilvaSorb™. SilvaSorb™ 
exhibits more elastic material properties than Acticoat™ 7. Both dressings should be taken 
into consideration as we try to enhance silver dressings which are the “Golden Standards” of 
the current wound dressings. 
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7. Analysis 
 
7.1 ANOVA Analysis for Instron® Mechanical Testing 
The results of a ANOVA statistical test performed at 10:12 on 26-JAN-2006 
 Source of     Sum of       d.f.    Mean         F 
 Variation     Squares              Squares 
 
  between      179.8          3     59.92        630.7     
  error       0.7600          8    9.5006E-02 
  total        180.5         11 
The probability of this result, assuming the null hypothesis, is 0.000  
 
Group A (PU Foam): Number of items= 3 
2.10 2.20 2.24  
Mean = 2.18  
95% confidence interval for Mean: 1.768 thru 2.589  
Standard Deviation = 7.129E-02  
Hi = 2.24 Low = 2.10  
Median = 2.20  
Average Absolute Deviation from Median = 4.633E-02 
Group B (Island Foam): Number of items= 3 
2.01 2.32 2.79  
Mean = 2.37  
95% confidence interval for Mean: 1.964 thru 2.784  
Standard Deviation = 0.396  
Hi = 2.79 Low = 2.01  
Median = 2.32  
Average Absolute Deviation from Median = 0.262 
Group C (Hydrocolloid): Number of items= 3 
1.17 1.56 1.73  
Mean = 1.49  
95% confidence interval for Mean: 1.077 thru 1.897  
Standard Deviation = 0.288  
Hi = 1.73 Low = 1.17  
Median = 1.56  
Average Absolute Deviation from Median = 0.187 
Group D (Coverlet™ O.R.): Number of items= 3 
10.7 10.8 11.3  
Mean = 10.9  
95% confidence interval for Mean: 10.51 thru 11.33  
Standard Deviation = 0.368  
Hi = 11.3 Low = 10.7  
Median = 10.8  
Average Absolute Deviation from Median = 0.227  
Figure:  Error Bar Plot 
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Figure 52: Instron Adhesive Strength Testing of Secondary Dressing 
 
The above plot, Figure 51, demonstrates that there is no significant statistical 
difference between samples PU Foam, Island Foam, or Hydrocolloid. However, there are 
notable statistical differences between PU Foam, Island Foam, and Hydrocolloid vs. 
Coverlet™ O.R. The adhesive strength of Coverlet™ O.R. was much greater than the other 
samples and was therefore ruled out from our selection for the outer dressing layer as one of 
our objects was ease of remove. Coverlet™ O.R. has such a high adhesive strength that, upon 
removal, it could damage the underlying wound bed and hinder successful wound healing. 
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8. Conclusions 
 
The activity of terpenes as antimicrobial agents against wound pathogens was 
confirmed by the in vitro assays conducted.  These results demonstrated the ability of terpenes 
to inhibit a wide range of wound pathogens.   The encapsulated terpene formulation, YP-ET, 
was determined to be effective in both in vitro assays and in vivo studies.  The use of terpenes 
did not inhibit healing of the infected wound model and did not have a negative effect on the 
health of the animal.  The study concluded that the terpenes were able to inhibit the growth of 
Staphylococcus aureus in the in vivo model, while decreasing the wound area resulting in 
enhanced wound healing.    
The antimicrobial combination of YP-ET and silver chloride proved to be more 
effective than either agent alone.  As a result of the addition of YP-ET, the antimicrobial 
combination proved effective against pathogens that were resistant to silver alone, supporting 
our initial hypothesis.  Therefore, our antimicrobial combination is able to inhibit the growth 
of a broader range of wound pathogens.  The addition of terpenes also decreased the 
concentration of silver required to inhibit the growth of wound pathogens, which in turn, 
should reduce the overall cost of our dressing design compared to current dressings which use 
high silver concentrations.   
The antimicrobial dressing is safe to use because it was constructed with CMC and 
alginate materials, which are currently used in numerous wound dressing formulations.  The 
dressing allows for the delivery of the antimicrobial agents to the wound site for a period of 
seven days.  The final dressing prototype also prevents contamination of the wound from the 
outside because it acts as an antimicrobial barrier.  The secondary dressing, Polyurethane 
Foam, provides mechanical stability to the wound area.  The adhesive properties of the foam 
   155
were tested and determined to be acceptable for our application. The prototype proved to be 
an effective antimicrobial dressing and with further refinement, could be made into a 
commercial wound dressing. 
   156
9. Recommendations 
   
The results demonstrate that YP-ET is effective in vivo not only in decreasing the 
amount of bacteria present over time but also in reducing wound area. Additionally, the 
actives and dressing proved to be successful in an in vitro environment. However, there are 
still improvements that can be made to the dressing to increase its usability and its chance of 
one day competing with current silver wound dressings.  
For example, silver chloride, the silver active chosen by the team, is insoluble and 
when it comes in contact with sodium chloride, which is often present in the wound, a white 
precipitate can form on the outside of the patient’s skin. This film could potentially hinder 
wound healing and is not aesthetically pleasing.  It should be noted though that our dressing is 
as effective in killing and inhibiting microbes as the current ones and it is possible that the 
team’s dressing may be more cost effective using this form of silver. 
Long-term resistance of our dressing formulation to terpene is also a concern that 
needs to be investigated when determining ways to package the dressing as it is known that 
terpenes cause many plastics especially polystyrene materials to deteriorate (Ostroff, 2006). 
Furthermore, terpene resistance may decrease the shelf life of the dressing therefore, more 
testing is necessary to address this topic.  
The team also recommends that more extensive mechanical analysis of the dressing be 
completed to assess its properties. It is very important to ensure that everything has been done 
to make sure the dressing is mechanically stable, durable, and strong, yet flexible in order to 
foster wound healing. Additionally, the dressing prototype has not been tested against a wide 
range of microbes.  Due to time and material constraints, the team focused on three of the 
most common wound pathogen, which leaves room for further studies against others. Finally, 
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promising but insufficient data has been collected in vivo. Due to the complexity of an animal 
study, the team only tested the YP-ET active in vivo. Therefore, it is suggested that the animal 
study be repeated with the YP-silver and combination YP-ET and YP-silver actives.  
Furthermore, future in vivo testing should be done using the final dressing formulation 
containing both actives to truly determine the worth of the design.  Also our terpene and silver 
concentrations were based on in vitro studies using S. aureus, however, in the in vivo animal 
study a bioluminescent S. aureus was used.  Tests should be completed to compare the two S. 
aureus strands used and to validate the chosen concentrations of antimicrobial actives. 
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10. Glossary  
 
Bioluminescent- the production of light as a result of chemical reactions of a living organism. 
 
Inhibition - To decrease, limit, or block the growth and action of bacterial cells 
 
Microbe – a small living organism such as a bacteria cell 
 
Minimal inhibition concentration (MIC) - lowest concentration of antimicrobial that 
inhibits 80% of bacterial growth. 
 
Parts per million (ppm) - equivalent to µg/ml, used to describe the concentration of silver in 
current wound dressing products. 
 
Terpene- organic oils with antimicrobial properties and microbial resistance. 
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APPENDIX A: Interview with Dr. Raymond Dunn 
 Dr. Ray Dunn from UMASS Medical School Department of Surgery and plastic 
surgery provided us with professional and experienced insight to our wound project. We 
interviewed him on the following questions which are preceded by his responses. 
 
1.) What kind of wounds are you most used to treating? 
Dr. Dunn: All wounds, none treated in particular, Arterial, Venous ulcers, 
Diabetic ulcers, Pressure Ulcers. 
 
a. How do you usually treat them? 
Dr. Dunn: They are usually treated by first being cleaned of dead 
compromised tissue followed by dressing management or an operation, 
depending on the severity of the wound. 
 
2.) What do you look for in a dressing when applying it to a wound? 
Dr. Dunn: The dressing must provide a moist wound environment and address 
the needs of the wound once it has been evaluated. The current dressings do a 
great job in keeping the wound moist and absorb as well as retain fluid. 
 
3.) How do you feel about the current wound dressings (particularly the 
silver dressings)? 
 
Dr. Dunn: All wounds are colonized with bacteria so it is often hard to 
distinguish a difference between the normal presence of bacteria or if the 
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wound has undergone further infection. The dressing should help to keep 
bacterial growth under control and not grow too much. The wound itself is not 
usually tested, just the exudate amount. 
 
a. Where are they lacking? 
Dr. Dunn: The silver based hydrogel dressing seems to be most effective but 
the actual areas that need to be worked on depends on the cause/type of 
wound. 
 
b. What wounds are they least effective against? 
      Dr. Dunn: infected wounds and wounds with necrotic tissue. 
 
4.) How often are additional treatments necessary? 
Dr. Dunn: 25% of the time, the usual additional treatment is surgery to 
remove tissue debris. 
 
Dr. Dunn not only provided us with insight to the dressing market and improvements, 
but also to our animal experiment. He advised us to avoid choosing diabetic foot ulcers 
for our wound model as they are not only difficult to mimic, but also hard to heal. With 
this type of wound, they require more care and the dressing must be changed every 1-3 
days due to the severity of the wound. Another constraint to using a diabetic ulcer model 
is that we would need a large sample size, which is costly to produce. 
 
        
APPENDIX B: Initial Objectives Tree 
 
 
 
    
APPENDIX C: Pairwise Comparison Chart- MQP Team 
 
1st Tier 
 
 
2nd Tier 
 
Goals Kills/Inhibits  
Microbes 
Reliable Durable Easy to 
apply 
Easy to  
Remove 
Cost Score
Kills/Inhibits  
Microbes 
X 1 1 1 1 1 5 
Reliable 
 
        0.5 X 1 1 1 1 4.5 
Durable 
 
0.5 0.5 X 1 1 1 4 
Easy to apply 
 
0 0 0 X 0.5 1 1.5 
Easy to remove 0 0 0 0.5 X 1 1.5 
Cost 
 
0 0 0 0 0 X 0 
 
 
3rd Tier 
 
Goals Includes terpenes Flexible Simple Design Score 
Includes terpenes X 1 1 2 
Flexible 0 X 1 1 
Simple Design 0 0 X 0 
Goals Increase 
wound  
Healing 
Safety Easy to  
Use 
Practical to 
Make 
Score 
Increase wound 
Healing 
X 0 1 1 2 
Safety 
 
1 X 1 1 3 
Easy to Use 
 
0 0 X 0 0 
Practical to make 
 
0 0 1 X 1 
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APPENDIX D: Pairwise Comparison Chart- Prof. George Pins 
 
 
1st Tier 
 
 
2nd Tier 
 
Goals Kills/Inhibits  
Microbes 
Reliable Durable Easy to 
apply 
Easy to  
Remove 
Cost Score
Kills/Inhibits  
Microbes 
X 1 1 1 1 0.5 4.5 
Reliable 
 
0 X 0.5 1 1 0 2.5 
Durable 
 
0 0.5 X 0.5 0.5 0 1.5 
Easy to apply 
 
0 0 0.5 X 0.5 0 1.0 
Easy to remove 0 0 0.5 0.5 X 0 1 
Cost 
 
0.5 1 1 1 1 X 4.5 
 
 
3rd Tier 
 
Goals Includes terpenes Flexible Simple Design Score 
Includes terpenes X 1 1 2.0 
Flexible 0 X 0.5 0.5 
Simple Design 0 0.5 X 0.5 
Goals Increase 
wound  
Healing 
Safety Easy to  
Use 
Practical to 
Make 
Score 
Increase wound 
Healing 
X 0.5 1 1 2.5 
Safety 
 
0 X 1 1 2.0 
Easy to Use 
 
0 0 X 1 1 
Practical to make 
 
0 0 0 X 0 
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APPENDIX E: Pairwise Comparison Chart- Gary Ostroff 
 
1st Tier 
 
 
2nd Tier 
 
Goals Kills/Inhibits 
Microbes 
Reliable Durable Easy to 
apply 
Easy to 
Remove 
Cost Score
Kills/Inhibits  
Microbes 
X 1 1 1 1 1 5 
Reliable 
 
0 X 0.5 1 1 0.5 3 
Durable 
 
0 0.5 X 0.5 0.5 0.5 2 
Easy to apply 
 
0 0.5 0.5 X 0.5 0 1.5 
Easy to remove 0 0 0 0.5 X 0 0.5 
Cost 
 
0 0.5 0.5 1 1 X 3 
 
 
3rd Tier 
 
Goals Includes terpenes Flexible Simple Design Score 
Includes terpenes X 1 1 2 
Flexible 0 X 0.5 0.5 
Simple Design 0 0.5 X 0.5 
 
Goals Increase 
wound 
Healing 
Safety Easy to 
Use 
Practical to 
Make 
Score 
Increase wound 
Healing 
X 1 0.5 1 2.5 
Safety 
 
0 X 1 0.5 1.5 
Easy to Use 
 
0.5 0 X 0.5 1 
Practical to make 
 
0 0.5 1 X 0.5 
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APPENDIX F: Pairwise Comparison Chart – Kerry Walker 
 
1st Tier 
 
 
2nd Tier 
 
Goals Kills/Inhibits  
Microbes 
Reliable Durable Easy to 
apply 
Easy to  
Remove 
Cost Score
Kills/Inhibits  
Microbes 
X 0.5 0.5 1 1 0.5 3.5 
Reliable 
 
        0.5 X 0.5 1 0.5 0.5 3.0 
Durable 
 
0 0.5 X 1 0.5 0.5 2.5 
Easy to apply 
 
0 0 0 X 0 0 0 
Easy to remove 0 0.5 0 1 X 0.5 2.0 
Cost 
 
0.5 0.5 0.5 1 0.5 X 3.0 
 
 
3rd Tier 
 
Goals Includes terpenes Flexible Simple Design Score 
Includes terpenes X 0 1 1 
Flexible 1 X 1 2 
Simple Design 0 0 X 0 
 
Goals Increase 
wound  
Healing 
Safety Easy to  
Use 
Practical to 
Make 
Score 
Increase wound 
Healing 
X 0 0.5 0.5 1.0 
Safety 
 
1 X 1 1 3 
Easy to Use 
 
0.5 0 X 0.5 1.0 
Practical to make 
 
0 0 0.5 X 0.5 
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APPENDIX G: Pairwise Comparison Chart – Lisa Szocik 
 
1st Tier 
 
 
2nd Tier 
 
Goals Kills/Inhibits  
Microbes 
Reliable Durable Easy to 
apply 
Easy to  
Remove 
Cost Score
Kills/Inhibits  
Microbes 
X 0.5 0.5 1 1 0.5 3.5 
Reliable 
 
        0.5 X 0.5 1 0.5 0.5 3.0 
Durable 
 
0.5 0.5 X 1 0 0.5 2.5 
Easy to apply 
 
0 0 0 X 0.5 0 0.5 
Easy to remove 0 0.5 1 1 X 0.5 3.0 
Cost 
 
0.5 
 
0.5 0.5 1 0.5 X 3.0 
 
 
3rd Tier 
 
Goals Includes terpenes Flexible Simple Design Score 
Includes terpenes X 1 1 2 
Flexible 0 X 0.5 0.5 
Simple Design 0 0.5 X 0.5 
 
Goals Increase 
wound  
Healing 
Safety Easy to  
Use 
Practical to 
Make 
Score 
Increase wound 
Healing 
X 0.5 1 1 2.5 
Safety 
 
0.5 X 1 1 2.5 
Easy to Use 
 
0 0 X 0.5 0.5 
Practical to make 
 
0 0 0.5 X 0.5 
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APPENDIX H: Pairwise Comparison Charts - Weighted Scores 
 
1st Tier 
 
 
2nd Tier 
 
Goals Professor Pins 
Final Score 
Gary 
Ostroff 
Final 
Score 
Lisa 
Szocik 
Final 
Score 
Kerry 
Walker 
Final 
Score 
MQP 
Team 
Final 
Score 
Weighted 
Score 
Delivers 
bioactive agent 
4.5 5 3.5 3.5 5 4.3 
Reliable 2.5 3 3 3 4.5 3.2 
Mechanical 
strength 
1.5 2 2.5 2.5 4 2.5 
Easy to apply 1 1.5 0.5 0 1.5 0.9 
Easy to remove 1 0.5 2 2 1.5 1.4 
Low cost 4.5 3 3 3 0 3.3 
 
 
 
3rd Tier 
 
Goals Professor Pins 
Final Score 
Gary 
Ostroff 
Final Score 
Lisa 
Szocik 
Final 
Score 
Kerry 
Walker 
Final 
Score 
MQP 
Team 
Final 
Score 
Weighted 
Score 
Pain Reliever/ 
Odor Reducer 
2 2 2 1 2 1.8 
Flexible 0.5 0.5 0.5 2 1 0.9 
Simple Design 0.5 0.5 0.5 0 0 0.3 
Goals Professor 
Pins 
Final Score 
Gary 
Ostroff 
Final 
Score 
Lisa 
Szocik 
Final 
Score 
Kerry 
Walker 
Final 
Score 
MQP 
Team 
Final 
Score 
Weighted 
Score 
Decrease wound 
healing time 
2.5 2.5 2.5 1 2 2.1 
Safety 2 1.5 2.5 3 3 2.4 
Easy to Use 1 1 0.5 1 0 0.7 
Practical to 
Make 
0 0.5 0.5 0.5 1 0.5 
        
APPENDIX I: Weighted Objectives Tree 
 
 
    
APPENDIX J: Metrics 
 
Increases wound healing 
 
Objective: Decrease wound closure time 
Units: Ranking the amount of wound healing on a scale of 1 (worst) to 3 (best) 
Metric: Measure the degree of wound healing on a scale of 1 to 3, assign the following 
ratings to wound healing: 1 is a score for a wound in which the size of the wound gets 
larger and larger surface area, 2 for which the size of the wound remains the same, and 3 
is the wound site gets smaller and shows signs of closure. 
 
Objective: Delivers bioactive agent 
Units: Ranking the effectiveness of the agents on a scale of 1 (worst) to 3 (best) 
Metric: Measure the minimum inhibitory concentration (MIC) of the antimicrobial 
agents. On a scale of 1 to 3 assign the following ratings killing/inhibiting microbes: 1 has 
a higher MIC and the least inhibition, 2 has some inhibition, and 3 is the lowest MIC and 
high inhibition. 
 
Objective: Includes pain reliever 
Units: Ranking the amount of wound healing on a scale of 1 (no) or 3 (yes) 
Metric: 1 is no it does not reduce pain, 2 is neutral or no indication, and 3 is yes it does 
reduce pain 
 
Objective: Odor reducer 
Units: Ranking the amount of wound healing on a scale of 1 (no) or 3 (yes) 
Metric: 1 is no it does not reduce odor, 2 is neutral or no indication, and 3 is yes it does 
reduce odor 
 
Safety 
 
Objective: Safety 
Units: Ranking the amount of safety on a scale of 1 (worst) to 3 (best) 
Metric: Measure the amount safety in the wound by determining the level of wound 
healing. On a scale of 1 to 3, assign the following ratings to safety, 1 is the safety is 
worse than current models, 2 the safety is the same as current models, 3 the safety is 
better than the current models. 
 
Objective: Reliable 
Units: Ranking the amount of reliability on a scale of 1 (no) to 3 (yes) 
Metric: Measure the amount of reliability in terms of effectiveness in killing pathogen in 
assays. On a scale of 1 to 3, assign the following ratings to reliable, 1 is low amounts of 
kill, 2 is average/substantial amounts of kill, and 3 is highest amounts of kill 
 
Objective: Mechanical strength 
Units: Ranking the amount of safety on a scale of 1 (worst) to 3 (best) 
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Metric: Measure the mechanical properties through Instron testing to ensure the dressing 
matches that of natural skin. On a scale of 1 to 3, assign the following ratings to durable, 
1 is low mechanical properties as compared with skin, 2 is average/substantial properties 
compared with skin, 3 is favorable and accurate mechanical properties compared with 
skin 
 
Easy to Use 
 
Objective: Easy to use 
Units: Ranking the amount of ease of use on a scale of 1 (worst) to 3 (best) 
Metric: Measure the ease of use of the dressing through the steps required for 
preparation, amount of re-application, amount of re-activation. On a scale of 1 to 3, 
assign the following ratings to easy to use, 1 being more steps as compared to current 
models, and 2 being similar amount of steps compared to current models, and 3 being the 
least amount of steps as compared to current dressing. 
 
Objective: Easy to apply 
Units: Ranking the amount of ease of use on a scale of 1 (worst) to 3 (best) 
Metric: Measure the ease of use of the dressing application. On a scale of 1 to 3, assign 
the following ratings to easy to apply, 1 being the longest amount of time, 3 being the 
shortest amount of time. 
 
Objective: Easy to remove 
Units: Ranking the amount of ease of removal on a scale of 1 (worst) to 3 (best) 
Metric: Measure the ease of use of the dressing removal by observing the amount of 
disturbed tissue around the wound site. On a scale of 1 to 3, assign the following ratings 
to easy to remove, 1 being much tissue removed, 3 being minimal disturbance of tissue 
(no tissue on dressing).  
 
Objective: Flexible 
Units: Ranking the amount of flexibility on a scale of 1 (worst) to 3 (best) 
Metric: Measure the amount of mechanical testing and flexibility using the Instron 
machine. On a scale of 1 to 3, assign the following ratings to flexibility, 1 being the 
mechanical flexibility does not match that of skin, 2 being the mechanical flexibility is 
within a few units to that of the skin, and 3 being the mechanical flexibility is 
representative of the units of the skin. 
 
Practical to Make 
 
Objective: Practical to make 
Units: Ranking the cost on a scale of 1 (worst) to 3 (best) 
Metric: Measure the production of our bandage versus that of the other silver dressings 
on the market. On a scale of 1 to 3, assign the following ratings to practical to make, 1 
being harder than current models, require multiple steps, 2 being equal steps and 
materials to the current models, 3 being easier with less steps and materials than the 
current models 
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Objective: Low Cost 
Units: Ranking the cost on a scale of 1 (worst) to 3 (best) 
Metric: Measure the cost of our bandage versus that of the other silver dressings on the 
market. On a scale of 1 to 3, assign the following ratings to cost, 1 being more expensive 
than current models, 2 being equal to the current models, 3 being less expensive than the 
current models 
 
Objective: Simple Design 
Units: Ranking the simplicity of the design on a scale of 1 (worst) to 3 (best) 
Metric: Measure the amount of simplicity of the dressing by measuring the amount of 
materials used compared with the current models. On a scale of 1 to 3, assign the 
following ratings to a simple design, 1 being more materials than current models, 2 being 
the same amount of materials than current models, 3 being fewer materials than current 
models. 
 
 
 
 
   180
APPENDIX K: Metric Justifications 
 
Decreases wound closure time:  The dressing must be effective in wound healing and 
will be evaluated by determining if the is remaining the same, or getting worse.  
Observations such as inflammation, swelling, color of skin, and amount of exudate are 
used to assess the healing process.  A skin color ranging from black to pink indicates a 
severely infected wound to a healing wound, respectively.  To examine if the infection is 
spreading, the inflammation around the wound is measured and the length and width and 
overall area of the wound is recorded at each observation.  The status of the wound 
healing can also be measured by examining the amount of exudate, and the color and 
viscosity of the exudate. 
 
Delivers bioactive agent:  The dressing must deliver a bioactive agent to the wound site 
to act as an antimicrobial to fight against wound pathogens. A swab technique will be 
used to determine the volume and type of bacteria in the exudate.  The surface 
contamination is not a problem for the swabbing technique because the dressing needs to 
be effective against a broad range of microbes.  The antimicrobial agents will be 
considered effective if they kill and inhibits the pathogens as indicated by the swab. 
 
Includes pain reliever: The dressing must deliver pain relief during the duration of time 
of usage. The incorporation of pain relievers will make the dressing more effective 
against a broader range of wound pathogens. Agitated behavior will be observed for pain 
and distress. 
 
Reduces odor: The dressing must reduce odor during the duration of time of usage. The 
incorporation of an odor reducer will make the dressing superior to other models. 
 
Safety: The wound dressing must be safe for the user, in that it must not hinder the 
wound healing process by providing an effective barrier from outside pathogens as well 
as hold in moisture to facilitate wound healing. The dressing should limit rashes and 
secondary infection to avoid allergic reaction or immune response. The physical state of 
the animal and the wound healing level will be assessed for a level of safety.  
 
Reliable: The dressing must be reliable, which can be determined by the amount of 
bacteria to assess the efficacy of the antimicrobial agents.  Growth inhibition and cidal 
assays will be completed to test the efficacy of the antimicrobial agents. 
 
Mechanical strength: The dressing must exhibit strengths and flexibility similar to that 
of the skin. 
 
Easy to use: The dressing would be ranked according to attention through observation, 
reapplication and remoistening. Ideally the dressing would require minimal observation, 
no re-application and no further re-moistening after initial application, which would 
receive the highest score. 
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Easy to apply: The most effective dressing would be available for use directly out of the 
package and can be applied directly to the wound without any additional time for 
application. For example, Acticoat™ is shipped sterile and in tact and needs to be 
activated through adding water to the dressing. 
 
Easy to remove: The dressing would not cause any additional stresses on healthy tissue 
surrounding the wound site as well as in the wound bed. For example, many of the 
current dressings consist of a two-component system of which the outer layer is 
composed of a breathable fabric, which should not adhere to the skin and cause further 
tissue damage.                    
 
Flexible: This dressing should not constrict any normal motions or movements of the 
skin. This dressing should exemplify the normal longitudinal stresses, transverse stresses 
and flexure properties of the skin. 
 
Practical to make: The dressing is not a hassle to produce and could be scaled up for 
larger quantities of production. Ideally this dressing would use less or equivalent numbers 
of materials as compared to the other dressings on the market.  This dressing must also be 
easily sterilized according to materials used, for example, certain materials will require 
easier sterilization processes than others. 
 
Low Cost: The dressing after production and care is around the ballpark of the current 
silver dressings on the market. Ideally our dressing would require less dressing changes 
and less home care providing an overall cheaper dressing. For example, with the current 
wound dressing Silverlon, it is currently the cheapest on the market with a total cost of 
~$55 including dressing changes and total nursing cost over a 1 week period (Argentum 
Medical, 2004).  
 
Simple Design: The device consists of an effective amount of layers, each serving aiding 
in providing a wound healing property to the dressing. For example, most dressings on 
the market such as Acticoat™ and Actisorb Silver 220™ which consist of a breathable 
non-woven layer, followed by one layer for transport of oxygen and fluid management to 
keep the wound healthy and provide a desirable environment for wound healing, and the 
main component being the antimicrobial layer which consists of silver. These layers are 
all manufactured together and do not require any additional materials or adhesives to 
keep the dressing compact. 
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APPENDIX L: Silver Protocol 
 
Eden - Produce free and YP encapsulated Silver Nitrate, Silver Chloride    
 and Silver Thiosulfate       
         
Purpose: To produce free and YP encapsulated silver nitrate, silver chloride and silver thiosulfate  
         
Materials: 1.  Silver nitrate (BDH 99.5%)      
 2.  5M Sodium chloride         
 3.  YGP - Levpan, YGMP - SAF-Mannan (Biospringer)    
         
Methods: Prepare silver nitrate       
 1.  Use BDH silver nitrate from bottle.  Keep dark to prevent light induced oxidation  
         
 Prepare YGP and YGMP silver nitrate     
 1.  Prepare  0.5 mg silver nitrate/ ul water - keep dark    
 2.  Weigh 400 mg YGP and YGMP into plastic tubes     
 3.  Add 250 ul silver nitrate per tube       
 4.  Mix to obtain crumbly dough in reduced light     
 5.  Freeze, lyophilize in the dark the remaining material    
 6.  Store dry product at room temperature in the dark    
 7.  Yield - YGP AgNO3 (_____mg) 55.5% AgNO3 w/w    
  
    -YGMP AgNO3 (______ mg) 
55.5% AgNO3 w/w    
         
 Prepare YGP and YGMP silver chloride     
 1.  Prepare  0.5 mg silver nitrate/ ul water - keep dark    
 2.  Weigh 100 mg LEV and SAF-Mannan into round bottom polypropylene tubes  
 3.  Add 250 ul silver nitrate per tube      
 4.  Mix to obtain crumbly dough      
 5.  Add 10 ml 5M NaCl with rapid mixing     
 6.  Collect insolubles by cfg      
 7.  Wash 3X with cold water to remove NaCl     
 8.  Wash 3X with ethanol        
 9.  Wash 2x with acetone      
 10. Dry in the dark - Cycle 1 load contains 55.5% silver nitrate silver equivalents w/w  
 11. Store dry product at room temperature in the dark    
 12. Yield - YGP AgCl (_____ mg) 55.5% AgNO3 w/w    
  
    -YGMP AgCl (_____ mg) 
55.5% AgNO3 w/w    
         
 
 
 
        
APPENDIX M: YP-Silver Assay 
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APPENDIX N: Synergy Experiment- Enterococcus faecalis  
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APPENDIX O: Synergy Experiment- Pseudomonas aeruginosa  
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APPENDIX P: Synergy Experiment: Pseudomonas aeruginosa & Enterococcus faecalis 
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APPENDIX Q: Terpene Resistance Test Protocol 
 
 
 
 
 
 Material Resistance to Terpenes    
      
Purpose: To determine whether the selected materials are resistant to terpenes.   
      
      
Materials: 1.  Terp (4 mg/ml) and YP-terp (25 mg/ml = 4 mg/ml terp) stock concentrations   
 2. Calcium Alginate    
 3.  Tegasorb    
 4.  Coverlet O.R. Inner/ Outer    
      
Protocol: 1.   Label three tubes for each material; Control, YP-ET, Free ET   
 2.  Place material in ucfg tube    
 3.  Add 500ul of liquid to indicated ucfg tube    
 4. Let material soak in liquid for 7 days.    
 5. Observer changes.    
      
Results:      
 Material Control YP-ET Free ET  
 Calcium Alginate No change No change Less absorbed  
          
 Tegasorb No change No change Fell apart  
          
 Coverlet O.R- Inner material No change No change No change  
          
 Coverlet O.R- Outer material No change No change No change  
          
 
P. U. Foam-Inner material 
     
 
P. U. Foam- Outer material  
     
        
APPENDIX R: Instron® Mechanical Testing- Peel Test 
Specimen 1: Polyurethane Foam 
 
 
 
 
 
 
 
 
 Specimen label Adhesive Strength 
(N) 
1 PU Foam 2.197 
2 PU Foam 2.100 
3 PU Foam 2.239 
Mean  2.179 
STD  0.072 
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Specimen 2: Island Foam 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Specimen 
label 
Adhesive Strength 
 (N) 
4 Island Foam 2.795 
5 Island Foam 2.317 
6 Island Foam 2.010 
Mean  2.374 
STD  0.396 
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Specimen 3: Hydrocolloid 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Specimen label Adhesive Strength 
(N) 
7 Hydrocolloid 1.170 
8 Hydrocolloid 1.560 
9 Hydrocolloid 1.731 
Mean  1.487 
STD  0.288 
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Specimen 4: Coverlet™ O.R. 
 
 
 
 
 
 
 
 
 
 
 
 
 Specimen label Adhesive Strength 
(N) 
10 Coverlet™ O.R. 10.661 
11 Coverlet™ O.R. 11.341 
12 Coverlet™ O.R. 10.755 
Mean  10.919 
STD  0.369 
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APPENDIX S: Instron® Mechanical Testing- Tensile Test 
 
Specimen 1: Acticoat™ 7 
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 Specimen 
label 
Max Extension 
(mm) 
Max Load 
(N) 
Tensile stress at Max Load 
(MPa) 
1 Acticoat™ 7 3.917 48.824 3.764 
2 Acticoat™ 7 4.899 44.425 3.425 
3 Acticoat™ 7 7.110 47.390 3.653 
Mean  5.309 46.880 3.614 
STD  1.636 2.244 0.173 
 
 Specimen 
label 
Tensile strain 
at Max Load 
(%) 
Max Tensile 
strain 
(%) 
Max Tensile 
stress 
(MPa) 
Modulus 
(MPa) 
1 Acticoat™ 7 3.161 3.763 3.764 183.442 
2 Acticoat™ 7 3.092 4.186 3.425 187.229 
3 Acticoat™ 7 3.306 6.847 3.653 175.340 
Mean  3.186 4.932 3.614 182.003 
STD  0.109 1.671 0.173 6.074 
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Specimen 2: SilvaSorb™ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   212
 
 Specimen 
label 
Tensile strain at 
Max Load 
(%) 
Max Tensile 
strain 
(%) 
Max Tensile 
stress 
(MPa) 
Modulu
s  
(MPa) 
4 SilvaSorb™ 89.431 89.431 0.297 0.339 
5 SilvaSorb™ 89.015 89.015 0.292 0.304 
Mean  89.223 89.223 0.294 0.322 
STD  0.294 0.294 0.004 0.025 
 Specimen 
label 
Max Extension 
(mm) 
Max Load 
(N) 
Tensile stress at Max 
Load 
(MPa) 
4 SilvaSorb™ 110.222 3.855 0.297 
5 SilvaSorb™ 110.951 3.784 0.292 
Mean  110.587 3.819 0.294 
STD  0.515 0.050 0.004 
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APPENDIX T: Alginate Hydrocolloid Protocol 
 
 Alginate Hydrocolloid Protocol        12406  
             
 Purpose:  Create and test variability in concentrations in a hydrocolloid as part of a dressing and each of the components individual effect 
             
 Materials:  Alginate powder ~1 g total weight        
  Sterile water          
  Calcium Nitrate ~ 10%         
  Sodium Azide ~ 0.1 mg         
  Glycerol Powder          
  Commercial grade YP-ET         
  Magnetic stir bar/stir plate         
             
n=3 1.) Obtain alginate. Make 3 sets of 0.5%, 1%, 2%, 3% solution by adding 225 mg, 450 mg, 900 mg, 1.35 g algin. to 45 mL sterile water respectively. 
 2.) Add 90 ul 1M sodium azide  to the CMC mixture to reach 2 mM sodium azide final concentration   
n=1 3.) To one group (1 set = 4 gels), add 7% glycerol (3.5 g)       
n=1 To another group (1 set = 4 gels) add 2.1 g YP-ET (160 mg/ml terp) for a final conc. of 6.6 mg/ml    
n=1 To the third group (1 set = 4 gels), no additive - to act as a negative control      
 4.) Add a stir bar and cover the tubes and place it on the rotator to dissolve the powder overnight    
 5.) Once dissolved, heat the tubes in a warm water bath at 50 degrees C for ~ 5 minutes, to make the hydrocolloid less viscous 
 6.) Pour the warmed liquid into a weigh trays.         
 7.) Dissolve 20 mg of calcium nitrate powder in 180 mL sterile water      
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 8.) Place magnetic stir bar in bottle and place on stir plate until dissolved.       
 9.) Pour 10 mls 1% calcium nitrate over the alginate gels and let solidify at room temperature in a sterile hood overnight.   
              
 Tube distribution:            
n=1 1 set of no additive for neg control (4 tubes)          
n=1 1 set of 0.5%, 1%, 2%, 3% alginate + glycerol (4 tubes)        
n=1 1 set of 0.5%, 1%, 2%, 3% alginate + YP-ET (4 tubes)        
              
 Glycerol Plasticizer concentration:           
 Barnes, Scott and Ding, Jim Jian Ling. Calendered Hydrocolloid dressing: US Patent 6923982. Published 02 August 2005. www.freepatentsonline.com/6923982 
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APPENDIX U: CMC Hydrocolloid Protocol 
 CMC Hydrocolloid Protocol          12406 
              
 Purpose:  Create and test variability in concentrations in a hydrocolloid as part of a dressing and each individual effect in a hydrocolloid 
              
 Materials:  Carboxymethylcellulose powder ~1 g total weight        
  Sterile water           
  Sodium Azide - 1M           
  Glycerol             
  Commercial Grade YP-ET          
              
              
n=3 1.) Obtain CMC. Make 3 sets of 0.5%, 1%, 2%, 3% solution by adding 225 mg, 450 mg, 900 mg, 1.35 g CMC to 45 mL sterile water respectively. 
 2.) Add 90 ul 1M sodium azide  to the CMC mixture to reach 2 mM sodium azide final concentration    
n=1 3.) To one group (1 set = 4 gels), add 7% glycerol (3.5 g)        
n=1 To another group (1 set = 4 gels) add 2.1 g YP-ET (160 mg/ml terp) for a final conc. of 6.6 mg/ml     
n=1 To the third group (1 set = 4 gels), no additive - to act as a negative control       
 4.) Add a stir bar and cover the tubes and place it on the rotator to dissolve the powder overnight     
 5.) Once dissolved, heat the tubes in a warm water bath at 50 C for ~ 5 minutes, to make the hydrocolloid less viscous   
 6.) Pour the warmed liquid into weigh trays.          
 7.) Let solidify/dry under sterile hood overnight         
              
 Tube distribution:            
n=1 No additive for neg control (4 tubes)          
n=1 1 set of 0.5%, 1%, 2%, 3% CMC + glycerol (4 tubes)         
n=1 1 set of 0.5%, 1%, 2%, 3% CMC + YP-ET (4 tubes)         
               
              
 GlycerolPlasticizer concentration:           
 Barnes, Scott and Ding, Jim Jian Ling. Calendered Hydrocolloid dressing: US Patent 6923982. Published 02 August 2005. www.freepatentsonline.com/6923982 
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APPENDIX V: Water Absorption Test 
 
 Water Absorption Test        13006 
          
Purpose: Test the amount of fluid absorptive capacity in each film      
          
Materials: Hydrocolloid samples         
 Microfuge tubes         
 24 mL sterile water (1 mL/tube)        
          
Procedure:          
1.) Weigh 24 empty microfuge tubes and label according to hydrocolloid sample, concentration, and additive  
2.) Cut a small sample of hydrocolloid and place in microfuge tube - weigh and record scale reading  
3.) Fill microfuge tubes with 1.0 mL sterile water        
4.) Leave at room temperature for 5 minutes        
5.) Extract surrounding water from the tube and weigh on the scale      
 Record final volume of water remaining in the sample      
 SET 2         
 Hydrocolloid Empty Tube (g) Tube+Sample (g) Final Sample  (g) Weight Sample Final Vol. (g) 
                   
 0.5 % CMC -  1.0051   1.0054   1.2121   0.003   0.207 0.204 
 1% CMC - 0.9999   1.0017   1.2588   0.0018   0.2589 0.2571 
 2% CMC - 0.9992   1.0022   1.1454   0.003    0.1462 0.1432 
 3% CMC - 0.9964   1.0176   1.7113   0.0212   0.7149 0.6937 
                   
 0.5 % CMC + glyc. 0.9954   -   -   - - 
 1% CMC + glyc. 0.9982   1.0122   1.1978   0.0140   0.1996 0.1856 
 2% CMC + glyc. 0.9934   1.0492   1.2169   0.0558   0.2235 0.1677 
 3% CMC + glyc. 0.9996   1.0624   1.7359   0.0628  0.7363 0.6735 
                   
 0.5 % CMC + YP-ET 1.0043   1.0122   1.249   0.0079   0.2447 0.2368 
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 1% CMC + YP-ET 0.9997   1.0075   1.696   0.0078   0.6963 0.6885 
 2% CMC + YP-ET 1.0008   1.014   1.509   0.0132   0.5082 0.495 
 3% CMC + YP-ET 0.9995   1.0204   1.98   0.0209   0.9805 0.9596 
                   
                   
 0.5% Alg.+ CaN2 - 0.9996   1.0056   1.1849   0.0060   0.1853 0.1793 
 1% Alg.+ CaN2 - 0.9967   1.0013   1.4557   0.0046   0.4590 0.4544 
 2% Alg. +CaN2 -  0.9996   1.0163   1.6941   0.0167  0.6945 0.6778 
 3% Alg. + CaN2 -  0.9952   1.0067   1.3995   0.0115   0.4043 0.3928 
                   
 
0.5% Alg.+ CaN2 + 
glyc. 0.9976   1.0444   1.1973   0.0468   0.1997 0.1529 
 1% Alg.+ CaN2 + glyc. 0.994   1.0299   1.129   0.0359   0.1350 0.0991 
 2% Alg. +CaN2 + glyc. 1.0029   1.0465   1.1212   0.0436   0.1183 0.0747 
 3% Alg. + CaN2 + glyc.  1.002   1.0649   1.2984   0.0629   0.2335 0.1706 
                   
 
0.5% Alg.+ CaN2 + 
YP-ET 0.9965   1.0098   1.1571   0.0133  0.1606 0.1473 
 
1% Alg.+ CaN2 + YP-
ET 1.0013   1.0306   1.3906   0.0293   0.3893 0.36 
 
2% Alg. +CaN2 + YP-
ET 0.9983   1.0117   1.2166   0.0134   0.2183 0.2049 
 
3% Alg. + CaN2 + YP-
ET 0.9945   1.0123   1.2856   0.0178   0.2911 0.2732 
          
          
 Overall:         
 
0.5% CMC + glycerol 
was too soft and 
couldn’t be removed 
for sampling    
 
    
 
The CMC + Terpene samples were all very swollen in water and were more in tact than the other 
samples 
 
  
 In all of the alginate gels, the negative controls and glycerol, much of them dissolved so only in the terpene addition 
 was there evidence of swelling and the gel stayed together      
          
 
Alone, the 1%, 2%, and 3% CMC + 
glycerol were stretchy and rubbery,  
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though the 3% was bubbly 
 The Alginate+terpene samples were all brittle, especially the higher concentrations   
          
 
Much of the samples dissolved so it was 
hard to absorb accurate amounts of 
water   
      
    
 
 
    
APPENDIX W: Particle Settling Vehicle for In Vivo Experiment 
Particle Settling Vehicle for In Vivo Experiment   13006 
       
Purpose: Test the concentration of vehicles for application of actives in an in vivo experiment 
 Test particle settling and ability to homogenize    
       
Materials:  YP-ET      
 CMC powder      
 Alignate       
 1 M Sodium Azide     
       
Methods:        
       
Make up azide diluent - 80 ul azide +40 mls water    
Make up 1% hydrocolloid solutions from CMC and alginate in 25 mL of water +50 ul azide  
Weigh in indicated volumes of water and 1% hydrocolloid    
       
  Final g  Final g     
  Alginate 1% CMC 1% g  
Tube  Concentration Alginate  Concentration CMC Azide Diluent  
1 1 4  -  - 0  
2 0.75 3  -  - 1  
3 0.6 2.4  -  - 1.6  
4 0.45 1.8  -  - 2.2   
5 0.3 1.2  -  - 2.8  
6 0.15 0.6  -  - 3.4  
7 0.1 0.4  -  - 3.6  
8 0 0  -  - 4  
9  -  - 1 4 0  
10  -  - 0.75 3 1  
11  -  - 0.6 2.4 1.6  
12  -  - 0.45 1.8 2.2  
13  -  - 0.3 1.2 2.8  
14  -  - 0.15 0.6 3.4  
15  -  - 0.1 0.4 3.6  
        
Add 165 mg YP-ET to achieve a final concentration of 6.6 mg/ml terpene - the high dose for the animal expt 
 280 mg/7mL total = 40mg/mL in tube of terpene    
Mix by vortex or rotation and leave overnight. Record the amount of settling after 24 hrs  
Measure the height of the clear layer and the height of the cloudy liquid layer to find the fraction   
 of settling that occurred - clear layer/cloudy liquid layer = <10% settling is favorable 
Enter height of clear and liquid layers into spreadsheet to calculate % settling   
Take a digital photograph of the tubes     
       
Tube Hydrocolloid % hydrocolloid cloudy layer (cm) liquid layer (cm) % settling  
1 Alginate 1% 1 4.2 23.80952381  
2 Alginate 0.75% 0.6 3.9 15.38461538  
3 Alginate 0.60% 0.8 4.1 19.51219512  
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4 Alginate 0.45% 0.8 4 20  
5 Alginate 0.30% 0.6 4 15  
6 Alginate 0.15% 0.5 4 12.5  
7 Alginate 0.10% 0.6 4.1 14.63414634  
8 Alginate 0% 0.5 4 12.5  
9 CMC 1% 3.9 0 none  
10 CMC 0.75% 4.1 0 none  
11 CMC 0.60% 4.1 0 none * 
12 CMC 0.45% 3.8 0.2 none thin film on top 
13 CMC 0.30% 0.6 4.1 14.63414634  
14 CMC 0.15% 0.7 4.1 17.07317073  
15 CMC 0.10% 0.7 4 17.5  
    
APPENDIX X: Glycerol + Terpene Combination Test 
Glycerol + Terpene Combination test   13106  
      
Purpose: Test and decide on most effective hydrocolloid formulations with glycerol and terpene  
      
Materials: CMC powder      
 Sterile water     
 Sodium Azide ~ 0.1mg    
 Glycerol     
 Commercial Grade YP-ET    
 2% CMC stock hydrocolloid ( 45 mL gel = 46 g)   
      
1.) Obtain CMC, make 1%, 1.5%, and 2% hydrocolloids by diluting stock 2% solution  
      
  Terpene addition (g) glycerol (g) grams 2% CMC grams water  
1% CMC alone - - 27.5 27.5  
1% CMC +terp 2.1 - 27.5 25.4  
1% CMC + glycerol - 3.5 27.5 24  
1% CMC +glycerol + terp 2.1 3.5 27.5 21.9  
           
1.5% CMC alone - - 41.25 13.75  
1.5% CMC +terp 2.1 - 41.25 11.65  
1.5% CMC + glycerol - 3.5 41.25 10.25  
1.5% CMC + glycerol + terp. 2.1 3.5 41.25 8.15  
           
2% CMC alone - - 55 0  
2% CMC +terp 2.1 - 52.9 0  
2% CMC + glycerol - 3.5 51.5 0  
2% CMC +glycerol +terp 2.1 3.5 49.4 0  
      
      
      
2.) Cast gels and let dry in hood for 48 hours     
3.) Run water absorbtion test to measure amount of volume the gels can hold and dissolving that occurs 
        
APPENDIX Y: Water Absorption Test 
 
 Water Absorption Test    20206   
        
Purpose: Test the amount of fluid absorptive capacity in each film     
        
Materials: CMC Hydrocolloid samples      
 Microfuge tubes       
 24 mL sterile water (1 mL/tube)      
        
Procedure:        
1.) Weigh 24 empty microfuge tubes and label according to hydrocolloid sample, concentration, and additive   
2.) Cut a small sample of hydrocolloid and place in microfuge tube - weigh and record scale reading   
3.) Fill microfuge tubes with 1.0 mL sterile water      
4.) Leave at room temperature for 5 minutes      
5.) Extract surrounding water from the tube and weigh on the scale     
 Record final volume of water remaining in the sample     
        
 SET 1       
 Hydrocolloid Empty Tube (g) Tube+Sample (g) Final Sample (g) Sample dry (g) Sample wet (g) Final Vol. (g) 
               
 1% CMC + glyc. 1.002 1.048 1.3504 0.046 0.3484 0.3024 
 1% CMC+glyc+YP-ET 0.998 1.0024 1.3925 0.0044 0.3945 0.3901 
 1% CMC - control 1.0043 1.0732 1.2403 0.0689 0.236 0.1671 
               
 1.5% CMC + glyc. 1.0007 1.061 1.3703 0.0603 0.3696 0.3093 
 1.5% CMC+glyc+YP-ET 0.9956 1.0357 1.5079 0.0401 0.5123 0.4722 
               
 2 % CMC + YP-ET 0.9963 1.0095 1.5976 0.0132 0.6013 0.5881 
 2% CMC + glyc. 0.9945 1.0912 1.4665 0.0967 0.472 0.3753 
 2% CMC - control 0.996 1.0207 2.0074 0.0247 1.0114 0.9867 
 2% CMC+glyc+YP-ET 1.0025 1.0918 1.6435 0.0893 0.641 0.5517 
        
 
 
 
 
 
 
 
 
 
 
        
 SET 2       
 Hydrocolloid Empty Tube (g) Tube+Sample (g) Final Sample (g) Sample dry (g) Sample wet (g) Final Vol. (g) 
               
 1% CMC + glyc. 1.0045 1.0796 1.2308 0.0751 0.2263 0.1512 
 1% CMC+glyc+YP-ET 0.9984 1.0032 1.2486 0.0048 0.2502 0.2454 
 1% CMC - control 0.996 1.0405 1.2484 0.0445 0.2524 0.2079 
               
 1.5% CMC + glyc. 0.9977 1.0433 1.3282 0.0456 0.3305 0.2849 
 1.5% CMC+glyc+YP-ET 1.0007 1.0275 1.2172 0.0268 0.2165 0.1897 
               
 2 % CMC + YP-ET 1.0025 1.0187 1.5271 0.0162 0.5246 0.5084 
 2% CMC + glyc. 0.9988 1.0643 1.3236 0.0655 0.3248 0.2593 
 2% CMC - control 0.9945 1.0167 2.005 0.0222 1.0105 0.9883 
 2% CMC+glyc+YP-ET 0.9969 1.0854 1.4786 0.0885 0.4817 0.3932 
               
        
 Chitosan       
 Hydrocolloid Empty Tube (g) Tube+Sample (g) Final Sample (g) Sample dry (g) Sample wet (g) Final Vol. (g) 
               
 1% CMC + 1% Chitosan 1.0045 1.0117 1.5181 0.0072 0.5136 0.5064 
 1% CMC+1% Chitosan 0.9991 1.0083 1.5181 0.0092 0.519 0.5098 
 2% CMC + 0.5% Chitosan 1.0043 1.0149 1.552 0.0106 0.5477 0.5371 
 2% CMC+0.5% Chitosan 0.9997 1.0141 1.6453 0.0144 0.6456 0.6312 
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APPENDIX Z: Uniformity Test 
 Purpose: to test the uniformity and ease of each homogeneous formulation and its spreading capabilities   
         
 1.) Using a 3 mL syringe, draw up active+ CMC vehicle formulations (1%, 0.75%, 0.6%, 0.45%) into separate syringes   
 2.) Spread active formulation in a 0.5-100 ul formulation on a small wound site simulation such as an orange piece   
 3.) Observe the distribution and diffusion of the ribbon.      
         
 % form. Observations Time to leave the tube Measurement on towel Notes:     
 1% Stayed put, harder put in syringe 0.4 sec 1.3 cm not mixed, small amt of settling @ 36 hrs     
 0.75% Stayed put, easy spread 0.35 sec 1.2 cm didn’t settle @ 36 hrs     
 0.60% very liquidy, quickly spread, drips 0.2 sec 2 cm settled @ 36 hrs     
 0.45% liquidy, stayed in clump 0.15 sec 1.7 cm settled @ 36 hrs     
 4.) Take pictures with a digital camera       
         
 Results:        
 
          
         
         
         
         
         
         
         
  0.75 % CMC + YP-ET formulation was easiest to apply and stayed in place, and also did not settle after 36 hours.  
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APPENDIX AA: Alginate Hydrocolloid plus Calcium Chloride Protocol 
Alginate Hydrocolloid Protocol plus Calcium Chloride       20606 
           
Purpose:  Identify CaCl2  concentration to crosslink alginate         
           
Materials:  Stock 2% alginate hydrocolloid  Prepare 1.5% (1.5 ml 2% + 0.5 ml water), 1% (1.0 ml 2% + 1.0 ml water)  
 and 0.5% ((0.5 ml 2% + 1.5 ml water) alginate solutions       
 Sterile water      % ul ul  
 Calcium Chloride - prepare 5% calcium chloride (1 g/20 ml)   [CaCl2] 5% CaCl2 Water  
       0 0 4000  
       0.1 80 3920  
       0.25 200 3800  
       0.5 400 3600  
       0.75 600 3400  
       1 800 3200  
       5 4000 0  
           
1.) Add 1000 ul of each CaCl2 concentration to the labeled Ep tubes        
2). Add 250 ul of indicated alginate concentrations to 1000 ul CaCl2       
3)  Allow to gel overnight          
4). Centrifuge. Remove liquid and assess if the alginate has gelled.  Identify the lowest concentration of CaCl2 that gels each    
     concentration of aliginate         
           
This will establish the relationship between alginate and CaCl2 to gel       
           
5. Add 1 ml water to the alginate samples that gelled        
6. Change the water hourly to remove any free chloride        
7. Assess stability of alginate gel after desalting.  Identify the lowest concentration of CaCl2 that produces a stable gel   
           
Next:  scale up washed calcium alginate production in tip covers using optimized conditions      
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%           
[CaCl2] 0.5% Alg 1% Alg 1.5% Alg 2% Alg       
0 - - - -       
0.1 soft, clear soft, clear soft, clear soft, clear       
0.25 soft less strong strong strong       
0.5 some dissolved softer stable, harder gel stable, harder gel       
0.75 some dissolved strong stable, harder gel stable, harder gel       
1 some dissolved strong stable, harder gel stable, harder gel       
5 some dissolved strong stable, harder gel stable, harder gel       
           
           
Eliminate 0.5% Alginate gels because they were not stable in water and after calcium was washed away.     
           
    
 APPENDIX BB : Glycerol + Terpene Combination Lyophilizer 
Experiment 
Glycerol + Terpene Combination Lyophilizer experiment  
     
Purpose: Test and experiment with lyophilizer effect on hydrocolloid formulations with CMC and combinations of glycerol and terp 
     
Materials:  CMC powder    
 Sterile water    
 2% CMC stock hydrocolloid   
 Glycerol    
 Commercial Grade YP-ET   
      
     
1.) Obtain CMC, make 1%, 1.5%, and 2% hydrocolloids by diluting stock 2% solution 
     
Formulation Terpene addition (g) glycerol (g) grams 2% CMC grams water 
1.5% CMC alone - - 41.25 13.75 
1.5% CMC + glycerol - 3.5 41.25 10.25 
          
2% CMC alone - - 55 0 
2% CMC +terp 2.1 - 52.9 0 
2% CMC + glycerol - 3.5 51.5 0 
2% CMC +glycerol +terp 2.1 3.5 49.4 0 
     
     
     
2.) Cast gels and freeze at -80C for 2 hours    
3.) Load gels into lyophilizer and run standard recipe   
Shelf temperature at -45C at 600mTorr vacuum ~1 or 2 hours to stabilize.  
It reaches 0C after stopping at -20C to let things stabilize, and reduces the vacuum to below 200mTorr 
Let sit for 12 hours while water sublimates and then warms gradually to 20C  
Note: The total time depends on the shelf temperature when sample is put in.  
     
4.) Run the water absorption test for absorptive properties of the gel  
     
        
 APPENDIX CC: Alginate + Calcium Chloride Test 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
       
Alginate + Calcium Chloride Test     
       
Purpose:  To determine the best combination of alginate and calcium chloride.   
       
Materials: Alginate      
 Calcium Chloride      
 Water      
 Gel plates      
       
Methods:       
1.)  Pour alginate into gel plates by weight using both 1.5% and 2.0% alginate    
2.)  Let gels dry overnight in 30 degree incubator     
3.)  After a minimum of 24 hours and there are no signs of wetness on the gel, peel alginate film from plate using a spatula  
4.)  Add, by weight, specified amount of calcium chloride to empty gel plate    
5.)  Place film back into plate on the calcium chloride ~1 minute    
6.)  Remove film once again, flip it over and allow other side to soak    
7.)  Allow film to soak in calcium chloride solution for a minimum of 24 hours    
8.)  After 24 hours, pour off CaCl2 solution and add enough water to submerge the gel careful not to disturb the gel. Allow 20 minutes to soak 
9.)  After 20 minutes, remove old water and replace it with clean water and continue the changing the water and soaking the gels  
at 20 min. intervals for at least 1 hour     
10.) Allow gel to remain in clean water to avoid drying out    
       
       
 Alginate (g) Alginate (%) Calcium Chloride (g) % Calcium Chloride   
 50 2 75 1.5   
 53 1.5 53 1   
 55 1.5 13.75 0.25   
 55 1.5 27.5 0.5   
 55 2 13.75 0.25   
 55 2 27.5 0.5   
       
 Conclusions: Need glycerol because gels are currently too wrinkly and lack necessary mechanical properties  
  Determined the best range for calcium chloride is 13.75g - 27.5g (0.25% - 0.5%) to obtain the best crosslinking 
Determined that 1.5% alginate is better than 2.0% alginate
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APPENDIX DD: Alginate + Glycerol + Calcium Chloride Test 
Alginate + Glycerol + Calcium Chloride Test    
      
Purpose:  To determine the best combination of alginate and calcium chloride.  
                  To determine if glycerol is an important constituents for the calcium alginate layer and if so over what range  
      
Materials:   1.5% Alginate     
  Glycerol     
  Calcium Chloride     
  Water     
 Weigh trays     
      
Methods:       
1.)  Pour 1.5% alginate into flask by weight according to the calculations below   
2.) Add, by weight, varying amounts of glycerol to alginate (final volume of 55 ml)   
3.) Vortex mixture and cast into weigh trays and label according to sample   
4.)  Let gels dry overnight in 30 degree incubator    
5.)  After a minimum of 24 hours, peel alginate film from tray    
6.) Cut alginate to specified weight     
6.)  Add, by weight, specified amount of calcium chloride and water to weigh tray   
7.)  Place film back into tray on top of the calcium chloride - soak for ~ 1 minute   
8.)  Remove film once again, flip it over and allow other side to soak   
9.)  Allow film to soak in calcium chloride solution for a minimum of 24 hours   
10.) After 24 hours, pour off CaCl2 solution and add enough water to submerge the gel careful not to disturb the gel. Allow 20 minutes to soak 
11.) After 20 minutes, remove old water and replace it with clean water and continue the changing the water and soaking the gels  
at 20 min. intervals for at least 1 hour     
12.) Allow gel to remain in clean water to avoid drying out    
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 1.5% Alginate (g) Glycerol (g) Glycerol (%)    
 54.125 0.875 1.75    
 53.25 1.45 3.5    
 52.375 2.625 5.25    
 51.5 3.5 7    
 55 0 0    
       
 Note:  5.25% and 7.0% glycerol take at least 5 days to dry, therefore they were ruled out due to time   
  manufacturing time constraints    
       
       
Glycerol (%) Wt of Dry Gel (g) Wt of piece (g) %of total wt g of CaCl2 using 55g gel g CaCl2 for piece g water for piece 
0 0.77 0.14 18.2 27.5 5 5 
0 0.77 0.16 20.8 20.63 4.29 7.15 
0 0.77 0.21 27.3 13.75 3.75 11.38 
1.75 1.64 0.24 14.6 27.5 4.02 4.01 
1.75 1.64 0.56 34.1 20.63 7.03 11.7300 
1.75 1.64 0.37 22.6 13.75 3.11 9.32 
3.5 2.4 0.59 24.6 27.5 6.77 6.76 
3.5 2.4 0.77 32.1 20.63 6.62 11.04 
3.5 2.4 0.49 20.4 13.75 2.81 8.41 
       
       
       
 Conclusions: Using metrics (see Calcium Alginate Metrics) the best overall gel contained 1.75% and 3.5% glycerol  
  
The gel also contained 0.5% of calcium 
chloride    
 
 
        
APPENDIX EE: In Vivo Vehicle Formulation Preparation 
In Vivo Vehicle Formulation Preparation    21306  
         
Purpose:     To demonstrate the in vivo antimicrobial effect of the terpene + vehicle formulations in an incisional wound model 
 Safety study to determine the effect of terpene + vehicle formulations on wound healing   
         
Materials:  YP-ET        
 CMC powder        
 Sterile water        
  [Terpene] [Terpene]      
 Terpene: Final Conc. Stock Final [Terpene] Final Volume Final Terp weight    
 High 24 mg/mL 160 mg/mL 150 mg/mL 40 mL 6 g   
 Medium 6.6 mg/mL 160 mg/mL 41.25 mg/mL 40 mL 1.65 g   
 Low 1.5 mg/mL 160 mg/mL 9.375 mg/mL 40 mL 0.375 g   
         
Methods:          
         
Preparation of formulations        
Make up 2% hydrocolloid stock from CMC and with 8 g CMC, 400 mL sterile water     
Weigh in indicated volumes of water to form a 0.75% CMC solution and weigh in YP-ET as indicated to yield 40 mL volumes  
         
         
 Formulation Terpene (g) 2% CMC (g) Sterile water (g) Total Volume    
 high 24 mg/ml 6 15 19 40 mL    
 medium 6.6 mg/ml 1.65 15 23.35 40 mL    
 low 1.5 mg/ml 0.375 15 24.625 40 mL    
 control  0 15 25 40 mL    
         
         
Test in vitro antimicrobial activity       
Test 4 formulations in duplicate for activity in the in vitro primary assay against S. aureus prior to the animal study    
and again after the animal study        
        
APPENDIX FF: Infected Wound Model Research Chart 
 
ANIMALS
(species) WOUND HEALING MODEL LOCATION CORRESPONDING AUTHOR REFERENCE 
Pigs Burns Worcester, MA Tim Roth Word of Mouth 
          
  Varies Worcester, MA Mitch Sanders Word of Mouth 
Mini Pig Full Thickness University of Miami School of Medicine,   Sullivan, Tory P, Eaglstein, William H, Davis, Stephen C & Mertz, Patricia (2001) 
    
Department of Dermatology, Miami, 
Florida.   THE PIG AS A MODEL FOR HUMAN WOUND HEALING. 
        Wound Repair and Regeneration 9 (2), 66-76. 
          
          
  80 C burns to backs and flanks Stony Brook, NY Adam J. Singer, MD Adam J. Singer, MD, Mazhar Mohammad, BS, George Tortora, PhD  
  2 young pigs, 80 burns total   Dept. of Emergency Medicine Henry C. Thode, Jr., PhD and Steve A. McClain, MD 
  infected with Sa   L4-515, Stony Brook, NY 11794-7400 Octylcyanoacrylate for the Treatment of Contaminated  
       Fax 516-444-3919;  Partial-thickness Burns in Swine 
      asinger@epo.som.sunysb.edu Academic Emerg Med. 2000 Mar;7(3):222-7 
          
Domestic  Partial-thickness  Nashville, Tenn. Lillian B. Nanney, Ph.D. An in Vivo Comparison of Topical Agents on Wound Repair. 
Yorkshir
e pigs 3×3-cm excisional wounds, Dept of Plastic Surgery, Dept of Pathology, Department of Plastic Surgery Plastic & Reconstructive Surgery. 108(3):675-683, September 1, 2001. 
   4, 7 days and the Department of Cell Biology,  Vanderbilt Univ School of Medicine Bennett, Laura L. M.D.; Rosenblum, Richard S. M.D.; Perlov,  
    Vanderbilt Univ School of Medicine S-2221, Medical Center North Cathy B.S.N.; Davidson, Jeffrey M. Ph.D.; Barton, 
    and the Dept of Veterans Affairs. Nashville, Tenn. 37232-2631  Ronald M. M.D.; Nanney, Lillian B. Ph.D. 
      lillian.nanney@mcmail.vanderbilt.edu   
  cm × 2 cm × 0.4 mm Fort Saskatchewan, AB, T8L 3W4 Canada Robert E. Burrell Merle E. Olson, J. Barry Wright, Kan Lam, Robert E. Burrell 
        Healing of Porcine Donor Sites Covered with Silver-coated Dressings 
        Taylor & Francis Health Sciences, part of the Taylor & Francis Group 
        Volume 166, Number 6 / July 6, 2000 
  full thickness 
University of Calgary, Calgary, Alberta, 
Canada Robert E. Burrell Wright J.B.; Lam K.; Buret A.G.; Olson M.E.; Burrell R.E. 
  contaminated with Pa     Early healing events in a porcine model of contaminated wounds:  
        effects of nanocrystalline silver on matrix metalloproteinases,  
        cell apoptosis, and healing 
        Wound Repair and Regeneration, Volume 10, Number 3, May 2002,  
        pp. 141-151(11) 
  acute wounds Stony Brook, NY Richard A. F. Clark MD  http://www.biotech.sunysb.edu/educWork/ibrp/rclark.html 
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      RAFClark@epo.som.sunyb.edu http://www.bme.sunysb.edu/bme/people/faculty/fac_core.html#clark 
  excisional wound Stony Brook, NY Adam J. Singer, MD,  Singer, Adam J., Nable, Maria, Cameau, Paul, Singer, Daniel D.  
  swabbed with Sa   Dept of Emergency Medicine,  & Mcclain, Steve A. (2003) 
      Stony Brook Univ School of Medicine,  Evaluation of a new liquid occlusive dressing for excisional wounds. 
      Stony Brook, NY 11794-7400. Wound Repair and Regeneration 11 (3), 181-187. 
  Eight pigsw/ total of      Davis S.C.; Eaglstein W.H.; Cazzaniga A.L.; Mertz P.M. 
  645 partial-thickness wounds     An Octyl-2-Cyanoacrylate Formulation Speeds Healing of Partial- 
        Thickness Wounds 
        Dermatologic Surgery, Volume 27 Number 9, 1 September 2001 p. 783-788(6) 
  5x5x0.03 cm wounds on dorsum University of Utah Glenn D. Prestwich Kirker,K.R. BSE; Luo,Y. PhD; Morris,S.E. MD; Shelby,J. PhD; Prestwich,GD. PhD 
  12 excised wounds/pig   Univ. of Utah - Dept. Medicinal Chem. Glycosaminoglycan Hydrogels as Supplemental Wound  
      419 Wakara Way, Suite 205 Dressings for Donor Sites 
      Salt Lake City, UT, 84108-1257 Journal of Burn Care & Rehabilitation. 25(3):276-286, May/June 2004 
  human imitation bite wounds University of Toronto SL Avon Avon, SL, Wood, RE 
      University of Toronto Porcine skin as an in-vivo model for ageing of human bite marks 
      sylvie-louise.avon@fmd.ulaval.ca J Forensic Odontostomatol. 2005 Dec;23(2):30-9 
New 
Zealand 
white 
rabbit ear full-thickness dermal 
ulcers Northwestern University, Chicago, IL M.J. Lee Lee MJ, Roy NK, Mogford JE, Schiemann WP, Mustoe TA 
Rabbits 6 female rabbits   Division of Plastic and Reconst. Surg. Fibulin-5 promotes wound healing in vivo 
      Northwestern University, Chicago, IL J Am Coll Surg. 2004 Sep;199(3):403-10 
          
Adult 
Male 
Harlan  Full-thickness,  
Dept of Human Biological Chemistry and 
Genetics,    Stiernberg, Janet, Norfleet, Andrea M, Redin, William R,  
Sprague-
Dawley lasting 20 days 
Univ of Texas Medical Branch, Galveston, 
Texas,   Warner, W. Scott, Fritz, Richard R & Carney, Darrell H (2000) 
Rats   
Chrysalis BioTechnology, Inc., 
b Galveston, Texas   Acceleration of full-thickness wound healing  
        in normal rats by the synthetic thrombin peptide, TP508. 
        Wound Repair and Regeneration 8 (3), 204-215 
  8% full thickness burns Animal Studies of Massachusetts H. Shaw Warren Nathan A. Busch,Emily M. Zanzot,  
  infected with Ec, Pa  General Hospital, Boston, Mass Infectious Disease Unit, 5 floor,   Paul M. Loiselle, Edward A. Carter 
      Mass General Hospital, Jennifer E. Allaire, Martin L. Yarmush and H. Shaw Warren 
      149 13th St., Charlestown, MA 02129 A Model of Infected Burn Wounds Using Escherichia coli  
    (617) 726-5774 O18:K1:H7 for the Study of Gram-Negative Bacteremia and Sepsis 
      warren@helix.mgh.harvard.edu . Infection and Immunity, June 2000, p. 3349-3351, Vol. 68, No. 6 
  20% full thickness burns US Army Institute of Surgical Research   Chu CS, McManus AT, Mason AD, Pruitt BA Jr. 
      3400 Rawley E Chambers Ave Topical silver treatment after escharectomy of infected full  
      Fort Sam Houston, TX 78234 thickness burn wounds in rats. 
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        2005 May;58(5):1040-6. 
  20% TBSA full-thickness burn 
US Army Institute of Surgical Research, 
Texas David S. Kauvar, MD  Kauvar, David S. MD; Acheson, Eric MD; Reeder, Joanna BS;  
  infected with Pa   
USAISR, 3400 Rawley E. Chambers 
Ave Roll, Kristin BS; Baer, David G. PhD 
      Fort Sam Houston, Texas 78234–6315 Comparison of battlefield-expedient topical antimicrobial agents for  
        the prevention of burn wound sepsis in a rat model. 
        Journal of Burn Care and Rehabilitation, 26(4), July/August 2005, pp 357-361 
  
standard contact burn (20% 
TBSA). Department of Surgery,  John P. Heggers, PhD  Heggers, John PhD, CWS; Goodheart, Rick E. MLT; Washington, Joyce BS;  
  infected with Pa, Sa University of Texas Medical Branch Shriners Hospital for Children McCoy, Lana MT; Carino, Edith BS; Dang, Thanh BS; Edgar, Pat RN;  
    
Shriners Hospital for Children, Burns 
Hospital, TX 815 Market St., Galveston, TX 77550 Maness, Cassie; Chinkes, David PhD 
        Therapeutic Efficacy of Three Silver Dressings in an 
         Infected Animal Model 
        J. Burn Care Rehabil., Vol. 26(1), Jan/Feb. 2005, pp 53-56 
  Full-thickness, lasting 13 days Institute for Wound Research   Chen, Chin, Schultz, Gregory S., Bloch, Melissa, Edwards, Paul D.,  
    Department of Obstetrics and Gynecology   Tebes, Steve & Mast, Bruce A. (1999) 
    
Div. of Plastic and Rec. Surgery,Dept. of 
Surgery   Molecular and mechanistic validation of delayed healing rat wounds  
    University of Florida, Gainesville, Florida.   as a model for human chronic wounds. 
        Wound Repair and Regeneration 7 (6), 486-494. 
  Linear incision wound 
Burn Center, Brigham and Women's and 
Beth  Robert H. Demling Demling, Robert H (2000) 
    
Israel Hospitals, Department of Surgery, 
Harvard    Oxandrolone, an anabolic steroid, enhances the healing of a cutaneous  
    Medical School, Boston, Massachusetts.   wound in the rat. 
        Wound Repair and Regeneration 8 (2), 97-102. 
  scalding wound 20% TBSA Dept of Surgery, University of Michigan Lars Steinstraesser Lars Steinstraesser, Brian F. Tack, Alan J. Waring, Teresa Hong, Lee M. Boo 
  right and left lateral flanks 
Department of Microbiology, University of 
Iowa Plastic and Reconstructive Surgery Ming-Hui Fan,DI Remick,Grace L. Su,Robert I. Lehrer,and Stewart C. Wang 
    
Department of Medicine, UCLA School of 
Medicine Ruhr University Bergmannsheil Activity of Novispirin G10 against Pseudomonas aeruginosa  
    
Ruhr University Bergmannsheil, Bochum, 
Germany 
49(0234)302-6841 F:49(0234)302-
6379 In Vitro and in Infected Burns 
      
lars.steinstraesser@ruhr-uni-
bochum.de Antimicrobial Agents and Chemotherapy, June 2002, p. 1837-1844, Vol. 46, No. 6 
Mice Full thickness 
Research Animal Care of Mass General 
Hospital Michael R. Hamblin Michael R. Hamblin, David A. O'Donnell,Naveen Murthy, 
  8X12.5mm   BAR 314B, Wellman Laboratories    Christopher H. Contag,and Tayyaba Hasana 
  
5mm unbroken skin between 
wounds   of Photomedicine, Rapid Control of Wound Infections by Targeted PhotodynamicTherapy  
  4 wounds per mouse   Mass General Hospital Monitored by In Vivo Bioluminescence Imaging 
  E.coli injected   50 Blossom St, Boston, MA Photochemistry and Photobiology: Vol. 75, No. 1, pp. 51–57., 2001 
      02114-2698   
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      hamblin@helix.mgh.harvard.edu   
  several models of infections in  Harvard Medical School, Boston, MA,  Michael R. Hamblin Tatiana N Demidovaa, Faten Gada, Touqir Zahraa, Kevin P Francisd  
  wounds and soft-tissue abcesses   617 726 6182 and Michael R Hamblin 
        Monitoring photodynamic therapy of localized infections by 
         bioluminescence imaging of genetically engineered bacteria 
        Journal of Photochemistry and Photobiology B: Biology  
        Volume 81, Issue 1 , 3 October 2005, Pages 15-25  
  excisional wounds 
Research Animal Care of Mass General 
Hospital Michael R. Hamblin Hamblin, Michael R.; O'Donnell, David A.; Zahra,  
  Infected with Ec, Pa     Touqir; Contag, Christopher H.; McManus, Albert T.; Hasan, Tayyaba 
        Targeted photodynamic therapy for infected wounds in mice 
        Proc. SPIE Vol. 4612, p. 48-58, 2002 
 Burns 
University of Cincinnati College of 
Medicine Daniel J. Hassett Gee W. Lau, Bradley E. Britigan and Daniel J. Hassett 
 2X2 cm   Dept of Molecular Genetics, Pseudomonas aeruginosa OxyR Is Required for Full Virulence in  
 Infected with Pa    Biochemistry and Microbiology,  Rodent and Insect Models of Infection and for Resistance to  
     Univ of Cincinnati College of Medicine Human Neutrophils 
     231 Albert Sabin Way,  Infection and Immunity, April 2005, p. 2550-2553, Vol. 73, No. 4 
     Cincinnati, OH 45267-0524   
     (513) 558-1154   
     Daniel.Hassett@UC.Edu   
 incisional model SmithKline Beecham Pharmaceuticals Valerie Berry Valier Berry, Roni Page, Jennifer Satterfield, Christine Singley, Rob Straub,  
 2cm Collegeville, Pa   Gary Woodnutt 
 infected with Spy, Se, Sa     Comparative efficacy of gemifloxacin in experimental models of  
       pyelonephritis and wound infection 
       Journal of Antimicrobial Chemotherapy (2000) 45, Suppl. S1, 87-93 
 Burns Texas Tech Univ, Texas John A. Griswold MD Kendra P. Rumbaugh Ph.D, Abdul N. Hamood Ph.D. and John A. Griswold M.D 
     Department of Surgery,  Cytokine induction by the P. aeruginosa quorum sensing system  
     
Texas Tech University Health 
Sciences Center during thermal injury 
     3601 4th Street,  Journal of Surgical Research  
     Lubbock, TX 79430, , USA Volume 116, Issue 1 , January 2004, Pages 137-144  
 Injection Baltimore, MD Eric Nuermberger Eric Nuermbergera, Kris Helkeb and William R. Bishaia  
     1 410 502 0580 Low-dose aerosol model of pneumococcal pneumonia  
       in the mouse: utility for evaluation of antimicrobial efficacy 
       International Journal of Antimicrobial Agents  
       Volume 26, Issue 6 , December 2005, Pages 497-503  
 wound, approx 1-cm in diameter, Salt Lake City, UT Glenn D. Prestwich Kelly R. Kirkera, Yi Luob, J. Harte Nielsonc, Jane Shelby 
  was created on the dorsal    Dept of Medicinal Chemistry,  and Glenn D. Prestwich 
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     The University of Utah,  Glycosaminoglycan hydrogel films as bio-interactive dressings 
     419 Wakara Way, Suite 205,   for wound healing 
     Salt Lake City, UT 84108  Biomaterials  
     1-801-585-9051 Volume 23, Issue 17 , September 2002, Pages 3661-3671  
 
infection in excisional mouse 
wounds   Michael R. Hamblin Michael R. Hamblin, Touqir Zahra, Christopher H. Contag,  
       Albert T. McManus, and Tayyaba Hasan 
       Optical Monitoring and Treatment of Potentially Lethal Wound 
        Infections In Vivo 
       The Journal of Infectious Diseases, volume 187 (2003), pages 1717–1726 
 infected wounds, burns,  Wellman Center for Photomedicine,  Michael R. Hamblin Demidova TN, Hamblin MR. 
 and soft tissue infections in mice Mass General Hospital, Boston,    Photodynamic therapy targeted to pathogens. 
       Int J Immunopathol Pharmacol. 2004 Sep-Dec;17(3):245-54. 
 
infected burn and bacteria 
observ. 
Dept Medicine/Infectious Diseases, Univ. 
of Florida  Reuben Ramphal Shiwani K. Arora, Alice N. Neely, Barbara Blair, Stephen Lory, 
   
Shriners Hospital for Children, Cincinnati, 
Ohio Dept of Medicine/Infectious Diseases,  and Reuben Ramphal 
   
Dept. of Microbiology, Harvard Medical, 
Boston P.O. Box 100277, JHMHC, Univ. of FL Role of Motility and Flagellin Glycosylation in the Pathogenesis of  
     Gainesville, FL 32610.  . Pseudomonas aeruginosa Burn Wound Infections 
     Ph: (352)392-2932  F:(352)392-6481 Infection and Immunity, Vol. 73, No. 7, July 2005, p. 4395-4398  
     E-mail: ramphr@medmac.ufl.edu   
 partial-thickness and  Department of Research,  Steven T. Boyce, Ph.D Supp AP, Neely AN, Supp DM, Warden GD, Boyce ST 
 full-thickness wounds Shriners Hospitals for Children,  Research Department Evaluation of cytotoxicity and antimicrobial activity of Acticoat  
 infected with Pa Cincinnati, Ohio 45229-3095, USA Shriners Hospital for Children  Burn Dressing for management of microbial contamination in  
     3229 Burnet Ave, Cincinatti, OH cultured skin substitutes grafted to athymic mice 
     stboyce@shrinenet.org J Burn Care Rehabil. 2005 May-Jun;26(3):238-46 
 Sprague Dawley and diabetic 
Departments of Microbiology and 
Immunology Luisa A. DiPietro Julia V. Dovi, Li-Ke He and Luisa A. DiPietro 
 3 cm Skin punch biopsy Surgery, Burn and Shock Trauma Institute Loyola University Medical Center Accelerated wound closure in neutrophil-depleted mice 
   
Loyola University Medical Center, 
Maywood, Illinois  2160 S. 1st Ave., BSTI, Building 110 Journal of Leukocyte Biology. 2003;73:448-455 
     Maywood, IL 60153    
     ldipiet@lumc.edu   
 Full-thickness 
Section of Plastic Surgery, University of 
Michigan Riley S. Rees, MD, FACS Rees, Riley S., Adamson, Belinda F. & Lindblad, William J. (2001) 
   
 Medical Center, 1500 East Medical 
Center Drive,  Fax: (734) 763-5354 Use of a cell-based interactive wound dressing to enhance healing of  
   
2130 Taubman Center, Ann Arbor, MI 
48109-0340 rreese@umich.edu excisional wounds in nude mice. 
       Wound Repair and Regeneration 9 (4), 297-304. 
 full-thickness, third-degree burns Infectious Disease Division,   JA Fishman Wilkinson, Robert A. BS; Fishman, Jay A. MD  
 infected with Pa Massachusetts General Hospital and    Effect of thermal injury with Pseudomonas aeruginosa infection on 
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   Harvard Medical School   pulmonary and systemic bacterial clearance. 
   Boston, MA   Journal of Trauma-Injury Infection & Critical Care. 47(5):912, Nov. 1999 
 mouse oocytes WPI Eric Overstrom  Genetic strain variations in the metaphase-II phenotype of mouse  
        oocytes matured in vivo or in vitro 
 burns   Laurence Rahme  Fred Ausubel (works with Microbes) 
 
tissue transplants on athymic 
mice 
Department of Chemical and Biological 
Engineering S.T. Andreadis Geer DJ, Swartz DD, Andreadis ST 
   State University of New York at Buffalo Bioengineering Laboratory,  Biomimetic Delivery of Keratinocyte Growth Factor upon Cellular   
     908 Furnas Hall Demand for Accelerated Wound Healing in Vitro and in Vivo 
     State University of New York Am J Pathol. 2005 Dec;167(6):1575-86 
     Buffalo, NY 14260   
     sandread@eng.buffalo.edu   
 
10mm diameter dorsal skin 
wounds 
Section of Endocrinology, Diabetes, and 
Nutrition J.D. Safer Safer JD, Crawford TM, Holick MF 
   Department of Medicine Endocrinology, Diabetes, & Nutrition Topical thyroid hormone accelerates wound healing in mice 
   Boston University School of Medicine Boston University School of Medicine Endocrinology. 2005 Oct;146(10):4425-30. Epub 2005 Jun 23 
   Boston, MA 715 Albany Street, Room M-1016   
     Boston, Massachusetts 02118   
     jsafer@bu.edu   
 
tissue transplants on athymic 
mice Shriners Burns Hospital Dorothy M. Supp, Ph.D. Supp DM, Bell SM, Morgan JM, and Boyce ST 
     Adjunct Research Assistant Prof. Genetic modification of cultured skin substitutes by transduction of  
     Shriners Burns Hospital keratinocytes and fibroblasts with platelet derived growth factor A 
     dsupp@shrinenet.org Wound Repair Regen 2000; 8:26-35 
     (513) 872-6000 Fax: (513) 872-6072   
 3 mm in diameter biopsy punch 
Loyola University Medical Center, 
Maywood, Illinois Dr. Luisa A. DiPietro Quentin E.H.Low, Iulia A. Drugea, L.A. Duffner, D.G. Quinn, D.N. Cook 
 acute wound 
Schering-Plough Research Institute 
Kenilworth, NJ Burn and Shock Trauma Institute Barrett J. Rollins, Elizabeth J. Kovacs and Luisa A. DiPietro 
   
Dana-Farber Cancer Institute, Boston, 
Massachusetts  Loyola University Medical Center Wound Healing in MIP-1{alpha}-/- and MCP-1-/- Mice 
     ldipiet@luc.edu American Journal of Pathology. 2001;159:457-463 
db/db 
mice Full-thickness Laboratory of Microvascular Research and  Geoffrey C. Gurtner, MD Galiano, Robert D., Michaels, V, Joseph, Dobryansky, Michael, Levine, Jamie   
   Vascular Tissue Engineering, Institute of  New York University Medical Center, P. & Gurtner, Geoffrey C. (2004) 
   
Reconstructive Surgery, New York 
University  560 First Avenue, TH-169, New York Quantitative and reproducible murine model of excisional wound healing. 
   Medical Center, New York, New York.  NY 10016. Fax: (212) 263-0481 Wound Repair and Regeneration 12 (4), 485-492. 
     geoffrey.gurtner@med.nyu.edu   
 Full-thickness Department of Cell Biology and Molecular  S. Joseph Leibovich, PhD, Masters, Kristyn S. Bohl, Leibovich, S. Joseph, Belem, Paula, West, Jennifer  
   
Medicine, New Jersey Medical School, 
UMDNJ,  Fax: (973) 972-7489 L. & Poole-Warren, Laura A. (2002) 
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185 South Orange Avenue, Newark, NJ 
07103-2714 leibovic@umdnj.edu. Effects of nitric oxide releasing poly(vinyl alcohol) hydrogel  
       dressings on dermal wound healing in diabetic mice. 
       Wound Repair and Regeneration 10 (5), 286-294. 
Smad3 
null mice Full-Thickness 
Department of Dermatology and Skin 
Surgery Dr. Vincent Falanga, Professor and  Falanga, Vincent, Schrayer, David, Cha, Jisun, Butmarc, Janet, Carson, Polly, 
   Roger Williams Medical Center,  Chairman Roberts, Anita B. & Kim, Seong-Jin (2004) 
   Elmhurst Building, 50 Maude Street,   Fax: (401) 456-6449 Full-thickness wounding of the mouse tail as a model for delayed wound  
   Providence, RI 02908  vfalanga@bu.edu. healing: accelerated wound closure in Smad3 knock-out mice. 
        Wound Repair and Regeneration 12 (3), 320-326. 
Transgen
ic Mice transgenic mouse strain with the  Department of Pathology Jeffrey M. Davidson, PhD Nanjun Wu*, E. Duco Jansen†, and Jeffrey M. Davidson 
 
MMP-13 or the COL1A2 
promoter Vanderbilt University School of Medicine Department of Pathology Comparison of mouse matrix metalloproteinase 13 expression in  
 laser wounds, scalpel wounds Nashville, Tennessee 37232-2561 Vanderbilt Univ. School of Medicine free-electron laser and scalpel incisions during wound healing 
     C-3321 Medical Center North,  Journal of Investigative Dermatology, Vol. 121 p. 926 (2003) 
     Nashville, TN 37232-2561   
     jeffrey.m.davidson@vanderbilt.edu   
          
Rodents Inflammatory response Case Western University  Horst von Recum  Word of Mouth 
     Michael J. Cima    
 Varies Worcester, MA Mitch Sanders Word of Mouth 
 Burns University of Iowa  G. Patrick Kealey, MD Methamphetamine-associated burn injuries: a retrospective analysis. 
       J Burn Care Rehabil. 2004 Sep-Oct;25(5):425-9.  
         
         
N/A Burns Burns Service and Shriners Burns Institute  Dr Ronald Tompkins  Word of Mouth; Dr. J Fisherman 
 Burns 
Department of Physiology, Loyola 
University  Richard Gamelli Word of Mouth 
   
Center, 2160 South First Ave., Maywood, 
IL      
    60153, United States.     
     
    
APPENDIX GG:  In Vivo Animal Model- Wound Measurement 
 
  MGH WOUND ANIMAL STUDY (FEB. 18 - FEB. 25)   
   WOUND AREA (mm2)    
Treatment 
Cage 
# Mouse 1st timepoint 2nd timepoint 
Final 
timepoint Difference 
High 1 yellow 122.82 97.7284 76.9232   
      112.64 96.8438 92.9961   
      106.64 97.266 90.552   
      114.0333333 97.2794 86.82376667 27.20956667
High 1 purple 101.2476 106.9285 86.5348   
      116.1276 107.7234 91.8826   
      109.1111 108.0576 103.3032   
      108.8287667 107.5698333 93.90686667 14.9219
High 1 blue 99.83 EXPIRED EXPIRED EXPIRED 
      82.7113       
      97.9932       
      93.5115     0
High 2 purple-green 103.356 96.8272 88.6788   
      109.8251 104.4903 92.6276   
      100.1806 99.9075 95.5636   
      104.4539 100.4083333 92.29 12.1639
Medium 2 
black with 
pink 98.6884 96.714 69.3116   
      88.572 92.2031 70.2402   
      91.854 94.119 70.8152   
      93.03813333 94.34536667 70.12233333 22.9158
  2 
Yellow w/ 
pink EXPIRED EXPIRED EXPIRED EXPIRED 
             
              
           0
Medium 3 blue 102.7242 79.2642 62.9909   
      117.6184 80.0934 79.692   
      104.0778 78.9488 75.2335   
      108.1401333 79.43546667 72.6388 35.50133333
Medium 3 green 104.6261 96.558 80.1905   
      126.1212 108.1106 78.3232   
      103.6575 100.0278 83.9644   
      111.4682667 101.5654667 80.82603333 30.64223333
Medium 3 pink 88.638 106.6891 84.7308   
      105.3315 87.248 94.2624   
      85.95 98.6272 101.9649   
      93.3065 97.52143333 93.6527 -0.3462
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Low 4 
pink with 
green 91.2924 87.4375 EXPIRED   
      101.9342 93.2928     
      86.0952 78.2624     
      93.10726667 86.3309   6.776366667
Low 4 yellow 116.1594 95.571 EXPIRED   
      107.1534 88.4317     
      98.5842 81.2842     
      107.299 88.42896667   18.87003333
Low 4 
blue with 
green 91.8162 95.3304 EXPIRED   
      107.2305 95.1142     
      117.1924 109.725     
      105.4130333 100.0565333   5.3565
Low 5 blue-green 100.975 101.472 EXPIRED   
      88.1624 91.451     
      108.0777 103.74     
      99.0717 98.88766667   0.184033333
C-vehicle 5 
pink with 
black 83.4067 101.9769 EXPIRED   
      88.4588 92.5931     
      100.0296 95.8518     
      90.6317 96.80726667   -6.175566667
C-vehicle 5 pink 96.1644 106.0477 97.864   
      118.1862 108.2697 83.304   
      90.809 107.9148 97.6752   
      101.7198667 107.4107333 92.94773333 8.772133333
C-no treat. 6 yellow 101.5404 102.9766 89.67   
      108.9165 100.362 98.4932   
      103.5095 101.2128 84.8232   
      104.6554667 101.5171333 90.99546667 13.66
C- no treat 6 
pink with 
blue 94.024 104.6583 98.388   
      96.4712 101.1512 105.742   
      93.7368 110.8968 112.9887   
      94.744 105.5687667 105.7062333 -10.96223333
C-wound  6 green 84.2607 88.0686 70.4781   
      92.379 84.7008 96.88   
      76.8379 82.5792 100.488   
      84.49253333 85.1162 89.28203333 -4.7895
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APPENDIX HH: In Vivo Animal Model- Weight  
   WEIGHT (g)   
Treatment 
Cage 
# mouse 1st weigh (start) 2nd weigh (middle) 3rd weigh (end) 
High 1 yellow 20.38 17.8 18.36
            
High 1 purple 22.4 16.64 17.76
            
High 1 blue 21.64 EXPIRED EXPIRED
            
High 2 purple-green 21.68 18.38 18.94
            
Medium 2 black with pink 20.96 18.7 19.3
            
Medium 3 blue 22 18.58 19.5
            
Medium 3 green 19.84 16.44 19.12
            
Medium 3 pink 21.44 19.12 19.24
            
Low 4 pink with green 21.94 17.82 EXPIRED
            
Low 4 yellow 21.92 EXPIRED EXPIRED
            
Low 4 blue with green 21.42 19.0 EXPIRED
            
Low 5 blue-green 22.2 EXPIRED EXPIRED
            
C-vehicle 5 pink with black 20.4 EXPIRED EXPIRED
            
C-vehicle 5 pink 20.6 18.84 16.58
            
C- no 
treat. 6 yellow 21.68 18.78 17.9
            
C- no 
treat. 6 pink with blue 20.42 18.36 19.02
            
C- wound  6 green 23.02 19.74 20.34
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APPENDIX II: In Vivo Animal Model- Bioluminescent Values 
  Bioluminescence  
High Cage 1 Blue   
 Date  Total Intensity Pixels 
 21806  262428 3166
 21806  409684 3378
 21906  331560 3575
 22006  120156 4706
High Cage 1 Purple Total Intensity Pixels 
 21806  141094 4254
 21806  98532 4966
 21906  204126 4966
 22006  69464 4966
 22106  115492 4966
 22206  32332 4966
 22306  27395 3006
 22406  22456 3006
 22806  113880 3477
High Cage 1 Yellow Total Intensity Pixels 
 21806  166912 3806
 21806  69776 3806
 21906  24864 3806
 22006  89004 3806
 22106  93085 3806
 22206  16302 3806
 22306  21617 3806
 22406  21578 3806
 22806  82292 3806
High Cage 2 black w/pink Total Intensity Pixels 
 21806  110446 3806
 21806  130688 3806
 21906  77100 3806
 22006  110388 3806
 22106  30254 3806
 22206  27911 3806
 22306  19150 3806
 22406  20374 3806
 22806  48215 3806
Medium Cage 2 Purp w/green Total Intensity Pixels 
 21806  220712 3806
 21806  133416 3806
 21906  138512 3806
 22006  79560 3806
 22106  140036 3806
 22206  73568 3806
 22306  53292 3806
 22406  68120 3806
 22806  146484 3477
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Medium Cage 3 Blue Total Intensity Pixels 
 21806  143568 3806
 21806  329280 3806
 21906  238652 3806
 22006  81528 4010
 22106  37700 4254
 22206  21046 4254
 22306  25346 4254
 22406  19601 4254
 22806  33998 2274
Medium Cage 3 Green Total Intensity Pixels 
 21806  421856 22774
 21806  511696 2774
 21906  556368 2238
 22006  225608 5194
 22106  51264 2974
 22206  42146 4486
 22306  38396 3382
 22406  35168 3382
 22806  96070 3382
Medium Cage 3 Pink Total Intensity Pixels 
 21806  217594 4718
 21806  191348 4718
 21906  467008 2418
 22006  106144 4434
 22106  48812 3218
 22206  25075 4254
 22306  32974 3253
 22406  10878 1446
 22806  66374 3354
Low Cage 4 blue w/green Total Intensity Pixels 
 21906  2579392 4098
 21906  8597248 6138
 22006  251672 4706
 22106  480976 4706
 22206  45028 2078
 22306  euthanized  
Low Cage 4 Pink w/green Total Intensity Pixels 
 21906  3420512 5336
 21906  2904960 4372
 22006  231712 4372
 22106  110512 2659
 22206  44592 1359
 22306  euthanized  
Low Cage 4 Yellow Total Intensity Pixels 
 21906  243280 4018
 21906  382752 4132
 22006  69268 3378
 22106  48008 3170
 22206  euthanized  
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Low Cage 5 Blue-green Total Intensity Pixels 
 21906  2352640 4126
 21906  788400 7236
 22006  99664 2676
 22106  29048 1738
 22206  expired  
C- vehicle Cage 5 Pink Total Intensity Pixels 
 21906  418176 3179
 22006  177696 1738
 22106  38014 3168
 22206  74560 1738
 22306  23060 1738
 22406  48360 1738
 22506  89640 3107
 22806 expired whole plate  
C-vehicle Cage 5 Pink w/black Total Intensity Pixels 
 21906  1528176 4364
 22006  165744 3168
 22106  139784 3663
 22206  euthanized  
C - no treat. Cage 6 Green Total Intensity Pixels 
 21906    
 22006  272192 2791
 22106  47000 2791
 22206  49512 3070
 22306  109944 2791
 22406  62780 2791
 22506  22672 2791
 22806  69784 1919
C- no treat. Cage 6 Pink w/blue Total Intensity Pixels 
 21906  2709568 3793
 22006  91056 1419
 22106  91152 4710
 22206  58500 3454
 22306  108052 4014
 22406  156840 3688
 22506  82572 3688
 22806  103488 2762
C- wound Cage 6 Yellow Total Intensity Pixels 
 21906  48212 4026
 22006  60820 3354
 22106  100412 3354
 22206  38848 2670
 22306  18184 735
 22406  133856 735
 22506  198616 3926
 22806  400224 1216
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APPENDIX JJ: Final Dressing Construction Using YP-ET 
Alginate + Glycerol + Calcium Chloride Layer + CMC + Glycerol + Agarose + YP-ET Layer Dressing Construction  
     
Purpose: Create final dressing prototype using YP-ET antimicrobial agent    
     
Materials: CMC powder     
                Alginate powder     
                Sterile water     
                Agarose 1% - 0.5g in 50mL water, boil 30 seconds, until all powder is melted    
                Glycerol     
                Commercial Grade YP-ET - must vortex before each use     
     
Methods:     
     
Alginate Layer     
     
1.) Obtain and make 1.5% Alginate (900 ml total vol.) and pour into 1 liter bottle     
2.) Add, by weight, 1.75% glycerol (15.75g) to alginate in bottle     
3.) Vortex mixture and pour ~55g into large gel plates keeping the volume per plate constant by weight   
4.)  Let gels dry overnight in 30ºC incubator     
5.)  After a minimum of 24 hours and there are no signs of wetness on the gel, peel alginate film from plate using a spatula  
6.)  Add, by weight, specified amount of calcium chloride (0.5%) to empty gel plate    
7.)  Place film back into plate on the calcium chloride ~1 min     
8.)  After 1 minute remove film once again, flip it over and allow other side to soak    
9.)  Allow film to soak in calcium chloride solution for a minimum of 24 hours     
10.) After 24 hours, pour off CaCl2 solution and add enough water to submerge the gel careful not to disturb the gel. Allow 20 minutes to soak 
11.) After 20 minutes, remove old water and replace it with clean water and continue the changing the water and soaking the gels  
at 20 minute intervals for at least 1 hour     
12.) Allow gel to remain in clean water to avoid drying out     
13.) Using a razor, cut clean calcium alginate gels to size of smaller plates by tracing along the edge the blade   
Note: Be sure there is a tight seal between the edge of the gel and the tray edge. If necessary cut the gel larger than the actual plates. 
14.) Place in freezer for ~20 minutes to solidify the alginate layer     
     
        
APPENDIX KK: Final Dressing Construction Using YP-ET Continued 
 
Glycerol + Terpene + Agarose CMC Prototype    32806   
       
Purpose: Test and decide on most effective terpene concentrations with varied amounts      
              Determine the stability of prototype dressing by pouring the CMC onto the alginate layer     
       
Materials: CMC powder       
Sterile water       
Agarose 2% - 2g in 100 mL water, boil until all powder is melted       
Glycerol       
Commercial Grade YP-ET - vortex before each use!       
1.5% CMC stock       
2% CMC stock        
silver 1 mg/ml (20 mg diluted in 20 mL) water - homogenize using polytron       
       
Methods:       
1. Prepare 2% CMC and allow to mix overnight       
2.) Add 2 g of agarose powder to 100g water - boil to dissolve agarose       
3.) Place all materials into the warmed 50C water bath including bottles and water       
4.) Measure out indicated volumes (round to 2 decimal places) into glass 100 mL bottle, taring after each material    
       
 3 2 1 4 5  
Hydrocolloid YP-ET (g) glycerol (g) 2% CMC (g) 2% agar. (g) silver (g) water 
              
1.5% CMC + 0.3% agar. + 1.75% glycerol + 41.8 ppm silver control  0 0.963 41.250 8.25 2.3 2.238 
1.5% CMC + 0.3% agar. + 1.75% glyc. + 6.6 mg/ml YP-ET + 41.8 ppm silver 2.27 0.963 41.250 8.25 2.3 0.000 
       
        
5.) Mix throughouly by vortex or by shaking the bottle until all particles are evenly distributed.       
6.) Cast gels on top of thin alginate layer, freeze at -80C for ~ 1 hr and then lyophilize on standard recipe for 24 hrs.    
7.) Run water absorption test to measure amount of volume the gels can hold and stability of the gels     
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APPENDIX LL: Disc Diffusion Assay  
 
Disc Diffusion Assay     
      
Purpose:   To determine the optimal concentration of YP-ET for the prototype dressing by analyzing the  
                 antimicrobial activity of different concentrations on various microrganisms  
Materials:  5 mm biopsy punch     
 S. aureus     
 P. aeruginosa     
 Mueller-Hinton Agar Plates    
 0.5 McFarland Standard    
 prototype dressing     
 sterile filter paper (negative control)    
      
Method:      
1.) Punch out discs of protype dressing and sterile filter paper using 5 mm biopsy punch  
2.) Grow microrganisms overnight     
3.) Dilute microrganisms to the density of a 0.5 McFarland standard   
4.) Pour microrganisms over the surface of agar plates and decant excess   
5.) Allow plates to dry     
6.) Place dressing discs on the surface of the agar (2 microbes @ n=2 and sterile filter papers (negative control) @ n=2) 
7.) Incubate overnight at 35 degrees C     
8.) Measure clear zones around the disc     
      
*Any clear zones of 1 mm radius or greater means that actives have released from the dressing and migrated  
through the agar matrix. Also, the active was in high enough concentration to inhibit the growth of the microbes in the  
clear zone.      
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Plate 1 (Sa) Zone Radius (mm)  Plate 2 (Sa) Zone Radius (mm) 
Filter Paper    Filter Paper   
Control    Control   
6.6 mg/ml YP-ET    6.6 mg/ml YP-ET   
24 mg/ml YP-ET    24 mg/ml YP-ET   
     
Plate 3 (Pa) Zone Radius (mm)  Plate 4 (Pa) Zone Radius (mm) 
Filter Paper    Filter Paper   
Control    Control   
6.6 mg/ml YP-ET    6.6 mg/ml YP-ET   
24 mg/ml YP-ET    24 mg/ml YP-ET   
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APPENDIX MM: Antimicrobial Barrier Assay  
 
 Antimicrobial Barrier Assay         
          
 Purpose:  To determine if the prototype dressing is effective as an antimicrobial barrier, which does not allow microbes on the surface to    
                 enter the wound dressing        
 Materials:  S. aureus        
  Muller-Hinton Agar plates       
  0.5 McFarland Standard       
  prototype dressing       
  sterile filter paper (negative control)      
 Method:         
 1.) Grow microrganisms overnight        
 2.) Punch out discs of protype dressing and sterile filter paper using 5 mm biopsy punch     
 3.) Place squares on the surface of agar plates       
 4.) Innoculate test bacteria on top of the squares of dressing and filter paper     
  4a.) Dilute microrganisms to the density of a 0.5 McFarland standard   
  4b.) Pour microrganisms over the surface of the dressing squares    
  4c.) Allow plates to dry       
 5.) Incubate at 35 degrees C for a total of 24 h, removing one square of dressing and filter paper at 1, 2, 4, 8, and 24 h.  
 6.) Observe for evidence of microbial growth in the area, which was under the square that is removed at each time point  
          
   
  Bacterial Growth Under Dressing at Time 
Points            
 Plate 1 (Sa) 1h 2h 4h 8h 24h    
 Filter Paper (5 pieces)              
 Plate 2 (Sa)              
 Control (5 pieces)              
 Plate 3 (Sa)              
 6.6 mg/ml YP-ET (5 pieces)              
 Plate 4 (Sa)              
 24 mg/ml YP-ET (5 pieces)              
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APPENDIX NN: Corrected Zone of Inhibition Assay 
Corrected Zone of Inhibition Assay       
Purpose:  To determine if a single prototype dressing is effective in killing bacteria for a minimum of 7 days 
Materials:          
 S. aureus        
 Muller-Hinton Agar plates       
 0.5 McFarland Standard       
 prototype dressing       
 sterile filter paper (negative control)      
Method:         
1.) Punch out discs of prototype dressing and sterile filter paper using 5 mm biopsy punch    
2.) Grow microrganisms overnight        
3.) Dilute microrganisms to the density of a 0.5 McFarland standard     
4.) Pour microrganisms over the surface of agar plates and decant excess     
5.) Allow plates to 
dry         
6.) Incubate overnight at 35 degrees C       
7.) Place dressing squares and filter paper squares on each agar plate.     
8.) After 24 h, remove the squares, examine the plates to determine if colonies reside under the dressing and filter paper 
9.) Place the SAME squares on a NEW/FRESH plate.      
10.) After 24 h, remove the squares, examine the plates to determine if colonies reside under the dressing and filter paper 
11.) Continue the same procedure for 7 days       
Plate 1 (Sa)            Amount of Kill Under Dressing Square at Time Points              
Filter Paper 1 day 2 days 3 days 4 days 5 days 6 days 7 days  
Control                
6.6 mg/ml YP-ET                
24 mg/ml YP-ET                
         
Plate 2 (Sa)        Amount of Kill Under Dressing Square at Time Points              
Filter Paper 1 day 2 days 3 days 4 days 5 days 6 days 7 days  
Control                
6.6 mg/ml YP-ET                
24 mg/ml YP-ET                
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APPENDIX OO: In Vivo Experiment- Bioluminescent Pictures 
 
 
 T0- Bact. Applic. T0- Terp. -20 min  T1 – 24 hrs  T3 – 72 hrs  T2 – 48 hrs  T4 – 96 hrs  T5 – 120 hrs  T6 – 144 hrs  T9 –  240 hrs 
High Dose Terpene (24 mg/ml)
 T0- Bact. Applic.  T0- Terp. - 20 min  T1 – 24 hrs  T2 – 48 hrs  T3 – 72 hrs  T4 – 96 hrs  T5 – 120 hrs  T6 – 144 hrs  T9 – 240 hrs. 
Medium Dose Terpene (6.6 mg/ml)
 T0- Bact. Applic.  T0- Terp. – 20 min 
Low Dose Terpene (1.5 mg/ml)
 T1 –  24 hrs  T2 – 48 hrs  T3 –  72 hrs 
 T9 – 72 hrs. 
 T0- Bact. Applic.  T0- Terp. - 20 min  T1 – 24 hrs  T2 – 48 hrs  T3 – 72 hrs  T4 – 96 hrs  T5 – 120 hrs  T6 – plate 
Control – Vehicle only  
Signs of a systemic 
infection – heart swab 
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 T0- Bact. Applic.  T0- Terp. applic.  T1 – 24 hrs T3 – 24 hrsT2 – 24 hrs T4 – 24 hrs  T5 – 24 hrs T6 – 24 hrs
Control – No treatment
T3 – 24 hrs T4 – 24 hrs  T5 – 24 hrs T6 – 24 hrs
 T0- Bact. Applic. A li .  T1 – 24 hrs T2 – 24 hrs T3 – 24 hrs T4 – 24 hrs 8 48
 T1 – 24 hrs T2 – 24 hrs T3 – 24 hrs T4 – 24 hrs  T5 – 24 hrs
Control – Wound only (no infection)
 T0- Bact. Applic.  T0- Terp. Applic.  T1 – 24 hrs  T2 – 24 hrs  T3 – 24 hrs  T4 – 24 hrs  T5 – 24 hrs  T8 – 48 hrs 
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APPENDIX PP: CMC Hydrocolloid plus Agarose 
CMC Hydrocolloid plus Agarose        21406  
            
Purpose:  Identify Agarose concentration to stabilize CMC hydrocolloid        
            
Materials:  Stock 2% CMC hydrocolloid - heat to 50C         
 Sterile water - heat to 50C          
 Agarose - prepare 2 % agarose by suspending 0.75 gm in 50 ml water.  Boil until dissolved.  Cool in 50C water bath   
            
Prepare 1.5% CMC gels with varying agarose concentrations         
            
% ml   ml ml        
[Agarose] 2 % Agarose % CMC 2% CMC sterile water        
0 0 1.50% 11.25 3.8        
0.1 0.75 1.50% 11.25 3.0        
0.2 1.5 1.50% 11.25 2.3        
0.3 2.25 1.50% 11.25 1.5        
0.4 3 1.50% 11.25 0.8        
0.5 3.75 1.50% 11.25 0.0        
            
Methods:            
1.) Add amounts of sterile water, CMC and agarose to tubes in 50C water bath        
2.) Mix to form uniform suspension          
3)  Cast into small weigh boats. Allow to gel at room temperature and dry to form a film overnight      
4.) Run the water absorption test for assessment of dissolving that may occur.        
            
            
This will establish the relationship between agarose and CMC to produce a stable film       
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Appendix QQ: Agarose and CMC Water Absorption 
 
Agarose+CMC Water Absorption Test     21506 
        
Purpose: Test the amount of fluid absorptive capacity in each film     
 Measure the effect of agarose on the stability of the CMC hydrocolloid    
        
Materials: CMC Hydrocolloid + Agarose samples       
 Microfuge tubes       
 24 mL sterile water (1 mL/tube)      
        
Methods:        
1.) Weigh 24 empty microfuge tubes and label according to hydrocolloid sample, concentration, and additive   
2.) Cut a small sample of agarose+CMC hydrocolloid and place in microfuge tube - weigh and record scale reading   
3.) Fill microfuge tubes with 1.0 mL sterile water      
4.) Leave at room temperature for 5 minutes      
5.) Extract surrounding water from the tube and weigh on the scale     
 Record final volume of water remaining in the sample     
        
 SET 1       
 Hydrocolloid Empty Tube (g) Tube+Sample (g) Final Sample (g) Sample dry (g) Sample wet (g) Final Vol. (g) 
               
 0% Agarose + 1.5% CMC 0.9957 1.006 - 0.0103 - - 
 0.1% Agarose + 1.5% CMC 0.9958 1.0017 1.2317 0.0059 0.2359 0.23 
 0.2 % Agarose + 1.5% CMC 0.9965 1.0083 1.3965 0.0118 0.4 0.3882 
 0.3% Agarose + 1.5% CMC 0.9973 1.006 1.3213 0.0087 0.324 0.3153 
 0.4% Agarose + 1.5% CMC 0.9995 1.0102 1.3405 0.0107 0.341 0.3303 
 0.5% Agarose + 1.5% CMC 0.9995 1.0107 1.3474 0.0112 0.3479 0.3367 
 0.4% Agarose only control 0.9924 0.9982 1.0806 0.0058 0.0882 0.0824 
 0.3% Agarose only control 0.9965 0.9998 1.0567 0.0033 0.0602 0.0569 
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 SET 2       
 Hydrocolloid Empty Tube (g) Tube+Sample (g) Final Sample (g) Sample dry (g) Sample wet (g) Final Vol. (g) 
               
 0% Agarose + 1.5% CMC 1.0039 1.0104 - 0.0065 - - 
 0.1% Agarose + 1.5% CMC 1.0008 1.0068 1.2482 0.006 0.2474 0.2414 
 0.2 % Agarose + 1.5% CMC 0.9971 1.0073 1.3735 0.0102 0.3764 0.3662 
 0.3% Agarose + 1.5% CMC 0.9998 1.0095 1.4072 0.0097 0.4074 0.3977 
 0.4% Agarose + 1.5% CMC 1.003 1.011 1.2917 0.008 0.2887 0.2807 
 0.5% Agarose + 1.5% CMC 1.0002 1.0116 1.3646 0.0114 0.3644 0.353 
 0.4% Agarose only control 0.9999 1.0034 1.0848 0.0035 0.0849 0.0814 
 0.3% Agarose only control 1.0006 1.0012 1.1011 0.0006 0.1005 0.0999 
        
        
 Results: 0.2%, and 0.3% Agarose + 1.5% CMC were most stable with the highest amount of water absorption  
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Appendix RR: Glycerol Amount Variation Test 
Glycerol + Terpene + Agarose CMC Combination test   22006  
      
Purpose: Test and decide on most effective glycerol concentrations with varied amounts   
              Determine the stability of agarose in the CMC hydrocolloid     
      
Materials: CMC powder 2% CMC stock hydrocolloid      
 Sterile water     
 Agarose 1% - 0.5g in 50 mL water, boil 30 sec, until all powder is melted 
 Glycerol     
 Commercial Grade YP-ET - vortex before each use!   
Methods:      
1.) Obtain CMC, make 1.5% hydrocolloid by diluting stock 2% solution     
2.) Place all materials into the warmed 50C water bath including bottles and water    
3.) Measure out indicated volumes (round to 2 decimal places) into glass 100 mL bottle, taring after each material  
      
 4 3 1 2 5 
Hydrocolloid Terpene addition (g) glycerol (g) grams 2% CMC grams water grams 1% agarose 
            
1.5% CMC + 0.3% agarose alone - - 41.25 13.585 0.165 
1.5% CMC + 0.3% agarose+YP-ET 2.1 - 41.25 11.485 0.165 
1.5% CMC + 1.75% glycerol+0.3%agarose+YP-ET 2.1 0.875 41.25 10.61 0.165 
1.5% CMC + 3.5%glycerol + 0.3% agarose+ YP-ET 2.1 1.75 41.25 9.735 0.165 
1.5% CMC+5.25% glycerol+0.3% agarose+YP-ET 2.1 2.625 41.25 8.865 0.165 
1.5% CMC +7% glycerol+0.3%agarose+YP-ET 2.1 3.5 41.25 7.985 0.165 
      
4.) Mix throughouly by vortex or by shaking the bottle until all particles are evenly distributed.   
5.) Cast gels, freeze at -80C for ~ 1 hr and then lyophilize on standard recipe for 24 hrs.    
6.) Run water absorbption test to measure amount of volume the gels can hold and stability of the gels   
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Appendix SS: CMC Lyophilization Water Absorption 
 
Lyophilization CMC+glycerol+agarose Water Absorption Test     
        
Purpose: Test the amount of fluid absorptive capacity in each film      
        
Materials: CMC Hydrocolloid samples       
 Microfuge tubes       
 24 mL sterile water (1 mL/tube)       
        
Methods:        
1.) Weigh 12 empty microfuge tubes and label according to hydrocolloid sample, concentration, and additive    
2.) Cut a small sample of lyophilized hydrocolloid and place in microfuge tube - weigh and record scale reading    
3.) Fill microfuge tubes with 1.0 mL sterile water       
4.) Leave at room temperature for 5 minutes       
5.) Extract surrounding water from the tube and weigh on the scale      
 
Record final volume of water remaining in the 
sample       
        
 SET 1       
gel 
(g) Hydrocolloid Empty Tube (g) Tube+Sample (g) Final Sample (g) Sample dry (g) Sample wet (g) Final Vol. (g) 
               
0.7 1.5% CMC + 0.3% agarose alone 0.9969 1.0144 1.5131 0.0175 0.5162 0.4987 
1.24 1.5% CMC + 0.3% agarose+YP-ET 1.0044 1.0335 1.5288 0.0291 0.5244 0.4953 
2 1.5% CMC + 1.75% glycerol+0.3%agarose+YP-ET 0.9942 1.0258 1.3626 0.0316 0.3684 0.3368 
2.44 1.5% CMC + 3.5%glycerol + 0.3% agarose+ YP-ET 0.996 1.0447 1.3171 0.0487 0.3211 0.2724 
3.27 1.5% CMC+5.25% glycerol+0.3% agarose+YP-ET 0.9964 1.0646 1.4257 0.0682 0.4293 0.3611 
4.14 1.5% CMC +7% glycerol+0.3%agarose+YP-ET 0.9965 1.0825 1.4774 0.086 0.4809 0.3949 
        
 SET 2       
 Hydrocolloid Empty Tube (g) Tube+Sample (g) Final Sample (g) Sample dry (g) Sample wet (g) Final Vol. (g) 
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 1.5% CMC + 0.3% agarose alone 1.0029 1.025 1.6399 0.0221 0.637 0.6149 
 1.5% CMC + 0.3% agarose+YP-ET 1.0003 1.0209 1.6021 0.0206 0.6018 0.5812 
 1.5% CMC + 1.75% glycerol+0.3%agarose+YP-ET 0.9984 1.0288 1.3427 0.0304 0.3443 0.3139 
 1.5% CMC + 3.5%glycerol + 0.3% agarose+ YP-ET 1.0008 1.0423 1.4088 0.0415 0.408 0.3665 
 1.5% CMC+5.25% glycerol+0.3% agarose+YP-ET 0.994 1.0693 1.4075 0.0753 0.4135 0.3382 
 1.5% CMC +7% glycerol+0.3%agarose+YP-ET 0.999 1.0625 1.4391 0.0635 0.4401 0.3766 
        
        
 we want the % absorption by weight to be in the range of 13 g - 22 g based on current CMC wound dressings    
 therefore, any value higher than that is not favorable and we would ideally like to be within this range    
 Adding the lowest conc. of glycerol would therefore be most favorable, so 1.75% glycerol     
 Need glycerol to not absorb too much water, CMC alone is too high of an amt based on      
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APPENDIX TT: Antimicrobial Properties of In Vivo Vehicle Formulation 
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